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Abbreviation List. 
ABC, ATP-binding cassette; 
ArAA, aromatic amino acid; 
ATP, adenosine triphosphate; 
BBB, blood-brain barrier; 
BCAA, branched-chain amino acid; 
BCSFB, blood-cerebrospinal fluid barrier; 
bFGF, basic fibroblast growth factor; 
BMEC, brain microvascular endothelial cells; 
cAMP, cyclic adenosinemonoposphate; 
cGMP, cyclic guanosinemonophosphate; 
CNS, central nervous system; 
CO, carbon monoxide; 
CSF, cerebrospinal fluid; 
CVOs, circumventricular organs; 
L-DOPA, L-3,4-dihydroxyphenylalanine / levodopa; 
ECF, extracellular fluid; 
GABA, γ-aminobutyric acid; 
H2S, hydrogen sulfide; 
HIV, human immunodeficiency virus; 
HPLC, high-pressure liquid chromatography; 
HRP, horseradish peroxidase; 
IQ, intelligence quotient; 
ISF, interstitial fluid; 
iv, intravenous; 
Km, Michaelis constant; 
KO, knockout; 
LC-MS, liquid chromatography-mass spectrometry; 
LNAA, large neutral amino acid; 
MBMECs, mouse brain microvascular endothelial cells; 
mTOR, mammalian target of rapamycin 
NADPH, nicotinamide adenine dinucleotide phosphate; 
NMDA, N-methyl-D-aspartic acid; 
NO, nitric oxide; 
PBS, phosphate buffered saline; 
qPCR, quantitative polymerase chain reaction; 
mRNA, messenger ribonucleic acid; 
SLC, solute carrier; 
T3, triiodothyronine; 
T4, thyroxine; 
TCA cycle, tricarboxylic acid cycle; 
TGF, transforming growth factor; 
TEER, transendothelial electrical resistance; 
TNF, tumor necrosis factor; 
UTR, untranslated region; 
Vmax, maximal transport velocity; 
WHO, World Health Organization.
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1. Summary. 
The brain microvascular endothelial cells (BMECs) of the blood-brain barrier (BBB) provide 
a diffusion barrier between blood and brain interstitial fluid (ISF). The BBB plays a role in 
protecting the brain from changes in the blood. Amino acid transport through the BBB is 
crucial for establishing and maintaining an asymmetry in amino acid concentration between 
blood and brain and for the distribution of drugs and diagnostic markers. Interestingly, the 
cerebrospinal fluid (CSF) amino acid concentration is only about 10% that of plasma, except 
for glutamine [1].  
Characterizing the expression and localization of solute carrier (SLC) transporters is one of 
the first steps in understanding the mechanisms regulating BBB transendothelial transport. 
Our aim is to understand how the amino acid gradient is maintained by BMEC amino acid 
transporters. 
To address this aim, we first examined which (amino acid) transporters are expressed in total 
at the murine BBB on the mRNA level and how their expression is affected by a short culture 
step [2]. By mRNA microarray analysis using freshly isolated as well as single-cultured (5 
days) and co-cultured (with glial cells in non-contact) BMECs, we have shown that as much 
as 60% of the known amino acid transporters are expressed in BMECs. In freshly isolated, 
noncultured, BMECs Lat1-4F2hc is most prominently expressed, followed by the sodium-
dependent amino acid transporters Taut, Snat2, Snat5, and Eaat3. Although glial coculture is 
often used to mimic in vitro the BBB in vivo, levels of 73% of the amino acid transporter 
mRNAs were strongly altered by culture. In particular, for 78% of the transporters highly 
expressed in noncultured BMECs down-regulation was verified by qPCR (Lat1-4F2hc, Taut, 
Cat-1, Xpct, Snat3, and Snat5). In contrast, y+Lat2, xCT, and Snat1 are expressed at low 
levels in noncultured BMECs and are upregulated by culture. 
We hypothesize that down-regulation of transporter mRNA during culture is characteristic of 
transporters, such as Lat1-4F2hc, mediating transendothelial amino acid transport in vivo. 
Conversely, we postulate that transporter mRNA upregulated by culture do so to serve 
increased cellular amino acid demands for growth. 
To understand the functional organization of the BBB and the role of transporters in 
physiological and (neuro)pathophysiological states, many of them characterized by impaired 
brain amino acid concentrations, it is necessary to not only determine at the mRNA level 
which transporters are expressed at the BBB, but also whether the actual transporters are 
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expressed at the luminal and / or abluminal membranes of BMECs, and how they are 
regulated. 
Therefore, we studied the expression of Lat1-4F2hc (Slc7a5-Slc3a2), Snat1 (Slc38a1), and 
Snat3 (Slc38a3) in vivo on mouse brain tissue sections and additionally by in vivo 
biotinylation of the mouse brain vascular lumen with subsequent Western blot analysis. By 
combining the results obtained by the two different approaches, we, for the first time, could 
show that the sodium-dependent amino acid transporter Snat3, along with the exchanger Lat1-
4F2hc, is localized to both the abluminal and the luminal membranes of BMECs. 
Furthermore, they are subject to posttranslational modifications. For example, Snat3 
expressed in the luminal membrane has been found to be highly glycosylated, suggesting the 
possibility that glycosylation might play a role for its luminal membrane insertion. 
The finding of Snat3 present on the luminal membrane of the BBB challenges the current 
hypothesis that sodium-dependent amino acid transport is an exclusive feature of the 
abluminal membrane [1, 3-9], in a position to protect the brain from neurotoxic levels of 
amino acids.  
We also found Snat1, another sodium-dependent transporter, localized to the luminal 
membrane of vascular endothelial cells, with higher expression in the bigger vessels 
compared to brain microvessels. Therefore, we conclude that Snat1 seems not to play a 
pivotal role in the differentiated endothelial cells of the BBB, which stands in agreement with 
the finding that Snat1-mRNA shows very low expression in noncultured BMECs [2]. 
Taken together, we showed expression of a high number of not characterized amino acid 
transporters at the BBB, as well as their differing modulation by culture, implying functional 
differences. We also showed the unexpected localization of secondary active transport 
mechanisms at the luminal membrane, facing the blood with its high amino acid levels. 
Therefore, to be able to better understand the BBB transportome and its role in brain amino 
acid homeostasis, further studies and re-thinking of current hypotheses are needed. 
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2. Zusammenfassung. 
Mikrovasculäre Endothelzellen (BMECs) der Bluthirnschranke (BBB) bilden eine 
Diffusionsbarriere zwischen Blut und Interstitialflüssigkeit (ISF) des Gehirns. Die BBB 
schützt das Gehirn vor Veränderungen im Blut. Transport von Aminosäuren über die BBB ist 
ein wichtiger Schritt um die asymmetrische Aminosäurekonzentration zwischen Blut und 
Gehirn herzustellen und aufrechtzuerhalten. Aminosäuretransporter sind aber auch wichtig 
um Medikamente und diagnostische Marker im Gehirn zu verteilen. Interessanterweise ist die 
Aminosäurekonzentration in der Cerebrospinalflüssigkeit (CSF) nur ca. 10% die des Plasmas, 
mit Ausnahme von Glutamin [1]. 
Die Expression und Lokalisierung von “solute carrier” (SLC) Transportern zu 
charakterisieren ist einer der ersten Schritte um den Mechanismus zu verstehen mit dem BBB 
transendothelialer Transport reguliert wird. Unser Ziel ist es zu verstehen wie der bestehende 
Aminosäuregradient durch Aminosäuretransporter der BMECs erhalten wird. 
Um dieses Ziel zu erreichen haben wir als erstes untersucht welche Transporter überhaupt in 
der BBB von Mäusen exprimiert sind (mRNA) und wie ihre Expression durch eine kurze 
Kultur der Endothelzellen beeinflusst wird [2]. Durch eine Microarray-basierte Analyse der 
frisch isolierten, single-kultivierten (für 5 Tage) und co-kultivierten (mit Gliazellen ohne 
direkten Kontakt) BMECs konnten wir zeigen dass ganze 60% der bekannten 
Aminosäurentransporter in BMECs exprimiert sind. In frisch isolierten, nicht-kultivierten, 
BMECs zeigt Lat1-4F2hc die höchste Expression, gefolgt von den Natrium-abhängigen 
Aminosäuretransportern Taut, Snat2, Snat5, und Eaat3. Obwohl Co-Kultur von Endothel- mit 
Gliazellen oft verwendet wird um in vitro die BBB in vivo nachzuahmen, wurde die 
Expression von 73% der Aminosäuretransporter durch die Kultur der Endothelzellen stark 
verändert. Es konnte durch qPCR gezeigt werden dass 78% der Transporter mit hoher 
Expression in nicht-kultivierten BMECs einen weit niedrigeren Expressionslevel nach der 
Zellkultur aufweisen (Lat1-4F2hc, Taut, Cat-1, Xpct, Snat3, and Snat5). Im Gegensatz dazu 
zeigen y+Lat2, xCT, and Snat1 einen niedrigen Expressionslevel in nicht-kultivierten BMECs 
und eine höhere Expression nach dem Zellkulturschritt. 
Unserer Hypothese folgend repräsentieren Transporter deren mRNA während der Kultur der 
Zellen runter-reguliert wurde solche Transporter, die in vivo für transendothelialen 
Aminosäuretransport verantwortlich sind, wie z.B. Lat1-4F2h. Im Gegensatz dazu vermuten 
wir dass Transporter, welche während der Kultur der Zellen hoch-reguliert wurden, dies tun 
um den durch das Zellwachstum erhöhten zellulären Aminosäurebedarf zu decken. 
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Um die funktionale Organisation der BBB und die Funktion der Transporter in 
physiologischen und (neuro)pathophysiologischen Bedingungen zu verstehen, welche oft 
durch beeinträchtigte Aminosäurekonzentrationen charakterisiert werden können, ist es 
wichtig neben der mRNA-Expression auch die Expression der Transporter in der luminalen 
und /oder abluminalen Membran der BMECs und deren Regulation zu bestimmen. 
Deswegen haben wir die Expression von Lat1-4F2hc (Slc7a5-Slc3a2), Snat1 (Slc38a1), und 
Snat3 (Slc38a3) in vivo auf Gewebsschnitten von Mäusegehirnen und darüber hinaus durch in 
vivo Biotinylierung des vaskulären Lumen in Mäusegehirnen mit darauf folgender Western-
Blot Analyse untersucht. Die Ergebnisse der beiden unterschiedlichen Ansätze erlaubte es uns 
zum ersten Mal zu zeigen dass der Natrium-abhängige Transporter Snat3, ebenso wie der 
Exchanger Lat1-4F2hc, auf der luminalen wie auch abluminalen Membran der BMECs 
lokalisiert ist. Darüber hinaus sind die Transporter Objekt posttranslationaler Modifikationen. 
Zum Beispiel ist luminal exprimiertes Snat3 stark glykosyliert, was die Möglichkeit eröffnet 
dass Glykosylierung unter Umständen für die Insertion von Snat3 in die luminale Membran 
wichtig ist. 
Das Snat3 in der luminalen Membran der BBB zu finden ist steht im Gegensatz zu der 
gegenwärtige Hypothese dass Natrium-abhängiger Aminosäuretransport ausschliesslich an 
der abluminalen Membran stattfindet [1, 3-9], von wo aus sie das Gehirn vor neurotoxischen 
Aminosäureleveln schützten können. 
Wir fanden auch Snat1, einen anderen Natrium-abhängigen Transporter, in der luminalen 
Membran von vaskulären Endothelzellen, mit einer höheren Expression in grösseren wie in 
Mikrovesseln. Daraus folgerten wir dass Snat1 scheinbar keine entscheidende Funktion in den 
differenzierten Endothelzellen der BBB zu spielen scheint, was sich mit der sehr niedrigen 
Snat1-mRNA Expression in nicht-kultivierten BMECs deckt [2]. 
Zusammengenommen haben wir gezeigt dass eine grosse Anzahl nicht-charakterisierter 
Aminosäuretransporter in BBB Endothelzellen exprimiert ist, und dass diese Transporter 
unterschiedliche Regulation durch einen Zellkulturschritt zeigen, was wiederum auf 
funktionelle Unterschiede schliessen lässt. Darüber hinaus haben wir überraschenderweise 
auch gezeigt dass sekundäraktive Transporter in der luminalen Membran lokalisiert sind, wo 
sie in Kontakt mit den hohen Aminosäurekonzentrationen im Blut stehen. Um das BBB 
Transportom und seine Funktion in der Regulation der Aminosäurehomöostase im Gehirn 
besser zu verstehen sind deswegen weitere Studien und ein Überdenken der gegenwärtig 
vorherrschenden Hypothesen erforderlich. 
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3. Introduction. 
3.1 Progress of Neuroscience. 
The human brain is the most complex tissue in the body. It mediates behaviour ranging from 
simple movements and sensory perception to learning and memory. It is the centre of the 
nervous system and the organ of mind. But still today, many of the brain’s functions are 
poorly understood.  
For a long time the heart was seen as seat of soul and intelligence, the reason why the 
Egyptians removed the brain during mummification and kept the heart. Still Aristotle believed 
that thought occurs in the heart, Hippocrates finally located all mental processes in the brain. 
After establishment of the significance of the brain, it took until the 1890s before Santiago 
Ramón y Cajal and Camillo Golgi described the brain structure and established the neuron 
doctrin, telling that the nervous system is made up of discrete individual cells. In the 1940s, 
Alan Hodgkin, Andrew Huxley, and Bernard Katz could explain that electrical activity of 
neurons is based on concentration gradients of ions and movement of ions through pores. This 
was a pivotal moment in brain science, the first realistic promise that the CNS could be 
understood in detail [10]. 
During the latter part of the 20th century neuroscience became an interdisciplinary field. This 
will help to be able to understand the complex structure and interactions of the brain in 
normal and diseased states, with the aim to develop new therapeutic drugs. It is now well 
accepted that the brain can not just be seen as an accumulation of different cell types and that 
the neurons are not THE brain cell. The role of brain research will further increase since 
people get older and an increase in brain related diseases, like Alzheimer’s disease, is 
expected. The WHO estimates that neurological disorders will increase 12% from 2005 to 
2030. Among neurological disorders, 55% is contributed by cerebrovascular disease [11]. The 
physiological importance of the brain is also mirrored by the fact that the brain receives 15% 
of the cardiac output and consumes 25% of blood glucose, but represents only 2% of total 
body weight [12]. 
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3.2 The concept of a vascular blood-brain barrier. 
The concept of a blood-brain barrier (BBB) arose at the turn of the 19th to 20th century with 
the experiments of Paul Ehrlich (1885), when it was discovered that after intravenously, 
intraventricular or intrathecal injection of compounds or dyes no central action or staining of 
the brain could be observed. In the beginning, microscopy pictures did not give a hint that the 
capillaries of the brain are special and so Edwin Ellen Goldmann (1909), an associate of Paul 
Ehrlich, favoured the glial barrier. He also concluded that the main route of CNS nutrition is 
via the choroid plexus. In consequence in the 1920`s scientist didn’t see a role of the cerebral 
capillaries as a route of entry of nutrients and other essential substances. In 1933 Friedrich 
Karl Walter and Hugo Spatz made a clear distinction between the BBB and the blood-
cerebrospinal fluid (CSF) barriers. Experiments showed that the flow of the CSF is inadequate 
to support the gas exchange of the brain, and so the capillaries as route of supply became 
accepted. It took until 1940 when Tore Broman finally was able to situate the barrier at the 
level of the endothelial cells. By 1960, the concept of a BBB was viewed with scepticism by 
many, since the very small extracellular space seen under the electron microscope offered an 
easy explanation of the barrier phenomenon. This concept, on the other hand, could not be 
based on the old physiological experiments. In the consequence, during the early 1960s 
differing views concerning the nature of the BBB existed simultaneously: the BBB as 
vascular barrier, the BBB being due to an absence of extracellular space, and barrier because 
of metabolic limitation. In 1970 Emanuel Levin demonstrated that the absence of extracellular 
space was based on an electron microscopic artefact. The concept of a vascular barrier was 
finally accepted based on the findings of Thomas Reese and Morris Karnovsky (1967), 
showing that tight junctions are present in every interendothelial cleft examined, closing off 
the paracellular diffusion space. [13] 
 
 
3.3 Barriers of the brain. 
The blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB) maintain 
brain homeostasis by keeping brain interstitial fluid (ISF)* within the physiological range, 
partially protected from fluctuations within the blood, to maintain optimal conditions for 
neuronal function. The BBB is localized at the level of brain vascular endothelial cells (see 
section 3.3.1), the BCSFB at the level of the epithelial cells of the choroid plexus, between 
                                                 
* interstitial fluid (ISF), non-vascular extracellular fluid (ECF); ISF was cited in the literature as ECF 
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blood and ventricular CSF. There is also a third barrier, the arachnoid epithelium, which 
limits and regulates the molecular exchange between blood and subarachnoid CSF [14] (see 
Figure 1A). 
In vertebrates, the continuous inter-endothelial tight junctions were recognized as the 
morphological correlate of the BBB [15]. However, there are structures within the brain that 
lack an endothelial BBB and are collectively referred to as the circumventricular organs 
(CVOs) since they surround the ventricular system. These areas are located in the area 
postrema, lamina terminalis, subfornical organ, pineal gland [12, 16-17], organum 
vasculosum, median eminence, subcommissural organ [12, 17], posterior pituitary [12], and 
neurohypopphysis [16]. Capillaries within the CVOs are fenestrated, allowing free diffusion 
of proteins and solutes between the blood and CVOs [15]. Brain uptake rates for small solutes 
in these unprotected areas, representing less than 1% of the total cerebrovascular bed [18], 
exceed those of normal brain by 10- to 1,000-fold [17]. Neurons in the CVOs monitor 
hormones and other substances within the blood or secrete neuroendocrines into the blood 
[15]. They regulate autonomic nervous system and endocrine glands of the body [16]. A 
complex network of tight junctions connecting specialized ependymal cells (tanycytes) seal 
the CNS from the CVOs [15]. 
The endothelial cells of the choroid plexus also do not form a barrier and are fenestrated like 
those of the CVOs [15]. The choroid plexus is a villous structure that extends from the 
ventricular surface into the lumen of the four ventricles of the brain [15]. The choroid plexus 
consists of an extensive capillary network ensheathed by a single layer of epithelium, 
interconnected by tight junctions, forming a BCSFB [15]. Besides its barrier function, choroid 
plexus epithelial cells have a secretory function and produce the CSF that fills the ventricles 
and bathes the interstitium of the CNS [19]. 
 
 
3.3.1 The blood-brain barrier and the neurovascular unit. 
The BBB in vertebrates, excluding elasmobranch fishes [20-21], is located within the 
endothelium of the brain (micro)vasculature [22] (see section 3.3 and 3.3.1.1). The brain 
endothelial cells stand in close contact to neighbouring brain cells via physical and 
biochemical communication influencing each others properties. The network of neuro-glio-
vascular interactions (the so called neurovascular unit) is known to induce specific features of 
the BBB endothelial cells, like tightening the tight junctions and increasing the expression 
(and polarization) of transporters such as P-gp and GLUT1 [23] (see also Figure 6). The 
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neurovascular unit is a dynamic interface between the blood and the CNS that is involved in 
the regulation of blood flow and nutrient supply within the CNS [22], and in maintaining the 
neuronal microenvironment. 
The cellular and acellular components of the neurovascular unit are namely brain capillary 
endothelial cells (see section 3.3.1.1), the basement membranes (section 3.3.1.2), pericytes 
that reside within the basement membrane (section 3.3.1.3), astrocyte foot processes that 
ensheath almost the entire brain capillary network (section 3.3.1.4), perivascular microglia 
(section 3.3.1.5), and neurons (section 3.3.1.6) [23-24]. 
In so far as neurovascular signaling underlies normal BBB homeostasis, disruption in these 
networks may trigger BBB dysfunction in CNS disease [23]. BBB dysfunction has been 
observed in the majority of neurological diseases, e.g. stroke, head injuries, neurodegenerative 
diseases, bacterial and viral meningitis, encephalitis, and HIV-1 infection [25]. Therefore it 
has been proposed that treating brain diseases like Alzheimer’s disease should include in 
addition to neuroprotection also glioprotection and vasculoprotection (see Figure 5B) [23]. 
 
Figure 1: Barriers between blood and brain and the neurovascular unit.  
B) A) 
C) 
  
Figure legend see next page. 
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A) Barriers of the brain. There are three principal barrier sites between blood and brain interstitial fluid (labelled 
as ECF). (a) The BBB created at the level of the cerebral capillary endothelial cells by tight junction formation. 
It is the largest surface area for exchange and in the adult human is 12 - 18 m2 in surface area. No brain cell is 
further than about 25 µm from a capillary, so once the BBB is crossed, diffusion distances to neurons and glial 
cell bodies are short. (b) The BCSFB lies at the choroid plexuses in the lateral, third and fourth ventricles of the 
brain where tight junctions are formed between the epithelial cells at the CSF-facing surface (apical) of the 
epithelium. (c) The arachnoid barrier. The brain is enveloped by the arachnoid membrane lying under the dura. 
The arachnoid is avascular but lies close to the superior sagittal sinus and is separated from it by the dura. The 
arachnoid is a multi-layered epithelium with tight junctions between cells of the inner layer that form an 
effective seal. Arachnoid villi project into the sagittal sinus through the dura and a significant amount of CSF 
drains into the sinus through these valve-like villi which only allow CSF movement out of the brain to blood. 
Source: Figure 1 from Abbott et al. (2009) [26]; B) The neurovascular unit. The mature BBB consists of close 
association and physical contact between endothelial cells, neurons, astrocytic endfeet, basal lamina, and 
pericytes. The neurovascular unit not only enables efficient cellular communication for proper brain function, 
such as cerebral blood flow and neurotransmission, but also drives CNS angiogenesis and barrier formation 
during development. Source: Figure 5a from Tam and Watts (2010) [27]; C) The neurovascular unit (sagittal 
section). Source: [28]. 
 
 
3.3.1.1 Endothelial cells. 
Vascular system. The vascular system is diverse in structure, architecture, and physiology. An 
endothelium lines the entire vascular system and is composed of a monolayer of endothelial 
cells. In an adult, the endothelium consists of approximately 1 x 1013 endothelial cells forming 
an almost 1 kg organ [29], with a large surface of approximately 350 m2 [30]. 
Vascular and neural networks share physical space, as a result of parallel anatomical 
distribution and development, but share also growth factors and receptors [31]. Therefore, in 
the adult mammalian brain angiogenesis is tightly coupled to neurogenesis [31]. In the CNS 
the capillaries are only about 40 µm apart [32] [33] and neuronal cell bodies are about 10 µm 
from the nearest capillary [14] (8-20 µm [32]), so that every neuron is virtually perfused by its 
own capillary [32] [33].  
The principal functions of the endothelium include, in addition to it’s role as a permeability 
barrier [29], controlling cell and nutrient trafficking [34], and the control of blood flow and 
blood vessel tone [29, 34]. Furthermore, the endothelium is a multifunctional paracrine and 
endocrine organ [29], is involved in regulation of immune responses, vasculogenesis and 
angiogenesis [30], as well as production of extracellular matrix components [29]. 
 
Heterogeneity. Mature cerebral capillary endothelial cells of the BBB differ from other 
mammalian capillary endothelial cells. Endothelial heterogeneity occurs at multiple levels, 
between different organs, within the same organ [20], between endothelial cells in different 
portions of the vascular tree [29], between macro- and microvessels, between adjacent 
vascular segments [20], between arterial and venous endothelial cells [20, 35], and even 
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between adjacent endothelial cells [30]. Cells from different individuals can vary greatly in 
their response to stimuli, even when obtained from the same portion of the vasculature [29]. 
There are different morphologic phenotypes, classified as continuous, fenestrated or 
discontinuous [36] (see Figure 2). Continuous endothelium lines the large vessels and forms 
the capillaries e.g. in the heart, lung, skeletal muscle, and brain [36-37]. Fenestrated 
capillaries are found within endocrine and exocrine glands, kidney and intestine [36-37], 
choroid plexus [36], and CVOs [22] (see section 3.3). Discontinuous endothelium is a 
characteristic of the liver, spleen, and bone marrow [37]. 
Furthermore, endothelial cells differ in size, shape, thickness, orientation with respect to the 
direction of blood flow, and the nature of the endothelial cell junction [34]. They are 
heterogeneous in gene and protein expression [34], antigenic determinants, cell surface 
protein expression, patterns of glycosylation, enzyme activity, and metabolic properties [37].  
 
Determination of heterogeneity. The phenotypic heterogeneity of the endothelium is 
determined by a combination of genetic and environmental factors [34]. One of the important 
determinants of endothelial cell differentiation is the local environment, especially the 
interaction with surrounding cells [38]. Even small differences in expression and intracellular 
signaling between endothelial cells may account for large differences due to locally induced 
gene programs (e.g., soluble factors, cell-cell communication, synthesis and organization of 
matrix proteins) [34, 38]. For example, development of BBB characteristics in endothelial 
cells is induced by the neuroectodermal microenvironment and is not pre-determined, since 
non-brain vessels are able to gain BBB characteristics [22]. 
 
Functions of the BBB. Brain endothelial cells and their intercellular tight junctions form a 
cellular interface between the blood and the CNS. In addition to the physical permeability 
barrier, endothelial cells constitute a functional metabolic barrier [15]. All nutrients consumed 
by brain must pass this cellular barrier which at the same time protects the CNS from noxious 
substances in the systemic circulation [39]. Additionally, the endothelial cells affect 
homeostasis by adding or removing constituents from the brain interstitial space [18]. The 
barrier helps to keep the pools of neurotransmitters and neuroactive agents that act in the CNS 
and peripherally separate, so that similar agents can be used in the two systems without 
crosstalk [14]. Because of its large surface area (about 20 m2 per 1.3 kg brain) and the short 
diffusion distance between neurons and capillaries, the endothelium has a predominant role in 
regulating the brain microenvironment [14]. 
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BBB characteristics. The BBB endothelial cells differ from endothelial cells in the peripheral 
vasculature. Brain capillary endothelial cells are characterized by their small height, a low 
number of luminal caveolae [15] and cytoplasmic vesicles, a high mitochondrial content 
suggesting high metabolic activity [1, 22], the absence of fenestrae and an extremely low 
pinocytic activity inhibiting transcellular passage of molecules [15], along with specialized 
transport systems and complex tight junctions regulating traffic between blood and CNS [40]. 
Tight junctions between brain endothelial cells are the structural basis for the paracellular 
impermeability and high electrical resistance of the BBB endothelium [40] (see section 
3.3.1.1.1). The basal lamina surrounding brain capillary endothelial cells is common with that 
of the perivascular astrocytic endfeet and that of the pericytes [22] (see Figure 2C and section 
3.3.1.2).  
There are about 400 miles of capillaries in the human brain and more than 100 billion 
capillaries [33] (100 million capillaries [32]). The average luminal diameter is about 4.8 µm, 
smaller than the diameter of an erythrocyte [18]. Endothelial cells are thin (about 0.1 µm 
thick), giving them a cell volume of only about 20 µL/cm3 (1 µL/g brain) or about 0.2% of the 
total cell volume in brain [18, 41]. The cytoplasmic space separating the luminal (blood-
facing) and abluminal (facing brain parenchyma) capillary membranes is 300-500 nm in 
human brain microvessels [42]. All nutrients consumed by the brain must traffic through this 
cellular volume and across its two membranes that have an estimated surface area of 
approximately 240 cm2/cm3 [18]. 
The BBB acts as anatomical as well as biochemical barrier. The metabolic barrier is 
maintained by expression of a high number of transport systems and enzymes [15]. Luminal 
and abluminal membranes of brain capillaries are biochemical, and functional, distinct [43] 
(see section 3.6.1.1/2; see Figure 10). This polarity is a special feature of the BBB [42]. The 
two membranes are characterized by asymmetric qualitative and quantitative expression 
differences [42]. For example, alkaline phosphatase and γ-glutamyl transpeptidase are 
reported as being luminal markers, whereas Na+/K+-ATPase and 5´-nucleotidase activities 
seem to be specific for the abluminal membrane [43]. Cell polarization helps to direct the 
transport of solutes from the luminal to the abluminal membrane and vice versa [38]. For 
many BBB transporters, e.g. GLUT1 (Slc2a1, see section 3.6), abluminal-luminal membrane 
shifts have been found, also under normal physiologic conditions [42]. But differences in the 
expression of GLUT1 between adjacent endothelial cells can be greater than between the 
luminal and abluminal membranes [42]. 
 
3. Introduction.  16 
 
Figure 2: Different types of capillaries.  
  
Electron micrographs of several types of blood vessels (Source: Figure 2 a, b, c from Wolburg et al. (2009) 
[22]). a) Fenestrated capillary of the choroid vasculature of the mouse eye. The vessel is surrounded by a thick 
basal lamina (arrows, some fenestration); b) Muscle capillary in a human biopsy. The capillary is continuous, but 
the space between the capillary and muscle cell is large; c) Brain capillary in mouse (E, endothelial cell; P, 
pericytes). The capillary is continuous and closely integrated within the neuropil (NP). 
 
Localization of the BBB within the vascular tree [20]. The BBB phenotype has nearly 
exclusively been described in the endothelium of one particular branch of the microvascular 
tree, the capillary. The terms “capillaries” and “microvessels” are often used interchangeably, 
but the microvasculature is heterogeneous, comprised of arterioles (10-100 µm diameter), 
capillaries (4-10 µm), and venules (10-100 µm). 
In vivo, it is known that P-gp is highly expressed in cortical capillaries, but not by 
intraparenchymal or meningeal arterioles and venules. Na+/K+-ATPase is more abundant in 
arteriolar endothelial cells than in capillary and venular endothelia. Furthermore, the surface 
biochemistry is heterogeneous and there are structural distinctions along the brain 
microvascular endothelium. Therefore, different branches of the brain microvasculature may 
respond different to specific stimuli and the BBB may actually be the function of only a 
specific branch of the brain microvascular tree. Another possibility is that selected aspects of 
the BBB are differentially expressed by specific microvascular segments, with no segment 
representing the BBB in its entirety. 
Since in vitro BBB models usually represent a mixture of cells derived from different 
microvascular branches, together with the artefacts induced by culturing the cells (see section 
3.4.2), this is probably one of the reasons why it is not possible to obtain a phenotypic, in-vivo 
like BBB model (e.g., with high TEER). 
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3.3.1.1.1 Tight junctions. 
Endothelial (and epithelial) cells are interconnected by tight and adherens junctions [44]. 
Tight junctions are responsible for the polarization of the cell, separate the luminal from the 
abluminal membrane domain (“fence function”), and restrict the paracellular pathway 
between endothelial cells (“gate function”) [7, 22]. 
The structure of the tight junction in endothelial cells of BBB capillaries has been found to be 
the most complex among the entire vasculature of the body [22]. The complexity of the tight 
junction network, the number of tight junction strands, is proposed to be logarithmically 
related to the transcellular electrical resistance [22]. The BBB tight junctions are highly 
dynamic structures and are unique among all endothelial tight junctions in that their P-face / 
E-face particle association ratio equals one or is slightly higher than one (1.22) [22]. This 
indirectly indicates a close linkage to the cytoskeleton [38]. In non-BBB endothelial cells 
tight junctions are almost completely associated with the E-face. 
In addition, by comparing in vivo with in vitro data, the dependence of the barrier quality on 
the brain microenvironment, including the basal lamina, pericytes, astrocytes, and microglia, 
has been indicated [22]. The electrical resistance across the tight brain endothelium in vivo is 
reported to be 2,000 Ω•cm2 [45] - 8,000 Ω•cm2 [41, 46], in peripheral capillary endothelial 
cells this value is much lower, e.g. 20-30 Ω•cm2 in muscle capillaries [47]. The 
transendothelial resistance measured in in vitro BBB models compared to the in vivo situation 
is much less (approximately 100-fold) [41] (see Figure 6). 
The molecular components of tight junctions can be separated into different classes, the 
integral membrane proteins (e.g. occludin, claudins) and the adaptor proteins (e.g., ZO-1, ZO-
2, ZO-3) over which the tight junctions are linked to the actin cytoskeleton [15]. Occludin and 
claudin family members are proteins with four transmembrane domains and two extracellular 
loops [22]. Occludin was the first tight junctional transmembrane molecule discovered [48]. It 
seems that occludin has a function in tight junction modulation via the induction of 
intracellular signaling rather than participating directly in the formation of tight junction 
strands [22-23]. In contrast, the claudins are required to establish barrier properties and are 
sufficient for the formation of tight junction strands [15]. At present, the claudin family 
contains 24 members [15], with claudin-3, claudin-12, and claudin-5 found to be expressed in 
the BBB. Claudin-5-deficient mice have normal tight junction morphology but exhibit size 
selective (<800 Da) opening of the BBB [49] (see Figure 3). In rat brain capillaries, 
expression of claudin-5 mRNA was found to be 751-fold greater than that of claudin-12 [50], 
suggesting that claudin-5 plays the key role in establishing a tight BBB. 
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Figure 3: The tight junctional protein claudin-5 (Cld5) is establishing a tight blood-brain barrier.  
   
Impairment of the BBB in the Cld5-/- brains of 18.5-d embryos. Primary amine-reactive biotinylation reagent 
(443 Da) was perfused from the heart of resuscitated embryos. After 5-min incubation, sagittal frozen sections 
from the whole body were incubated with HRP-conjugated streptavidin. In the wild-type mouse (a) the reagent 
was completely excluded from the brain (arrow) and the spinal cord (arrowhead). In the Cld5-/- mouse (a´) the 
CNS showed intense peroxidase activity. Bar: 2 mm. Source: Figure 5 a, a´ from Nitta et al. (2003) [49]. 
 
 
3.3.1.2 Basement membranes. 
The basement membrane at the BBB plays important roles in maintaining the capillary vessel 
morphology and in cell adhesion [51]. Furthermore, basement-membrane related molecules 
are reported to be associated with cell proliferation, extracellular proteolysis [51], and 
signaling properties [22]. This acellular layer separates tissue compartments, physically limits 
BBB permeability, and contributes to microvessel integrity and function [15]. 
At the level of smaller vessels (precapillary arterioles and postcapillary venules) two 
basement membranes can be distinguished, an endothelial cell basement membrane 
underlying the endothelium, and an astroglial (parenchymal) basement membrane underlying 
the astrocyte endfeet [15, 22]. However, in brain capillaries they fuse to form one basement 
membrane [15, 22]. The negatively charged basement membrane is almost as thick as the 
endothelial cytoplasm (in human 200 nm [42]) and is possibly involved in the movement of 
(charged) solutes between blood and brain extracellular fluid [52]. 
Endothelial and parenchymal basement membranes differ biochemically and are complex 
assemblies of four major glycoprotein families, namely laminins, collagen type IV isoforms, 
nidogens, and heparan sulphate proteoglycans [15]. Only two laminin isoforms, laminin 411 
(composed of laminin α4, β1, γ1 chains) and laminin 511 (α5, β1, γ1) are found in the 
endothelial basal lamina [15]. In contrast, the parenchymal basement membrane contains 
laminin 111 (α1, β1, γ1) and laminin 211 (α2, β1, γ1) [15]. Laminin α4 and α5 are produced 
by brain endothelial cells, laminin α1 by leptomeningeal cells, and laminin α2 by astrocytes 
[15]. Collagen type IV [15] and agrin [22], an extracellular heparan sulphate proteoglycan, 
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have been shown to be important for structural integrity of the BBB. In another study an 
elevation of the TEER in in vitro cultured brain capillary endothelial cells by laminin and 
collagen type IV could be shown [53]. 
 
 
3.3.1.3 Pericytes. 
Pericytes are the cells situated closest to the brain endothelial cells and share a common 
basement membrane [24] (see Figure 1B/C). Pericytes are completely surrounded by a basal 
lamina [22] and are located luminal to parenchymal cells [54] and abluminal to brain capillary 
endothelial cells, covering 20-30% of their surface [55]. There is about one pericyte for every 
two to four endothelial cells [56]. The distribution of pericytes and the degree of coverage of 
the vascular endothelium varies among different vessel types [44]. In the larger vessels 
(arterioles, arteries and veins), smooth muscle forms a continuous layer, replacing pericytes 
[14]. Pericytes form direct contacts with vascular endothelial cells in vivo [24] via long 
cytoplasmic processes along and around capillaries [44]. 
 
Function. Pericytes are thought to be local regulatory cells and important for the maintenance 
of homeostasis and hemostasis [54]. Reciprocal interactions between pericytes and 
endothelial cells play a role in angiogenesis of the nervous system, and in formation, 
maturation, maintenance, and regulation of normal BBB structure and function [22, 24]. 
Pericytes do so not only through direct contact, but also through matrix deposition and 
activating signals promoting endothelial cell differentiation [44]. Pericytes may also be key 
cells in the maintenance of the basement membrane at the BBB [51] (see section 3.3.1.2). 
Pericytes are multipotential stem cells in the adult brain [54], and some BBB pericytes might 
have the capacity to phagocytize exogenous proteins and present antigens [44]. In addition, 
pericytes express receptors for a number of vasoactive mediators, suggesting a role in cerebral 
vascular autoregulation [23]. Furthermore, pericytes have contractile capabilities and play a 
role in blood flow regulation by controlling the capillary diameter in response to neuronal 
activity [57]. Loss or injury of pericytes, leads to formation of microaneurysms and 
hemorrhage [23]. 
 
Pericytes-endothelial cells interactions. Due to structural proximity, bidirectional signaling 
between endothelial cells and pericytes [58] via direct cell-cell interaction or by release of 
growth factors and cytokines is possible [59]. 
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Pericytes regulate microvascular permeability, remodelling and angiogenesis [44]. Pericyte-
derived angiopoietin-1 (Ang-1) which binds to the endothelial receptor tyrosine kinase Tie-2 
induces remodelling and stabilization of the vasculature and therefore decreases its 
permeability [60]. In vitro the effects of Ang-1 have been shown to occur through induction 
of occludin gene expression [61]. TGF-β produced by pericytes impairs the normal actin 
network in endothelial cells, leading to increased BBB permeability [58]. TGF-β1, however, 
which is likely expressed by both endothelial cells and pericytes [60], induces barrier 
functions by inhibiting migration and proliferation of endothelial cells and pericytes. 
Platelet-derived growth factor (PDGF)-B produced by endothelial cells binds to its receptor 
PDGFR-β on pericytes, consequently recruiting pericytes near the endothelial cells and 
leading to vascular maturation [44, 60]. Pericytes migrate away from brain microvesssels in 
response to hypoxia or brain trauma, conditions which are associated with increased BBB 
permeability and disorganization of actin filaments in endothelial cells [44]. 
In vitro BBB models have shown significantly increased TEER values in models 
incorporating pericytes with endothelial cells and astrocytes, as compared to models 
combining only endothelial cells and astrocytes [15, 62]. This effect seems to be species 
dependent. Pericytes-endothelial interactions in a rat in vitro model showed an endothelial 
barrier tightening effect [24] (see Figure 6). In contrast, pericytes-endothelial interactions in a 
porcine in vitro co-culture model resulted in a decrease in barrier tightness due to increased 
matrix metalloproteinase (MMP)-9 secretion by the endothelial cells [59]. 
 
 
3.3.1.4 Astrocytes. 
All vertebrates started out with a glial BBB 4-500 million years ago, and elasmobranch fishes 
(sharks, skates, rays) still have a glial barrier [21]. Astrocytes are the most abundant cells in 
the brain [63]. Anatomically, most astrocytes have stellate shapes with multiple processes 
[63]. Through these processes, one astrocyte can contact several neuronal synapses and 
cerebral blood vessels [64], making it possible to integrate signals generated from both cell 
types [63] (see Figure 4). The distance between the astrocyte foot process and the capillary 
endothelial cells and the pericytes is only 20 nm [56]. 90% [44] - >99% [39] of the abluminal 
surface of the cerebral microvascular endothelium is ensheated by astrocytic endfeet, a unique 
feature of CNS capillaries [65] (see Figure 1B/C). Astrocyte endfeet wrapping around 
capillary endothelial cells have a mean diameter of 4-8 µm [66]. Astrocytes each cover a 
territory of about 30-80 µm [66] and show a number of different morphologies, depending on 
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their location and association with other cell types [14]. Eight of eleven known astrocyte 
phenotypes specifically interact with blood vessels [14]. In the past, astrocytes were 
considered just glue providing physical support for neurons [63]. Today, astrocytes are known 
to play active roles in various brain functions [63]. 
 
Figure 4: Astrocyte processes covering vessels in 8-10 weeks old male rats.  
 
Not all vascular astrocytic endfeet processes are GFAP (glial fibrillary acidic protein) positive. A) GFAP 
immunolabeling of astrocytes in cortex. Individual astrocytes are star-shaped and distributed symmetrically, with 
minimal contact with neighboring astrocytes. Vascular processes differ from other processes by being straight, 
unbranched, and of wide diameter (red arrowheads). Inset: an astrocyte with two vascular processes; B) Double 
immunolabeling of aquaporin-4 (AQP-4; red) and GFAP (green). AQP-4 immunolabeling of astrocytes reveals 
that the entire network of vessels, including capillaries, is covered by astrocytic processes, albeit GFAP negative. 
Smaller vessels and capillaries are mostly GFAP negative but display intense AQP-4 labeling. The AQP-4 
labeling reveals continuous coverage by astrocytic end feet. Source: Figure 1 A, B from Simard et al. (2003) 
[66]. 
 
Functions. It has been shown that astrocytes participate in synapse formation and function 
[44, 63], regulate the strength of synaptic transmission [66], and control adult neurogenesis 
and cerebral vascular tone [44]. Astrocytes are also involved in the maintenance and control 
of brain ISF’s pH and ion concentrations (e.g., potassium clearance [67]), in maintaining ISF 
glutamate concentration low [39, 68] (see section 3.5.3.2), in nutrition of neurons [39] (e.g., 
glycogen stores [67]), and in the process of gliotransmission [63]. Furthermore, astrocytes 
function as adult neural stem cells [63]. 
Astrocytes are electrically nonexcitable cells that are interconnected by gap junctions 
allowing long-distance communication through calcium waves [66], the so called glial 
syncytium [67]. In cell culture, stimulation of single astrocytes resulted in expanding waves 
engaging >20-100 neighboring astrocytes [66]. In brain, an increase in astrocytic intracellular 
calcium concentrations regulates arteriole diameter [57]. Astrocytes are sensors of neuronal 
activity, for example responding to synaptic release of glutamate with elevations in the 
intracellular calcium concentration triggering the release of vasoactive compounds such as 
eicosanoids [64]. The calcium waves can also be transmitted to neighbouring neurons [66]. 
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Astrocytic endfeet show a high density of AQP-4 (see Figure 4) and Kir4.1, which are 
involved in ion and water regulation [23], and of which the localization is dependent on the 
basal lamina protein agrin [14] (see section 3.3.1.2). 
Astrocytes are less sensitive to glutamate excitotoxicity than neurons, they even can survive a 
glutamate concentration of 10 mM [67]. Ischaemic conditions are characterized by cell 
swelling and glutamate release in the extracellular space through reversal of glial glutamate 
transporters [67] (see addendum). Astrocytes showed a neuroprotective function in 
moderately increased extracellular glutamate concentrations but seem to amplify the damage 
under conditions of severe ischaemia [67]. 
Astrocytes show altered gene expression, hypertrophy and proliferation as response to injury, 
infection and degenerative diseases of the CNS, a process known as reactive astrocytosis [39]. 
 
Figure 5: Astrocytes-endothelial signaling interactions and importance of glio- and vasculoprotection.  
A) 
 
B) 
 
 
A) Astroglial-endothelial signaling interactions. Astrocytes are strongly implicated in induction of certain BBB 
characteristics such as tighter tight junctions, specialized enzyme systems, and polarized transporter localization 
(1). In addition they also play key roles in gliovascular signaling and in the regulation of brain water and 
electrolyte metabolism under normal and pathological conditions (2). GDNF, glial cell line-derived neurotrophic 
factor; IL-6, interleukin-6; bFGF, basic fibroblast growth factor; TGF-β1, transforming growth factor β1; A1, 
angiopoietin; LIF, leukaemia inhibitory factor; γGT, γ-glutamyl transpeptidase; AAD, aromatic acid 
decarboxylase; AP, alkaline phosphatase; two filled circles, AQP-4; one dashed circle, agrin; one open circle 
with two arrows, potassium channel Kir4.1. Source: Figure 3 from Correale and Villa (2009) [44]; B) Schematic 
for the hypothesis that true neuroprotection must be accompanied by glioprotection as well as vasculoprotection. 
In addition to preventing neuronal death, salvaging glial and vascular compartments should also help preserve 
coupling within the entire neurovascular unit that underlies functional integrity in the brain. Source: Figure 3 
from Lok et al. (2007) [23]. 
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Astrocytes-endothelial cells interactions. Astrocytes can be seen as mediators between 
endothelial cells and neuronal activity and are known to regulate BBB function [14, 25, 39, 
69] (see Figure 5A). Inductive influences from astrocytes contribute to the differentiation of 
the specialized BBB phenotype of the brain endothelium [15], also in non-neural vascular 
endothelial cells [70-71]. It seems that astrocytes may play a role in barriergenesis [63], the 
maturation of the BBB [22, 65], rather than in angiogenesis, since the period of astrocyte 
differentiation coincides with that of BBB formation [63], but vessel sprouting is completed 
before birth [63].  
Astrocytes have been reported to mediate the induction of several BBB features, for example 
by: (1) induction and maintenance of tight junctions, resulting in an increase of the TEER [14, 
25, 44, 72]; (2) the upregulation of expression as well as polarized localization and activity of 
transporters (P-gp, GLUT1) [14, 44]; (3) the upregulation of expression and localization of 
enzyme systems [14, 44] (γ-GTP† [14, 72], alkaline phosphatase [72]); (4) the increase of 
neutral amino acid transport [72]; (5) an increase of Na+/K+-ATPase [72]; (6) the stimulation 
of glucose uptake [72]; (7) the correct association of endothelial cells and pericytes in tube-
like structures in vitro [14, 72]; (8) and the modulation of endothelial differentiation [25]. 
Like mentioned under (4), astrocytes increase the endothelial transport of neutral amino acids, 
which is in the case of leucine due to increased transport efficiency [73]. Like mentioned 
under (6), conditioned medium from glucose-deprived astrocytes increased endothelial 
GLUT1 expression and glucose uptake, whereas that from normal astrocytes didn’t show this 
effect [74]. 
Astrocytes secrete a large number of factors, many with matching receptors on brain 
endothelial cells [14] (see Table 1). Since the two cell types are separated by a basement 
membrane, inducing factors are likely to be small molecular weight molecules [15]. These 
factors, which can induce aspects of the BBB phenotype in endothelial cells in vitro, include 
TGF-β, GDNF, bFGF, and Ang-1 [14, 23, 73] (see Figure 6). For example, TGF-β1 reduces 
occludin gene expression in brain capillary endothelial cells [61]. Another astrocytic released 
factor, thrombospondin-1 (TSP-1), is known to influence both endothelial cells and neurons, 
for example promotes synaptogenesis and anti-angiogenesis [60]. Lee et al. [75] showed that 
SSeCKS overexpression in astrocytes triggers vessel maturation, results in tighter tight 
junctions and may therefore be involved in BBB barriergenesis. 
Induction of the BBB phenotype is a two-way process, with endothelial cells known to 
enhance growth, induction and differentiation of astrocytes [14, 23]. Also the extracellular 
                                                 
  γ-GTP, γ -glutamyl transpeptidase 
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matrix is believed to contribute to the inductive communications between endothelial cells 
and astrocytes [14]. Astrocytic differentiation is induced by leukaemia inhibitory factor (LIF), 
a factor secreted by endothelial cells [14, 23, 60]. Furthermore, co-culturing astrocytes with 
endothelial cells results in the upregulation of antioxidative enzymes in both cell types [14, 
23]. In conclusion, astrocytes upregulate the physical, transport, and metabolic barrier 
properties of endothelial cells, mirrored by the fact that astrocyte foot-processes facing the 
abluminal endothelial membrane are also polarized [42]. 
 
Table 1: Astroglial-derived factors that regulate BBB and / or epithelial barrier functions.  
  
Source: Table 1 from Savidge (2007) [39]. 
 
 
3.3.1.5 Microglia cells. 
The cerebral perivascular macrophages, also named perivascular microglia, are in close 
contact with cerebral blood vessels [44]. They are derived from leptomeningeal mesenchymal 
cells or from circulating monocytes [31]. Microglia express molecules involved in antigen 
recognition, antigen presentation and co-stimulation [44], and can release a large number of 
immunoregulatory, inflammatory, and cytotoxic mediators [60]. Microglia play an essential 
role in the immune response and become activated in response to brain injury and 
immunological stimuli [76]. In the absence of pathology, the microglia are cells with small 
bodies and long, thin processes. During activation, microglia transform finally to a 
phagocytotic form. [31] 
 
Microglia-endothelial cells interactions. Microglia are found in the perivascular space, 
indicating that interactions between microglia and endothelial cells play a role in BBB 
physiology [60]. Culture of brain capillary endothelial cells with human blood-derived 
macrophages has been shown to decrease paracellular permeability [44, 60]. On the other 
hand, microglia are a source of tumor necrosis factor (TNF)-α which is known to disrupt tight 
junctions [60]. In an in vitro BBB model in which rat brain endothelial cells were co-cultured 
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with microglia, Sumi et al. [76] showed that lipopolysaccharide (LPS) activates microglia to 
induce functional impairments of the endothelial barrier by producing reactive oxygen 
species. Oxidative stress causes BBB disruption, degradation of basement membrane proteins, 
and enhanced tyrosine phosphorylation of tight junction proteins [77]. Finally, microglial 
activation and subsequent neuroinflammation are considered to be responsible for the 
progression of neurodegenerative diseases like Alzheimer’s- and Parkinson’s disease [76]. 
 
 
3.3.1.6 Neurons. 
Blood vessels and neurons use similar guidance cues [60] and are connected via extensive 
innervations [64]. In addition, astrocytes are closely located to the synaptic cleft [64]. 
Therefore, neuronal endings can either innervate the capillary endothelium directly or 
indirectly by innervating the astrocyte foot processes [23, 41]. The reciprocal interactions 
between blood vessels and neurons are involved in neurogenesis [23] and play essential roles 
for the neurovascular network and normal brain function [60]. Signaling pathways between 
the different cell types, the so called neurotrophic coupling, provide a specific extracellular 
environment for each cell type as well as for the neurovascular unit as a whole [23]. 
 
Neurons-endothelial cells interactions. The neuronal release of histamine, which transiently 
opens the BBB and allows the passage of growth factors and antibodies into the brain from 
plasma, or to sample plasma composition, is an example of direct neurovascular coupling [14, 
23]. The indirect neurovascular coupling via astrocytes is exemplified by the stimulation of 
glucose uptake into brain via endothelial cells by histamine and ATP released by astrocytes in 
response to neuronal firing [14, 23] and hypoglycemic conditions [23]. Furthermore, 
activation of neurons in a specific brain region increases blood flow [64]. This coupling of 
neuronal activity to cerebral blood vessel responses is known as functional hyperemia [64], 
and is proposed to include a triggering of astrocyte calcium oscillations through synaptically 
released glutamate, which then regulates the release of vasoactive agents like nitric oxide 
(NO) [23] from astrocyte endfeet, leading to increased cerebrovascular blood flow [64]. 
Neural precursor cells (NPCs) have been shown to reduce proliferation and increase TEER of 
the rat BBB [78]. In addition, endothelial cells release soluble factors that stimulate 
proliferation of neural stem cells [23, 78] while inhibiting their differentiation [78]. 
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3.4 Measuring transport processes across the BBB: in vivo and in vitro 
methods. 
The lack of knowledge regarding BBB transport systems arrives mainly from the limitations 
of techniques available to study transport across the BBB, especially in the direction from 
brain to blood [79]. In addition, most of the transport studies have been performed using 
animal models in vivo, which do not enable investigation of the BBB at the cellular level [79]. 
Data obtained by in vivo methods serve as reference for in vitro or in silico data, since they 
have been obtained in the normal physiological brain environment. In vitro BBB models are 
commonly used to assess the permeability of new therapeutic drugs, to test their efficacy and 
brain penetration. A major problem in the pharmaceutical industry is that more than 98% of 
candidate CNS-targeting drugs show poor permeability across the BBB [80]. The 
development of an in vitro cell system that mimics the BBB in vivo is important to be able to 
understand the functional biology of the BBB and to study the direct effects of different 
conditions on the brain endothelium. To be valid, in vitro BBB models must guarantee 
selective permeability to molecules, high predictability and reproducibility while being fully 
scalable and customizable [81]. 
 
 
3.4.1 In vivo methods. 
Transport polarity and its physiological significance for BBB function are difficult to study by 
in vivo techniques, since they measure at best net transendothelial flux across both membranes 
[82]. Thus, it is difficult to determine the individual contributions of the luminal vs. abluminal 
membranes. By measuring blood to brain transport, with the luminal membrane having direct 
access to the material injected into the vascular system, the only variables that can be 
measured directly are the concentration in the infusion medium and the accumulation of label 
in brain tissue [82]. 
Data interpretation is further complicated by the presence of transport systems in the choroid 
plexus, and the impact of endothelial cell metabolism and substrate binding on the 
transendothelial transport measured [82]. 
One important set of in vivo data would be measures of transport kinetics. This is very 
difficult, since the obtained values represent transport across two membranes in series [79] 
and since the artificial injection solution will mix with the plasma [82-83], therefore the 
measured Km will always be higher than the actual value [83]. 
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A promising approach is coupling of the different perfusion methods with imaging methods 
like autoradiography, intravital microscopy, and positron emission tomography (PET). And 
by using knockout (KO) animals it is possible to distinguish different transporters and their 
role in vivo [84]. 
 
Intravenous injection. To study the rate of brain penetration, the solute of interest can be 
administered intravenously to an animal. After, the solute concentration at different time 
points in brain, plasma, and CSF can be determined, reflecting their distribution between 
blood and brain or blood and CSF. “The method has the advantage that the system is intact, 
all transporters, junctional proteins, and enzymes are present at their physiological 
concentration, the unique architecture of the blood vessels and perivascular cells is present 
and undisturbed, cerebral metabolic pathways are not compromised and regulatory pathways, 
neuronal input, and second messenger systems have not been damaged or altered. In addition, 
it allows accurate incorporation of exchange and contributions of CSF and choroid plexus 
pathways.“ [85] On the other hand, the in vivo BBB is a very complex system and it can be 
difficult to determine the role of the single components. Also only limited control of the 
plasma levels of e.g. amino acids is possible, which makes it difficult to study the role of 
single transporters. The situation is further complicated by metabolism occurring in the liver 
and other organs. [85] 
 
In situ perfusion. Contrary to the intravenous injection method, in the in situ perfusion method 
the animal’s blood is replaced by a vascular perfusion fluid. The advantage of this method is 
that the solute concentration in the perfusion fluid can be altered over a large range. It is 
possible to characterize saturable transport, plasma protein binding and the effects of 
substances like hormones. Furthermore, artefacts due to metabolism in other organs are 
minimized since the solutes enter brain directly. On the other hand, as for the intravenous 
injection method, it can be difficult to determine the role of the individual components of the 
in vivo BBB. [85] 
 
Brain efflux index. Microinjection of radioactive labeled substances and a non-permeable 
reference substance, e.g. inulin, directly into the brain of the animal can be used to study 
mechanisms of brain to blood efflux. The ratio of test substance to inulin in brain and blood is 
determined at different time points and expressed as brain efflux index (BEI) value. The BEI 
value of a solute tells how much of it is transported from brain to blood and how much is 
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remaining in brain. A disadvantage of this technique is that BBB damage from needle tract 
injections may alter BBB transport or blood flow. [85] 
 
Intracerebral microdialysis. To perform microdialysis experiments, a semipermeable 
membrane with a catheter inside is implanted into the brain. Substances can be either perfused 
over the catheter, administered orally or intravenously. By using this method it is possible to 
sample the perfusate continuously, to gather concentration-time profiles, and to compare brain 
uptake or efflux in different brain regions. Advantages of intracerebral microdialysis include 
the possibility to determine the brain interstitial fluid (ISF) concentrations and to study the 
kinetics of solute exchange between plasma and brain ISF. Disadvantages of this technique 
are due to damage of the BBB and brain cell membranes due to microdialysis probe insertion 
which can cause overestimation of transport rates, especially for polar substances. [85] 
 
Isolated brain capillaries. The major advantage of this method is the close similarity to in 
vivo conditions, but it also allows studying molecular events underlying endothelial cell 
function [84]. By using isolated microvessels it is possible to control the external substrate 
concentration, and to measure mainly transport from the abluminal to the luminal side [84]. 
But since both membranes face the compound [84], it is still difficult to distinguish the 
contribution of the single membranes [82]. Furthermore it is difficult to distinguish whether 
the substrate has actually entered the endothelial cells or is membrane bound or retained in the 
lumen of the capillary [82]. In addition, cells in isolated microvessels are leaky and depleted 
in ATP (only 5-10% of the normal cellular concentration [86]), therefore not metabolically 
normal [82, 86]. But the cells are still able to sustain active amino acid transport and maintain 
the concentration gradients of amino acids between the capillary lumen and the medium [86]. 
 
Isolated membrane vesicles. Betz et al. (1980) [43] for the first time isolated brain 
microvessel membrane vesicles. Vesicles can be used to analyse the transport properties, 
including the kinetics [79, 82] of luminal and abluminal membranes of the BBB separately 
[85] and to study the expression and activity of specific transport systems, as well as their 
polarized function under different conditions [85]. Vesicle studies have the advantage that 
conditions on both sides can be controlled, that vesicles have almost no internal metabolism 
eliminating the need to work with substrate analogues, that binding controls can be included, 
and that more studies can be performed than with intact tissues [82]. Vesicle studies have the 
disadvantage of working with unpure fractions, with luminal and abluminal membrane-RICH 
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fractions [79], distinguished based on unspecific marker proteins [87]. Therefore, corrections 
must be made for contamination. Further, the isolation procedure may alter the characteristics 
and regulation of transporters [85]. 
 
 
3.4.2 In vitro models. 
In general, by performing in vivo studies, one cannot distinguish between different functions 
of the luminal and abluminal membrane in the transendothelial transport process [1]. In vitro 
models may not represent an intact in vivo system, e.g. the permeability of endothelial cells in 
vitro is generally greater than in vivo [88], but they can be used to estimate luminal to 
abluminal or abluminal to luminal transport. In vitro cell cultures have many advantages, 
including suitability for studying molecular mechanisms of transport in detail, and the 
opportunity to use human tissues, and to minimize animal studies [88]. In vitro models can be 
used to manipulate experimental conditions [88], to determine and influence BBB 
permeability, and to examine the effect of various normal and pathological conditions on the 
BBB [84]. To be valid, in vitro models need to fulfil a number of criteria, e.g. display a 
restrictive paracellular pathway [89], complex tight junctions and a “physiological relevant 
morphology”, the functional expression of the BBB transportome, as well as a good screening 
capacity [84]. Youdim et al. [90] also mention that often underestimated physiologically 
relevant in vitro conditions can affect permeation of compounds, e.g. pH (at luminal 
membrane ~7.4; at abluminal membrane ~7.33), serum protein concentration (blood ~6-8% of 
plasma, w/v; ISF and CSF ≤1/200 of the concentration in plasma), and cellular retention. 
Disadvantages of using in vitro models include that transport [2, 80, 88] and metabolic 
properties of cultured cells can vary depending on whether the cells are primary cultures, 
passaged cell lines, or transformed cell lines [88]. Cell properties also vary depending on the 
number of times the cells have been passaged, and the heterogeneity of the cell line [80, 88]. 
It is reported that endothelial cell cultures derived from populations of larger brain 
microvessels (>112 µm) grow quicker than cells from capillaries. Therefore, cultures derived 
from mixtures of brain microvascular endothelial cells might actually represent cultures of 
larger cells (see also section 3.3.1.1). [20] With serial cell passage in vitro conditions affect 
the dedifferentiating process and enhance the loss of BBB characteristics [25]. Even the 
properties of an individual cell line may vary depending on seeding density, stage of 
confluency and cellular differentiation, and on the presence or absence of essential nutrients, 
growth factors, or associated cells [88]. Brain endothelial cells, for example, lose the BBB 
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phenotype in cultures in the absence of cross-talk with other members of the neurovascular 
unit (see section 3.3.1 and Figure 6). 
 
Figure 6: Transendothelial electrical resistance (TEER) and endothelial permeability coefficient for sodium 
fluorescein (Na-F Pe) of different rat BBB in vitro models.  
 
 
 
TEER expressed as Ω•cm2, Na-F Pe, expressed in 10-6 cm/s. All data are presented as means ± S.E.M (n = 8). 
Statistically significant differences (P <0.05) in TEER are indicated compared to E00 (a), EA0 (b), E0A (c), EP0 
(d), E0P (e) and EAP (f), whereas these in Pe are indicated compared to E00 (A) and E0A (B), respectively. E, 
brain endothelial cells; A, astrocytes; P, pericytes; E00, endothelial cell monolayer; EA0, astrocyte-endothelial 
contact co-culture; E0A, astrocyte-endothelial non-contact co-culture; EP0, pericytes-endothelial contact co-
culture; E0P, pericytes-endothelial non-contact co-culture; EAP / EPA, triple co-culture models. Source: Figure 
4 from Nakagawa et al. (2009) [24]. 
 
Primary or low passage brain capillary endothelial cell culture. Primary cell cultures of 
freshly isolated cells retain many of the morphological and biochemical properties 
characterizing the BBB in vivo, including polarized expression of enzymes, transporters, and 
receptors, and complex tight junctions [84, 88]. Due to brain size and availability, bovine and 
porcine tissues have been the preferred source for brain endothelial cells, with almost as high 
TEER values as obtained in vivo [84]. Human material is, due to ethical reasons and due to 
constraints in obtaining large and fresh quantities, usually not an option [85]. But due to 
species specific differences in the transportome it remains an important source for the study of 
particular brain diseases and accurate prediction of drug permeability [84]. Rat in vitro 
models are of special interest since rats have extensively been used in in vivo studies, whereas 
mouse in vitro models offer the possibility to work with knockout and disease models [84]. 
The neurovascular unit has an important function in establishing BBB properties (see section 
3.3.1) and therefore several approaches to mimic this influence have been used [25]. The first 
approach is to co-culture brain endothelial cells with primary astrocytes or glial cells 
(astrocytes, oligodendrocytes and microglia) [85] (see section 3.3.1.4 and Figure 6). For this 
purpose, the Transwell system, a bi-dimensional diffusion system where cells are cultured in 
contact or non-contact (on the bottom of the well), can be used [85]. A disadvantage of the 
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Transwell system is the irregular patterns of cell adhesion (“edge effect”) which may impede 
the measurement of BBB permeability [25]. Another option is to use astrocyte-conditioned 
media, harvested from growing astrocyte cultures [25]. A third approach to mimic in vitro the 
tight in vivo BBB endothelium is to substitute the tissue culture medium with different factors 
like cAMP, and glucocorticoids, or by growing the cells on an extracellular matrix. A lack of 
laminin (see section 3.3.1.2), and of luminal flow (see under “three dimensional BBB 
models”), has been shown to lead to an increased cell cycle rate and to cause endothelial cells 
to “pile up in a multilayer fashion” [25]. 
 
Immortalised brain endothelial cell lines. The advantage of using immortalized cell lines is to 
work with a relatively consistent system [84]. On the other hand, they generally fail to 
generate a sufficiently restrictive paracellular barrier [89]. Also gene expression differs from 
that in vivo (b.End5) [2], and the transport function was shown to be affected, with 20% of in 
vivo glucose transport being retained (TM-BBB) [80]. The rat RBE4 cell line is the most 
extensively characterized immortalized brain endothelial cell line and retains the expression 
of many typical endothelial markers. The same is true for human cell lines such as SV-HCEC 
or hCMEC/D3 [84]. A murine brain endothelial cell line (cEND) is reported to form tight 
monolayers under influence of hydrocortisone [84]. 
 
Cell lines of non-cerebral origin. All cell lines that meet at least some of the criteria of an in 
vitro BBB permeability model can be used. The epithelial cell lines from the intestine (Caco-
2) and the kidney (MDCK), as well as the ECV304 cell line, a clone of human bladder 
carcinoma, are currently used. These cells differ in morphology, cell-cell junctions, and gene 
expression compared to BBB endothelial cells. Furthermore, they lack expression of 
endothelial specific proteins like the vascular endothelial adherens junction protein (VE-
cadherin) and the platelet-endothelial cell adhesion molecule (PECAM). [84] 
 
Three-dimensional BBB models. Endothelial cells in vivo are long-lived cells which are 
continuously exposed to shear stress [85]. Intraluminal flow is important to maintain the BBB 
phenotype and is known to affect endothelial signalling pathways [89], cell differentiation, 
tight junction formation, and to induce metabolic changes and mitotic arrest [81]. The 
dynamic in vitro BBB model (DIV-BBB) is comprised of a hollow fibre tube that allows to 
co-culture brain endothelial cells (intraluminally) and glial cells (extraluminally) under flow 
[84]. DIV-BBBs enable maintenance of in vivo-like conditions, such as shear stress (4 
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dyn/cm2), oxygen and glucose homeostasis [81]. Furthermore, they reduce the unstirred water 
layer (UWL) on the luminal side to physiological values and therefore enable measurement of 
in vivo-like permeability (passive transport)[90]. 
Brain slices. By using brain slices it is theoretically possible to examine the interactions 
between the different brain cells similar to the in vivo situation [85], especially the role of 
neuronal modulation on the BBB [84]. 
 
 
3.5 Role of amino acids for brain function. 
3.5.1 General aspects of brain energy metabolism. 
The total cerebral resting metabolic rate in adults is ~20% of the whole body metabolism, 
about 0.25 kcal/min [68]. Approximately 75% of the energy consumed by brain is related to 
signaling, the remaining 25% serves to maintain cellular activities like protein synthesis, 
protein degradation, and nucleotide turnover [68]. Since the brain cannot store glucose, it is 
dependent on a continuous supply of oxygen and energy-yielding substrates via the 
circulation [68]. Astrocytes account for 20% of the oxidative glucose metabolism in the 
human brain cortex, and are in a position to control the microenvironment of brain by 
transmitting signals and buffering metabolism [91] (see section 3.3.1.4). Most of the 
metabolic pathways in the brain are similar to those in other tissues [68]. However, the 
situation in the brain is more complex due to the fact that metabolism in the brain is highly 
compartmentalized [68]. This implies differential cellular and subcellular distribution of 
transporters, enzymes and metabolic pathways, requiring a coordinated function of the 
different cell types with intercellular trafficking of metabolites between them [91]. 
The rate and pathways of cerebral metabolism changes during development, starting at a high 
level and plateauing after maturation [68]. Glucose is essential for the developing brain and is 
also the most important energy-yielding substrate used by the adult brain. The brain has a 
respiratory quotient of 0.97, indicating that it depends almost exclusively on carbohydrate 
oxidation. [68] There exist large regional variations in brain glucose metabolism at rest, 
affected by local brain activation, suggesting a strong link between energy metabolism and 
brain function. [68] In addition, substrates other than glucose can provide energy for brain 
cells (e.g. glutamate, glutamine, lactate, fatty acids, ketone bodies). Newborns tend to be 
hypoglycemic but become ketotic when they begin to nurse. [68] Lactate has a special role as 
a readily available source of energy during the immediate postnatal period, but can also be 
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used in the adult human brain and is formed under both aerobic and anaerobic conditions 
(e.g., astrocyte-neuron lactate shuttle, see section 3.5.3). Glycogen, which is present at only 
low levels in brain, mainly in astrocytes [67, 92], is the only fuel store endogenous to the 
brain that can provide significant amounts of energy in periods during which the supply of 
glucose does not meet the metabolic demand [68]. Furthermore, phosphocreatine has a role in 
maintaining ATP levels in brain [68]. 
 
 
3.5.2 Amino acids in brain function and nutrition. 
The brain requires continuous supply of amino acids to sustain normal cerebral development 
and function [93]. Amino acids play a role as building blocks of proteins and peptides and in 
nutrient metabolism. While the brain requires over 20 separate amino acids for normal 
development and function, only approximately half can be synthesized within the CNS [93] 
(see Table 3). Because of variations in their side chains, amino acids have different 
biochemical properties and functions (see Table 3). The most important gluconeogenic amino 
acids in humans are alanine and glutamine, accounting for 50-70% of gluconeogenesis from 
amino acids [94]. Along with proteinogenic amino acids, ornithine, citrulline, taurine and β-
alanine also play important roles in cell metabolism [95]. Additionally, D-amino acids are 
present in high concentrations and fulfil specific biological functions [96]. D-serine, for 
example, is synthesized and metabolized endogenously and plays a role in excitatory amino 
acid metabolism, being a co-agonist of the NMDA receptor [96]. D-aspartate is involved in 
development and endocrine function [96]. 
The brain is dependent on a constant supply of amino acids from the periphery, but does itself 
not play an important quantitative role in the interorgan flux of amino acids [97]. The 
availability of amino acids is determined by the rate at which they appear in the plasma and 
the rate at which they disappear through conversion to other amino acids, breakdown, 
excretion, and incorporation into proteins. It was also shown that an increase in the brain 
content of a nonessential amino acid like glutamine can be used to promote uptake of an 
essential amino acid like tryptophan [98] (see section 3.6.1.1). Furthermore, the supply of 
essential amino acids via the plasma shows consistent fluctuations during the day, with lowest 
values at 12 a.m. and peaks between 4 a.m. and 8 a.m. [99].  
On a molar basis, oxidation of amino acids is less efficient for ATP production than oxidation 
of fat and glucose. The efficiency of energy transfer from amino acids to ATP ranges from 
29% for methionine to 59% for isoleucine [95]. Though not used primarily for cerebral 
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energy metabolism [93], amino acids can be used as carbon source and be funnelled into the 
TCA cycle via transamination and decarboxylation (see section 3.5.3.1). As an example, the 
malate-aspartate shuttle was shown to be essential to brain glucose metabolism [100]. 
The oxidation of amino acids by the brain for energy requires the disposal of generated 
ammonia [68]. The CNS lacks a complete urea cycle, therefore glutamine synthesis is the 
only way by which CNS cells can recycle ammonia [98]. Glutamine is not a ligand of any 
known neurotransmitter receptor and therefore can be viewed as a non-toxic ammonia carrier 
between the different CNS compartments [98]. 
The need of amino acids for proper brain function varies throughout development. The 
rapidly growing brain of an immature animal synthesizes protein at a high rate and therefore 
requires more amino acids from the blood than an adult brain [101]. Additionally, mouse 
brain utilizes ketone bodies to form amino acids [100]. Yudkoff et al. [100] examined the 
relationship between ketosis and brain amino acid metabolism in mice fed a ketogenic diet, a 
diet used in the management of epilepsy in children. The anti-epileptic effect of this diet is 
possibly due to reduced brain aspartate formation from glutamate which might then favour the 
synthesis of γ-aminobutyric acid (GABA) [100] (see section 3.5.3). 
Amino acids play a role in the regulation of several pathways involved in gene expression and 
cell signaling. Regulation of gene expression by amino acids can occur at any step of 
transcription, translation, and post-translational modifications. Amino acids are important in 
cellular signalling via mTOR, cAMP, and cGMP activation pathways, as well as in generation 
of NO, CO, and H2S, and therefore in endothelial function and blood flow [95]. 
Furthermore, amino acids participate in the regulation of cerebral osmotic and anionic balance 
[93] and the cellular redox state, with glutathione being the major anti-oxidant in cells [95] 
(see Table 3). Amino acids are also involved in hormone synthesis and secretion, e.g., insulin 
secretion is stimulated by glutamine, leucine, and arginine, and tyrosine is a precursor for the 
synthesis of epinephrine and dopamine. Furthermore, amino acids play a role in immune 
function and health (e.g., T-cell proliferation, B-cell maturation, and antibody production), a 
role which is impaired in protein deficiency [95] (see Table 3). 
 
 
3.5.3 Amino acids and neurotransmission. 
The three major categories of substances that act as neurotransmitters are amino acids, 
peptides and monoamines [102]. It was not until the 1960s and 70s that this function of amino 
acids was identified [13]. Amino acids can be precursors for neurotransmitters like for 
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serotonin, dopamine, norepinephrine and histamine, or can be neurotransmitters or 
neuromodulators themselves (glutamate, aspartate, glycine and GABA) [93] (see Table 3). 
Although there are many neurotransmitters in the CNS, the peripheral nervous system has 
essentially only two, acetylcholine and norepinephrine [102]. All of the known amino-acid 
neurotransmitters are nonessential amino acids [102]. 
Glutamate is the most common neurotransmitter in brain and is, like aspartate, an excitatory 
neurotransmitter [102] (see section 3.5.3.1), while GABA is the major inhibitory 
neurotransmitter of the brain, occurring in 30-40% of all synapses [102]. Another, vertebrate 
specific, inhibitory neurotransmitter is glycine [102]. Brain function represents a dynamic 
balance between excitatory and inhibitory neuronal signaling, integrated in time and location 
within the brain [68, 103], responsible e.g. for sensory perception, motor control, and 
cognition [103]. 
Glutamate is also known to couple energy metabolism and synaptic activity, namely via 
induction of glucose uptake into astrocytes [104]. In response, astrocytes release lactate, the 
preferred energy substrate of activated neurons, and converse glutamate to glutamine [104] 
(see also section 3.5.3.2). 
The monoamine neurotransmitter serotonin in brain represents 1-2% of body’s serotonin and 
is synthesized from, and is therefore largely dependent on, tryptophan transported across the 
BBB [102] (see also section 3.5.3.3 and 3.6.1.1). In general, the synthesis of neurotransmitters 
in mammalian brain responds rapidly to changes in precursor availability. It has been shown 
that brain serotonin concentration can be increased up to 10-fold by a tryptophan-
supplemented diet [102]. 
 
 
3.5.3.1 Glutamate/GABA-glutamine cycle. 
Glutamate. In the vertebrate CNS, the nonessential amino acid glutamate functions as the 
predominant excitatory neurotransmitter (see section 3.5.3). 90% of the synapses in the brain 
utilize either glutamate or GABA as neurotransmitters [68]. Glutamate plays a critical role in 
synaptic maintenance and plasticity, and further contributes to learning and memory [17]. 
Glutamate metabolism is closely linked to the TCA cycle. The oxidation of glutamate to 
oxalacetate yields 12 ATP per molecule of glutamate [7]. Therefore, under hypoglycaemic 
conditions, the brain mobilizes glutamate as a fuel (see section 3.5.1). Under normal 
conditions, most free glutamate in brain is derived from glutamine and TCA cycle 
intermediates, but also from recycling of brain proteins [17]. Furthermore, glutamate is the 
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most abundant free amino acid in the brain (10,000-12,000 µmol/L [7]). However, in 
comparison to the levels in plasma (50-100 µmol/L [7]) and intracellular (~12,000 µmol/L 
[1]), the glutamate concentration in the ISF is very low (0.5-2 µmol/L [7]). The concentration 
of glutamate (<0.4 µmol/L [17]) and aspartate in CSF is lower than that of any other amino 
acid group [7]. The low ISF concentration is essential for optimal brain function [7], to 
maximize the signal-to-noise-ratio upon the synaptic glutamate release and to minimize the 
risk of excitotoxicity [105]. If ISF glutamate rises, nerve cells may be damaged due to 
overexcitation which is thought to play an important role in the neural damage that occurs in 
diseases such as trauma, stroke, epilepsy and hypoglycaemia [17]. Plasma glutamate 
concentrations fluctuate during the day as a result of changes in diet, metabolism and protein 
turnover [17] (see section 3.5.2). The BBB helps to protect the brain from these changes by 
limiting the passive influx of glutamate (and other polar solutes) to a level <1% of that 
occurring at the blood vessels of most other tissues [17] (see also section 3.5.4.1). In the 
brain, glutamate exists in two separate metabolic compartments located in astrocytes and 
neurons (see section 3.5.3.2). This compartmentation is almost absent at birth and develops in 
parallel with glial cells [7]. 
 
Glutamate-glutamine cycle. The best characterized example for compartmentation (see 
section 3.5.1) in brain is the glutamate-glutamine cycle, which couples brain energy 
metabolism directly to excitatory and inhibitory neurotransmission [106-107]. Glutamine is 
the most abundant α-amino acid in the body [106], cannot cause excitotoxicity [102] (see 
section 3.5.2), and flat glutamine gradients ensure controlled movement between the different 
CNS compartments [98] (see Table 2 and Table 3). In contrast, glutamate exhibits a very 
large gradient between the intracellular space and the ISF (5,000- to 10,000-fold), with low 
ISF concentrations [17] (see section 3.5.3.1). 
During neurotransmission, nerve impulses trigger the calcium-dependent presynaptic release 
of glutamate [7]. Glutamate can then either bind and activate postsynaptic glutamate receptors 
[7] and is directly reabsorbed into neurons, or is taken up into astrocytes [91, 102]. In the 
latter case, conversion of glutamate to glutamine occurs, which is then transferred back to 
neurons for re-conversion into glutamate [91, 102] (see Figure 7). Enzymes and amino acid 
transporters involved in this cycle show differential distribution, with glutamine synthetase 
being astrocyte-specific and phosphate activated glutaminase being neuronal-specific [68]. 
SNAT3 (see section 3.6.1.3.2) exports glutamine from astrocytes and SNAT1 (see section 
3.6.1.3.1) mediates neuronal glutamine uptake [106]. The glutamate-glutamine cycle does not 
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operate in a stoichiometric fashion [68]. One reason for this fact is that in astrocytes not all 
glutamate is converted into glutamine, there is also glutamate metabolism [68], and glutamine 
can be oxidized for energy [68]. Because the cycle is not stoichiometric, glutamatergic and 
GABAergic neurons cannot refill their neurotransmitter pools unless precursors are received 
from surrounding astrocytes [68]. 
The cycle also operates between GABAergic neurons and astrocytes and is important to 
maintain the GABA pool [68]. 
There is evidence for a glutamate-glutamine cycle inside the BBB endothelial cells [1]. This 
is based on the fact that endothelial cells show glutaminase activity and that the two 
membranes of the BBB show a polarized expression of transporters. The intracellular 
glutamate concentration can be increased by either sodium-dependent glutamate transport 
from the ISF across the abluminal membrane, or by conversion of glutamine to glutamate via 
glutaminase. When the intracellular glutamate concentration is higher than in plasma, 
facilitative transport of glutamate across the luminal membrane into blood occurs [1]. 
Therefore the BBB endothelial cells may play an important role in clearing the ISF of 
glutamate to prevent neurotoxic levels. 
 
Figure 7: The glutamate-glutamine cycle between astrocytes and neurons.  
  
Schematic diagram of glutamate-glutamine cycles [12]. In glutamatergic neurons, glutamate and GABA (γ-
aminobutyric acid) are synthesized from glucose or glutamine, which neurons themselves cannot make. 
Neurotransmitters released in the synaptic cleft can then interact with receptor sites. To terminate this effect, 
transport to astrocytes is performed with higher affinity than to neuron cells. In astrocytes there is a higher 
glutamine synthetase activity and glutamate and GABA are metabolized to glutamine, which has no 
neurotransmitter effects and can be recycled to neurons to form glutamate (in excitatory neurons) or GABA (in 
inhibitory neurons). [108-109] 
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3.5.3.2 Branched-chain (BCAA) and large neutral amino acids (LNAA). 
Unlike glutamate and aspartate, lysine, arginine, and the LNAAs (except histidine; see Table 
3) are essential amino acids [17]. Phenylalanine, leucine, tyrosine, tryptophan, threonine, 
isoleucine, valine, methionine, and histidine belong to the group of the LNAAs, whereas 
alanine, serine, and cysteine are small NAAs. Amino acids are further divided into BCAAs 
(valine, leucine, and isoleucine) and aromatic amino acids (ArAAs; phenylalanine, 
tryptophan, and tyrosine). [110] 
BCAA uptake at the BBB exceeds that of all other amino acids. It is also reported that the 
uptake of valine [111], respective leucine [105], is more rapid than that of other amino acids. 
BCAAs participate in protein synthesis and energy production, e.g. leucine can be oxidized 
for energy via conversion to 3-hydroxybutyrate [68]. Furthermore, neurons can buffer 
excessive ISF glutamate concentrations via leucine and therefore prevent excitotoxicity [105]. 
The proposed BCAA shuttle between astrocytes and neurons is via transamination connected 
to the glutamate-glutamine cycle (see section 3.5.3.1), and 30-50% of all α-amino groups of 
brain glutamate and glutamine are derived from leucine [105, 112]. It has been suggested that 
the plasma concentrations of BCAAs may influence brain function and affect appetite, 
physical and mental fatigue, mental performance, physical endurance, sleep, hormonal 
function, blood pressure, and affective state [1] (see also section 3.5.5). BCAAs influence 
brain function by modifying LNAA and ArAA transport at the BBB [113], the transport of 
which is shared and competitive [113] (see also section 3.6.1.1). Consequently, when plasma 
BCAA concentrations rise they impair the entry of ArAAs, therefore implying brain synthesis 
of serotonin, which directly depends on the availability of tryptophan [1] (see section 3.5.3). 
Additionally, the synthesis and release of catecholamines (from tyrosine and phenylalanine) is 
reduced by reduced brain ArAA concentrations [113]. The functional effects of such changes 
in the neurochemical homeostasis include altered hormonal function, blood pressure, and 
affective state [113]. 
 
 
3.5.4 Different amino acid concentrations in brain ISF, CSF, and plasma. 
The brain is divided into several fluid compartments with distinct properties, including the 
intracellular compartments, the interstitial fluid (ISF) surrounding the brain cells, the 
cerebrospinal fluid (CSF), and the plasma facing the lumen of the brain vasculature. This 
different compartments stand in constant exchange with each other. 
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The BBB protects the brain cells from fluctuations in the plasma amino acid concentration 
and determines the brain content of essential amino acids [1]. With an intact BBB, amino 
acids with transmitter functions have little access to the brain from blood, and there is 
evidence for a net efflux from the brain of glutamate and aspartate also under physiological 
conditions [114]. 
The brain ISF is a complex, dynamic microenvironment, which can buffer changes and is 
influenced by secretion and uptake of brain cells, homeostatic mechanisms of blood and CSF, 
and it is the main medium of communication between neurons [115]. Any solutes that do 
cross the BBB and enter the brain ISF will diffuse into the CSF and end up in the blood, 
therefore keeping their brain value low [116]. Once within brain ISF, solutes can move into 
adjacent brain areas via intercellular diffusion or via flow along the Virchow-Robin spaces 
[17]. The contribution of brain ISF to CSF has been estimated as 10-60% [26]. The ISF in 
human (~15% of total brain volume) has about twice the volume of the CSF (250-300 ml), but 
the rate of formation is only one-tenth of that of CSF (0.2 µl/g/min in rat). [116] The entire 
CSF volume is turned over completely every 4-5 h [117].  
Glutamine is the dominant amino acid in the ISF, while aspartate and glutamate show the 
lowest concentration [115]. A concentration gradient exists between plasma and both CSF 
and brain ISF, and also between CSF and ISF [115], as shown in Table 2. Amino acid 
concentrations in the ISF are reported to be about one third the levels in CSF [115]. Amino 
acid levels also show several qualitative differences between these compartments [115]. ISF 
and CSF are formed by different tissues, the BBB and the BCSFB, respectively [26, 116, 
118], which could be one explanation for the existing amino acid gradients between CSF and 
ISF, which also show intersubject variability [118]. The concentration of some amino acids is 
also influenced by their metabolism in the endothelial cells [114] and by the sink effect of 
brain cells [118-119]. If they take up a given amino acid at a constant rate, its ISF 
concentration could be lower than that in the constantly renewed CSF [118]. On the other 
hand, in localized regions cells may release amino acids leading to higher ISF concentrations 
[118]. Taken together, the CSF can not be taken as equivalent to the brain ISF [116], even if 
there is no anatomical barrier separating CSF and ISF [117]. Roettger and Goldfinger [118] 
suggested that such a barrier may be due to the ependymal surfaces and / or the toruosity 
within the ISF diffusion paths. To summarize, the concentration of amino acids on the 
abluminal side of the BBB is not directly known [119]. But since the normal direction of flow 
is from the brain ISF towards the CSF [116], the composition of ISF and CSF is considered to 
be similar [1, 118] and CSF amino acid concentration values are used as representative [119]. 
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Table 2: Concentration ratios of amino acids and other biochemicals between different brain compartments.  
  Plasma / CSF Plasma / ISF CSF / ISF Tissue / ISF 
Aspartate [114] 5.8 19.9 3.4 2111‡ 
Glutamate [114] 14.0 55.0 3.9 4069‡ 
Serine [114] 4.0 10.0 2.5 42* 
Glutamine [114] 1.6 4.3 2.7 26* 
Arginine [114] 7.0 32.9 4.7 13* 
Taurine [114] 5.4 15.7 2.9 409○ 
Alanine [114] 5.0 55.8 11.1 92* 
GABA [114] - - - 2600‡ 
Total free amino acids [119] 4.3    
Sodium [119] 0.9    
Potassium [119] 1.4    
Chloride [119] 0.8    
Calcium [119] 1.8    
Magnesium [119] 0.7    
Glucose [119] 1.3    
Protein [119] 256.2    
 
There is a concentration gradient between plasma and both CSF and ISF, between CSF and ISF, and between 
intracellular pools and ISF (tissue / ISF). Amino acid concentrations in the ISF are about one third the levels in 
CSF. Qualitative differences between the compartments indicate the existence of barriers between plasma, CSF 
and ISF [115]. The amino acid profile in ISF differed from that of whole tissue. Three main groups of values 
may be defined: *amino acids with non-postulated transmitter role; ‡amino acids with known neurotransmitter 
roles; and ○amino acids with intermediate ratio acting as neuromodulators [115]. Experiments were performed 
on adult Sprague-Dawley rats [115] and normal human individuals after overnight fast [120]. Tissue / ISF ratios 
were calculated taking the tissue density value as 1.0 [115]. ISF was cited in the literature as ECF. 
 
The CSF is characterized by a low content of amino acids, presumably a condition necessary 
for neuronal sensitivity in neurotransmission. The concentrations of all naturally occurring 
amino acids in the CSF, with the exception of glutamine, are ~10% or less than the plasma 
concentrations [1] (see Figure 8). The mean total concentration of free amino acids in the CSF 
was found to be 826 µmol/L (± 102), glutamine being the major amino acid component 
(67.4%). The mean total concentration of free amino acids in plasma was found to be 3556 
µmol/l (± 904). [120] Plasma is a major determinant of the CSF concentration. A low CSF / 
plasma concentration ratio is constant for each amino acid [120] (see Table 2 and Table 3). 
The CSF concentration of threonine, serine, glutamate, glutamine, glycine, methionine, 
leucine, tyrosine, phenylalanine, lysine, histidine, and arginine has been shown to be directly 
related to the plasma concentration. However, asparagine, valine, and isoleucine did not show 
such a relationship. [120] This indicates that the plasma amino acid concentration is not the 
only determinant of the CSF concentration. The differences in the concentrations of the 
cerebral amino acids can not be explained by the consumption of amino acids by brain [1] or 
the energy requirements of the various transporters [121]. As possible explanation it has been 
suggested that amino acids leave the brain against a concentration gradient [1]. Concerning 
the amino acid concentrations in plasma it has to be considered that there are differences in 
the profile between arterial and venous blood and that the arterial concentrations are more 
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representative of amino acid homeostasis [122]. Furthermore, the plasma levels differ from 
those of whole blood [122]. There are also gender and age differences measured, with higher 
concentrations of phenylalanine, proline, and ornithine in males than in females, and lower 
concentration of BCAAs in old than in young adults [122]. 
 
Figure 8: Comparison of CSF and plasma amino acid concentrations.  
  
Comparison of mean normal CSF (shaded bars) and plasma (open bars) amino acid concentrations in 37 normal 
human individuals of both genders. Individuals were on a normal diet and lumbar CSF and blood were collected 
simultaneously after 16 h overnight fast. With the exception of phosphoserine, phosphoethanolamine and 
glutamine, mean concentrations are much higher in plasma than in CSF. Ser (P), phosphoserine; EtN (P), 
phosphoethanolamine; Tau, taurine; Cit, citrulline; Abu, 2-aminobutyric acid; Orn, ornithine. Source: Figure 1 
from McGale et al. [120]. 
 
 
3.5.5 Diseases related to amino acid misbalance. 
An optimal balance among amino acids in the diet is crucial for whole body homeostasis. 
Elevated amino acid levels are pathogenic factors for neurological disorders [95]. Imbalance 
in brain amino acid concentrations are known to occur in a number of conditions, including 
liver disease, diabetes, uremia and the aminoacidurias [93]. 
 
Phenylketonuria (PKU). PKU is an inborn error of amino acid metabolism that results in 
severe mental retardation and seizures if not treated early [110]. Classical PKU results from 
impaired activity of the liver enzyme phenylalanine hydroxylase (PAH) [123]. The result is a 
raised blood phenylalanine level and a reduction in the level of tyrosine [123]. Although PAH 
deficiency occurs at the hepatic level, the clinical effects of hyperphenylalaninaemia are on 
brain development and function [110]. Untreated patients show a progressive and irreversible 
neurological impairment, with low IQ levels, hyperactivity, stereotypy, aggressiveness, 
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anxiety, social withdrawal, a mousy odour, reduced pigmentation, reduced growth and 
microcephaly [110]. Since the brain phenylalanine concentration results mainly from its 
transport across the BBB (see section 3.6.1), the primary consequence of increased blood 
phenylalanine is increased brain phenylalanine [110]. The neurotoxicity of phenylalanine is 
enhanced by the fact that LNAA transport across the BBB by LAT1 is subject to transport 
competition [102, 110] (see section 3.6.1). This means that blood ratios of LNAAs and the 
individual affinity of LAT1 for each of them, with highest affinity for phenylalanine, 
determines their net uptake from blood into the brain [110]. Therefore, high plasma 
phenylalanine concentrations impairs uptake of the other LNAAs (tyrosine and tryptophan) 
into the brain [110]. Less tryptophan results in reduction of brain serotonin synthesis, less 
tyrosine in reduced dopamine, noradrenaline and adrenaline biosynthesis [110] (see Table 3). 
High brain phenylalanine concentrations have also been shown to cause a reduction in brain 
weight, increased myelin turnover and decreased myelin production [110]. The treatment of 
PKU includes a phenylalanine restricted diet [113, 123] supplemented with tyrosine [123]. 
PKU patients eating a normal protein diet show up to 20-times elevated plasma phenylalanine 
levels [113]. 
 
Maple syrup urine disease (MSUD). MSUD is a rare inherited metabolic disorder that occurs 
with a frequency of 1:200,000 births. Patients with MSUD exhibit a diminished BCAA 
metabolism due to defects in the enzyme branched-chain α-keto acid dehydrogenase. [113] As 
a consequence, plasma and tissue levels of the BCAAs (particularly leucine) [113] and α-
ketoisocaproate [124] are greatly elevated. This causes neurotoxicity [113] and neurological 
dysfunctions, such as seizures, coma, psychomotor delay, and mental retardation [124]. 
Patients with MSUD show, besides elevated leucine levels, a depletion of glutamate and 
consequent reduction in the concentration of brain glutamine, aspartate, alanine, and other 
amino acids [105]. The result is a failure of the malate-aspartate shuttle (see section 3.5.2), a 
diminished metabolism and rate of protein synthesis [105]. Tetsuka et al. [124] suggested that 
aspartate efflux may be inhibited by the increased concentration of leucine in MSUD. 
 
Nonketotic hyperglycinemia (NKH). Patients with NKH show seizures, coma and apnea, 
causing death in the neonatal period. In NKH an increase in the CSF / plasma glycine ratio 
can be observed. Lowering the plasma glycine level by using sodium benzoate leads to 
improved seizure control. [123] 
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Table 3: Overview of amino acids, their function, concentration in CSF and plasma, and their transporters from different SLC families. 
 
Amino acids Nutritional 
status in 
brain [4] 
products Non-protein functions [95] CSF [µM] 
[4] 
Plasma / CSF 
[4] 
transported by [124] 
Alanine A NE directly gluconeogenesis; transamination; glucose-
A cycle 
20 12 ASCT1; ASCT2; ATB0,+ [125]; NTT4 [126]; 
B0AT3/Coll [127]; B0AT1/Coll [128]; 
y+LAT2/4F2hc [129]; LAT2/4F2hc [130]; 
b0,+AT/rBAT [130]; Asc1/4F2hc [129]; PAT1; 
PAT2; SNAT1; SNAT2; SNAT3; SNAT4 
 
directly mTOR signaling; antioxidant; NH4+ 
detoxification; immunity; N reservoir; 
methylation and deimination of proteins 
10 5 ATB0,+ [125]; CAT-1 [129]; CAT-2 [125]; 
CAT-3 [125]; y+LAT2/4F2hc [129]; 
y+LAT1/4F2hc [129]; b0,+AT/rBAT [130]; 
ORC2; ORC1 
 
NO signaling molecule; regulator of nutrient 
metabolism, vascular tone, angiogenesis, 
immunity, neurotransmission 
 
   
Ornithine NH4+ detoxification; synthesis of P, E, and 
polyamines 
 
2 22 CAT-1 [129]; b0,+AT/rBAT [129]; ORC2; 
ORC1 
Methylarginine competitive inhibition of NOS 
 
   
Arginine R E 
Creatine  
(R, M, and G) 
antioxidant; antiviral; energy metabolism 
in muscle and brain; neurological and 
muscular development and function 
 
  CT1; CT2 
Asparagine N NE directly cell metabolism and physiology; 
immunity; NH4+ detoxification; CNS 
function 
8 7 ATB0,+ [125]; B0AT1/Coll [128]; LAT2/4F2hc 
[130]; SNAT1; SNAT2; SNAT3; SNAT4; 
SNAT5  
 
Aspartate D NE directly purine, pyrimidine, N, and R synthesis; 
transamination; urea cycle; activation of 
NMDA receptors 
 
0.2 20 EAAT3; EAAT2; EAAT1; EAAT4; EAAT5; 
AGT-1; AGC1 
directly disulfide linkage; transport of sulphur; 
immunity; cellular metabolism and 
nutrition 
 
3 21 ASCT1; ASCT2; ATB0,+ [125]; B0AT1/Coll 
[128]; y+LAT2/4F2hc [129]; LAT2/4F2hc 
[130]; Asc1/4F2hc [129]; SNAT1; SNAT2; 
SNAT4 
Cysteine C E 
Taurine antioxidant   TAUT; PAT1 
 
3. Introduction.  44 
 
Glutathione  
(C, E, and G) 
antioxidant; formation of leukotrienes; 
apoptosis; immunity 
 
   
Amino acids Nutritional 
status in 
brain [4] 
products Non-protein functions [95] CSF [µM] 
[4] 
Plasma / CSF 
[4] 
transported by [124] 
directly Q, citrulline, and R synthesis; bridging 
urea cycle with TCA cycle; 
transamination; NH4+ assimilation; 
activation of NMDA receptors 
 
3 30 EAAT3; EAAT2; EAAT1; EAAT4; EAAT5; 
xCT/4F2hc; AGT-1; vglut2; vglut1; vglut3; 
AGC1; GC2; GC1 
GABA excitatory neurotransmitter; inhibition of 
T-cell response and inflammation 
 
  GAT1; GAT3; BGT1; GAT2; VGAT; PAT1 
Glutamate E NE 
Citrulline antioxidant; R synthesis; osmoregulation; 
NH4+ detoxification; N reservoir  
  ORC2; ORC1 
directly mTOR signaling; immunity; major fuel for 
rapidly proliferating cells; inhibition of 
apoptosis; syntheses of purine, pyrimidine, 
ornithine, citrulline, R, N, and P; N 
reservoir; synthesis of NAD(P) 
 
547 1 ASCT2; ATB0,+ [125]; B0AT1/Coll [128]; 
(LAT1/4F2hc [130]); y+LAT2/4F2hc [129]; 
y+LAT1/4F2hc [129]; LAT2/4F2hc [130]; 
SNAT1; SNAT2; SNAT3; SNAT5 
E and D excitatory neurotransmitters; components 
of the malate shuttle; cell metabolism; 
NH4+ detoxification  
   
Glucosamine-6-P synthesis of aminosugars and 
glycoproteins; inhibition of NO synthesis 
 
   
Glutamine Q NE 
Ammonia (NH4+) renal regulation of acid-base balance; 
synthesis of E 
 
  NHE1; NHE2; NHE3; RhAG; RhBG; RhCG 
directly Ca2+ influx (G-gated channel); purine and 
S synthesis; antioxidant; one-carbon unit 
metabolism; inhibitory neurotransmitter in 
CNS; co-agonist with E for NMDA 
receptors 
 
6 23 GlyT2; GlyT1; NTT4 [126]; B0AT3/Coll 
[127]; B0AT1/Coll [128]; (LAT2/4F2hc [130]); 
Asc1/4F2hc [129]; VGAT; PAT1; PAT2; 
SNAT2; SNAT4 
Glycine 
 
 
 
 
 
 
 
 
G NE 
Heme Hemoproteins; production of CO 
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Amino acids Nutritional 
status in 
brain [4] 
products Non-protein functions [95] CSF [µM] 
[4] 
Plasma / CSF 
[4] 
transported by [124] 
directly protein methylation; antioxidative 
dipeptides; one-carbon unit metabolism 
4 10 ATB0,+ [125]; B0AT1/Coll [128]; CAT-1 [129]; 
CAT-2 [125]; LAT1/4F2hc [130]; 
y+LAT2/4F2hc [129]; y+LAT1/4F2hc [129]; 
LAT2/4F2hc [130]; PHT2; PHT1; ORC2; 
SNAT1; SNAT2; SNAT3; SNAT5 
 
Histidine H NE 
Histamine allergic reaction; vasodilator; central 
acetylcholine secretion; regulation of gut 
function 
 
  VMAT1; VMAT2 
Isoleucine I E directly synthesis of Q and A; balance among 
BCAA 
3 15 ATB0,+ [125]; B0AT2 [129]; B0AT3/Coll [127]; 
B0AT1/Coll [128]; LAT1/4F2hc [130]; 
LAT2/4F2hc [130]; LAT3 [131]; LAT4 [132] 
 
directly immunity; inhibits NO production by 
endothelium; mTOR signaling; activator 
of glutamate dehydrogenase; BCAA 
balance 
6 12 ATB0,+ [125]; B0AT2 [129]; NTT4 [126]; 
B0AT3/Coll [127]; B0AT1/Coll [128]; 
LAT1/4F2hc [130]; y+LAT2/4F2hc [129]; 
y+LAT1/4F2hc [129]; LAT2/4F2hc [130]; 
b0,+AT/rBAT [130]; LAT3 [131]; LAT4 [132] 
 
Leucine L E 
Q and A interorgan metabolism of nitrogen and 
carbon 
 
   
directly regulation of NO synthesis; protein 
methylation, acetylation, ubiquitination, 
O-linked glycosylation 
9 16 ATB0,+ [125]; CAT-1 [129]; CAT-2 [125]; 
CAT-3 [125]; y+LAT2/4F2hc [129]; 
y+LAT1/4F2hc [129]; b0,+AT/rBAT [130]; 
ORC2; ORC1 
 
Lysine K E 
OH-lysine structure and function of collagen 
 
   
directly C, carnitine synthesis; SAM as methyl 
donor; immunity; one-carbon unit 
metabolism 
1 20 ATB0,+ [125]; B0AT2 [129]; B0AT3/Coll [127]; 
B0AT1/Coll [128]; (LAT1/4F2hc [130]); 
y+LAT2/4F2hc [129]; y+LAT1/4F2hc [129]; 
LAT2/4F2hc [130]; SNAT2; LAT3 [131]; 
LAT4 [132] 
 
Homocysteine oxidant; inhibition of NO synthesis 
 
   
Methionine M E 
DCSAM methylation of proteins and DNA; 
polyamine synthesis 
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Taurine antioxidant; osmoregulation; organ 
development; vascular functions; anti-
inflammation 
 
   
Amino acids Nutritional 
status in 
brain [4] 
products Non-protein functions [95] CSF [µM] 
[4] 
Plasma / CSF 
[4] 
transported by [124] 
Phenylalanine F E directly synthesis of Y; neurological development 
and function 
5 9 ATB0,+ [125]; B0AT1/Coll [128]; LAT1/4F2hc 
[130]; LAT2/4F2hc [130]; TAT1 [133]; LAT3 
[131]; LAT4 [132] 
 
directly collagen structure and function; 
neurological function; osmoprotectant 
5 28 PROT; B0AT2 [129]; NTT4 [126]; B0AT1/Coll 
[128]; SIT1/Coll; PAT1; PAT2; SNAT2 
 
H2O2 killing pathogens; intestinal integrity; a 
signaling molecule; immunity 
 
   
Proline P NE 
OH-proline structure and function of collagen 
 
   
directly one-carbon unit metabolism; syntheses of 
C, G, purine, pyrimidine, ceramide and 
phosphatidylserine; gluconeogenesis; 
protein phosphorylation 
 
15 6 ASCT1; ASCT2; ATB0,+ [125]; B0AT3/Coll 
[127]; B0AT1/Coll [128]; LAT2/4F2hc [130]; 
Asc1/4F2hc [129]; SNAT1; SNAT2; SNAT4; 
SNAT5 
Serine S NE 
D-Serine activation of NMDA receptors 
 
   
Threonine T E directly synthesis of the intestinal mucin protein; 
immunity; protein phosphorylation and O-
linked glycosylation; G synthesis 
 
13 6 ASCT2; ATB0,+ [125]; B0AT1/Coll [128]; 
LAT2/4F2hc [130]; Asc1/4F2hc [129]; SNAT4 
directly  1 30 ATB0,+ [125]; B0AT1/Coll [128]; LAT1/4F2hc 
[130]; LAT2/4F2hc [130]; TAT1 [133] 
 
Serotonin neurotransmitter; inhibiting production of 
inflammatory cytokines and superoxide 
 
  SERT 
Melatonin antioxidant; inhibition of the production of 
inflammatory cytokines and superoxide 
 
   
Tryptophan 
 
 
 
 
 
 
 
 
 
 
 
W E 
Niacin component of NAD(P) 
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Amino acids Nutritional 
status in 
brain [4] 
products Non-protein functions [95] CSF [µM] 
[4] 
Plasma / CSF 
[4] 
transported by [124] 
directly protein phosphorylation, nitrosation, and 
sulfation; thyroid hormones 
7 9 ATB0,+ [125]; B0AT1/Coll [128]; LAT1/4F2hc 
[130]; LAT2/4F2hc [130]; b0,+AT/rBAT [130]; 
TAT1 [133] 
 
Dopamine neurotransmitter; regulation of immunity 
 
  NET; DAT; VMAT1; VMAT2 
Tyrosine Y E 
Epinephrine and 
Norepinephrine* 
 
neurotransmitters; cell metabolism   NET* 
Valine V E directly synthesis of Q and A; balance among 
BCAA 
12 15 ATB0,+ [125]; B0AT2 [129]; B0AT3/Coll [127]; 
B0AT1/Coll [128]; LAT1/4F2hc [130]; 
LAT2/4F2hc [130]; LAT3 [131]; LAT4 [132] 
 
 
Major metabolites and functions of amino acids in addition to functions in protein synthesis, as osmolytes, in regulation of hormone secretion, gene expression and cell signaling 
are given (adapted from [95]). The nutritional status in brain (after [4]), the amino acid concentrations in CSF (in µM) and respective plasma / CSF ratio (after [4]) is given for 
each amino acid separately. The possible transporters of different SLC families (see also Table 4) are listed according to their reported substrates (adapted from [125] where not 
otherwise stated).  
Essential amino acids cannot be synthesized by brain at adequate rates to meet the needs for brain metabolism and protein synthesis and must therefore be supplied from the diet 
[93]. Conditionally essential amino acids are those that normally can be synthesized in adequate amounts by the organism, but which must be provided from the diet to meet 
optimal needs under conditions where rates of utilization are greater than rates of synthesis. Nonessential amino acids are those amino acids which can be synthesized de novo in 
adequate amounts by the body to meet optimal requirements. [95] 
AA, amino acid; BCAA, branched-chain AA; CNS, central nervous system; DCSM, decarboxylated S-adenosylmethionine; E, essential AA; GABA, γ-aminobutyrate; mTOR, 
mammalian target of rapamycin; NE, non-essential AA; NMDA, N-methyl-D-aspartic acid; NOS, nitric oxide synthase; SLC, solute carrier; TCA, tricarboxylic acid cycle. 
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3.6 Transport processes across the blood-brain barrier. 
The BBB protects the brain from fluctuations in blood, provides an optimal chemical 
environment for cerebral function, and guarantees the nutrition of the brain by uptake of 
substrates from blood via transporters expressed at the BBB [1] (see section 3.3.1.1). 
For a solute to enter the brain from blood it has to pass the blood-brain barrier (BBB) or the 
blood-cerebrospinal fluid barrier (BCSFB) (see section 3.3). But since the brain microvessels 
comprising the BBB have a surface area of up to 5,000 times that of the choroid plexus [52], 
the extent to which a solute enters the brain is determined almost exclusively by the 
permeability characteristics of the BBB [4], implicating the major role of the BBB in brain 
(amino acid) homeostasis. 
After amino acids have entered the brain they must be transported into brain cells (neurons, 
glia). Since the surface area of the brain cell membranes is much greater than the surface area 
of the BBB, transport across the BBB is the rate limiting step in amino acid movement from 
blood to brain intracellular spaces [83].  
 
There is more than one barrier between blood and brain. In addition to the endothelial cells 
that are in direct contact with the blood and its constituents, all the layers of the neurovascular 
unit (see section 3.3.1) can potentially restrict the movement of solutes into the brain [1, 7] 
and influence their distribution into various brain regions [135]. This is also true for the 
negatively charged basement membrane (see section 3.3.1.2), which is almost as thick as the 
endothelial cytoplasm (in human 200 nm [42]) and which may influence movement of 
charged solutes between blood and brain ISF [52]. The endothelial cells themselves possess 
several lines of defense, first the negatively charged endothelial glycocalyx [136], then the 
metabolically active endothelial cytoplasm [136], and the luminal and abluminal membranes, 
the combined characteristics determine which molecules cross the barrier and how fast [1, 7]. 
 
Transport across the BBB can occur via different routes, depending on the characteristics of 
the molecule to be transported (see Figure 9). The BBB can not simply be seen as a passive 
barrier, the cells actively participate in regulating the composition of the brain ISF. 
 
Paracellular diffusion. The tight junctions connecting the endothelial cells of the BBB inhibit 
paracellular diffusion (see section 3.3.1.1.1). The high TEER of the BBB in vivo is indicative 
of a restriction to the movement of even ions [1, 7]. Most hydrophobic molecules can still 
3. Introduction.  49 
 
passively diffuse across the BBB, also the blood gases oxygen and carbon dioxide, but entry 
of hydrophilic solutes from blood to brain has to be guaranteed and regulated via different 
transport systems. There is a correlation between the rate a solute enters the brain and its lipid 
solubility [26]. 
 
Transport proteins. It is generally assumed that at least 5% (>2,000) of all human genes are 
transporter-related [137] and it is estimated that about 15% of all genes selectively expressed 
at the BBB encode for transporter proteins [33]. 
Transporters can be divided into active and passive transporters. Passive (facilitative) 
transporters transport solutes across membranes down their electrochemical gradients. Active 
transporters are classified as primary- or secondary-active transporters and build up ion or 
solute gradients across membranes. Primary-active transporters are directly ATP dependent, 
e.g. ATPases and members of the ATP-binding cassette (ABC) transporter family. Secondary-
active transporters, like SNAT1 (Slc38a1), use the electrochemical gradient build up by 
primary-active transporters, like Na+/K+-ATPase, to drive solute transport against a 
concentration gradient. [137] Even if not directly coupled to the sodium gradient, transporters 
can be dependent on the substrate gradient generated by secondary active transporters and are 
therefore named tertiary active transporters (e.g., LAT1-4F2hc) [138]. The polarized BBB 
endothelial cells selectively localize specialized transport systems to the luminal and / or 
abluminal membrane. This polarized distribution is assumed to be the prerequisite for 
directional transcellular transport from blood to brain or from brain to blood (see section 
3.6.1.2 and 6). 
Solute carriers. The solute carrier (SLC) gene series currently includes 48 families and 368 
transporters genes [125]. SLC members encode for passive transporters, ion-coupled 
transporters and exchangers of various substrates. Members of a SLC family have at least 20-
25% amino acid sequence identity [137]. Names are given using the root symbol SLC, 
followed by a numeral indicating the family, the letter A (which acts as a divider between the 
numerals) and the number of the individual transporter [137]. 
The best examined SLC member at the BBB, in regards to its expression, localization, and 
regulation, is GLUT1 (Slc2a1). GLUT1 is a sodium-independent, facilitative diffusion protein 
transporting glucose, galactose, mannose, and glucosamine. It is highly expressed in blood-
tissue barriers, in particular in the BBB endothelial cells [139], where it is even considered as 
a marker molecule. GLUT1 is reported to be asymmetrically distributed, with about 11% 
located in the luminal membrane, 44 % in the abluminal membrane, and 45% intracellular 
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[140-141]. Additionally, to explain the observed discrepancy of polarized expression, but 
equal glucose transport activity in the two membranes, a conformational alteration in the 
GLUT1 proteins on the luminal membrane has been suggested [140]. Recently, Glut1-mRNA 
was shown to be expressed at very high levels in primary, non-cultured mouse brain 
microvascular endothelial cells, and to be linked to BBB transendothelial transport in vivo [2]. 
ABC transporters. ABC transporters in the human are a superfamily with 48 members 
grouped into seven sub-families based on structural homology [26] and function as active 
efflux pumps, carrying a neuroprotective and detoxifying function. They posses a polarized 
expression like the SLCs, with luminal expression of e.g. P-gp (P-glycoprotein, ABCB1) and 
BCRP (Breast Cancer Resistance Protein, ABCG2), in a position to transport substrate from 
the BBB endothelial cells to blood [26]. 
Additional “non-SLC” transporters. Channels, receptors, and aquaporins are also involved in 
transport processes across membranes [137]. Channels control ion / solute flow via gating 
mechanisms, not by a fixed stoichiometry like transporters. 
 
Transport of macromolecules via transcytosis. Endocytotic mechanisms provide the main 
route by which large molecular weight solutes such as proteins and peptides can enter the 
CNS intact [26]. In general, the rate of transcytosis across the BBB is reduced, since the 
endothelial cells are characterized by reduced numbers of endocytotic vesicles in the 
cytoplasm (see section 3.3.1.1), e.g., only 16-20% of that seen in muscle capillary endothelia 
[1, 26]. Smaller peptides can also be transported by either non-specific fluid-phase 
endocytosis or peptide-specific transport proteins [26]. Transcellular permeability is caveolae-
mediated [22]. 
Receptor-mediated transcytosis (RMT). Binding of ligands, e.g. insulin, to specific receptors 
on the cell surface trigger endocytosis, followed by exocytosis at the opposite pole of the cell 
[26]. 
Adsorptive-mediated transcytosis (AMT). Cationic molecules, e.g. lectins, interact with cell 
surface binding sites, which induce endocytosis and subsequent transcytosis [26]. 
 
Movement of cells. In the normal BBB, mononuclear cells penetrate via diapedesis directly 
through the cytoplasm of the endothelial cells. In inflammatory pathological states, 
mononuclear cells can enter by both transcellular and paracellular routes [26]. 
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Figure 9: Possible transport processes across the blood-brain barrier endothelium.  
  
Routes of transport across the BBB. (a) Solutes may passively diffuse through the cell membrane and cross the 
endothelium; (b) Active efflux carriers (ABC transporters) may intercept some of these passively penetrating 
solutes and pump them out of the endothelial cell either as they diffuse through the cell membrane or from the 
cytoplasm; (c) Carrier-mediated influx via solute carriers (SLCs) may be passive or primarily or secondarily 
active and can transport many essential polar solutes into the CNS. The SLCs may be bi-directional, the direction 
of net transport being determined by the substrate concentration gradient (1), unidirectional either into or out of 
the cell (2/3), or involve an exchange of one substrate for another or be driven by an ion gradient (4). In this last 
case the direction of transport is also reversible depending on electrochemical gradients; (d) RMT requires 
receptor binding of ligand and can transport a variety of macromolecules such as peptides and proteins across the 
cerebral endothelium (transcytosis). AMT appears to be induced in a non-specific manner by positively charged 
macromolecules and can also transport across the endothelium. Both RMT and AMT appear to be vesicular-
based systems; (e) Leukocytes cross the BBB either by a process of diapedesis through the endothelial cells, or 
via modified tight junctions. Source: Figure 4 from Abbott et al. (2010) [26]. 
 
 
3.6.1 Amino acid transport. 
Amino acid transporters are members of different solute carrier (SLC) families, with different 
substrate specificities, transport mechanisms, and ion dependencies [137]. Amino acid 
transporters are grouped according to their structure (SLC families), their transport 
mechanisms, and their substrate specificities (transport systems, see Table 4). In respect to 
structure, only SLC7 family members are heterodimeric proteins, constituted by a heavy 
(SLC3 member) and a light chain (SLC7 member). The light chain determines the functional 
properties of the transporter, the main function of the heavy chain is the trafficking of the 
complex to the plasma membrane. [142] 
Prior to the molecular identification of amino acid transporters, transport was described in 
terms of transport systems. Conventions for the naming of amino acid transport systems 
include: “(1) upper case to indicate sodium-dependence, lower case for sodium-independence 
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(exception: system L); (2) designations y+ and x- for transporters of cationic and anionic 
amino acids, respectively; (3) the superscript 0, indicating transport of zwitterionic amino 
acids, used single or in combination with + or – for transporter of amino acids with differing 
net charge” [143]. Furthermore, systems indicate substrate preferences, e.g. members of the 
sodium-independent system L prefer amino acids like leucine (hence “L”) [143]. System A 
members transport substrates like alanine in a sodium-dependent way (hence “A”), and 
system ASC transports substrates like alanine, serine, and cysteine also in a sodium-
dependent way [143] (see Table 3 and Table 4). 
In respect to physiological functions, transporters can be grouped into highly accumulating 
transporters (e.g., EAATs), weakly accumulating transporters (e.g., SLC38 members), 
antiporters or exchangers, and uniporters [142] (see Table 4). Antiporters represent the 
majority of amino acid transporters in mammalian tissues and mediate preferentially an 
exchange of essential amino acids against nonessential amino acids without causing a net loss 
or increase of the total amount of amino acids. Antiporters can also display an asymmetry, 
particularly when they are involved in vectorial transport. One example for asymmetry is 
LAT1-4F2hc, which shows a higher substrate binding affinity extra- than intracellular [144]. 
[142] Furthermore, the driving force of a transporter can be fine-tuned by co-transporting ions 
like protons, potassium or chloride which are close to electrochemical equilibrium (see 
section 3.6.1.3.2). Therefore, “one cannot judge the net direction of a transport solely by the 
direction in which its gradient is oriented” [145]. The number of true uniport systems is low, 
maybe because this mechanism does not protect the cell from fluctuations in the plasma. An 
exception is the transport of cationic amino acids (see Table 4), therefore it has been 
suggested that the intracellular arginine concentration reflects the nutritional status and could 
present a metabolic signal. In this regard it is interesting that LAT1 (Slc7a5) is regulated by 
arginine availability, although arginine is not a substrate of the transporter. [142] 
 
Amino acid transport across the BBB. Amino acid uptake into brain depends on the type of 
amino acid. Nonessential amino acids show minimal uptake from blood since they are derived 
from intracerebral synthesis. Essential amino acids, in contrast, are derived almost exclusively 
from the blood. [93] By increasing plasma levels of glycine, tryptophan, aspartate, arginine, 
serine, threonine, isoleucine, and methionine above brain levels in the mouse, it could be 
observed that the relative uptake of the amino acids normally high in the brain was smaller 
than that of amino acids at lower levels in brain (e.g., isoleucine, methionine) [135]. Although 
brain levels increased, for example, about four-fold in the case of isoleucine, none of the 
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amino acids reached levels in brain equal to those in plasma (see Table 3) [135]. The 
excitatory neurotransmitter amino acids aspartate and glutamate were not taken up by brain 
[135]. The rate of synthesis and the brain concentration of neurotransmitters has been shown 
to be influenced by brain levels of the respective precursor amino acids, since the key rate-
limiting enzymes are not saturated at normal brain concentrations [93]. Furthermore, in 
pathological conditions like the hyperaminoacidemias (see section 3.5.5), protein synthesis 
becomes substrate limited and rate affected by amino acid transport across the BBB [119]. 
Functional experiments in vivo and in vitro have been performed to characterize the 
transendothelial transport of specific amino acids. Studies on isolated membrane vesicles have 
been used to determine the distinct role of the luminal and abluminal membranes of the 
microvascular endothelial cells in this process, and the identity and functionality of the 
transporters involved [5-6, 79, 82]. In this way, it was proposed that system ASC, A, N, 
EAAT, and LNAA members are expressed exclusively abluminal, system n, and XG- 
exclusively on the luminal membrane, and system L1 and y+ members on both membranes [1] 
(see Table 4, Figure 10, and section 3.6.1.1/2).  
In general, transporters expressed in CNS and the same transporters expressed in peripheral 
tissues are not necessarily controlled the same way, as shown e.g. for SNAT1 (Slc38a1) and 
SNAT2 (Slc38a2) [106]. This could in some cases be explained by the special 
microenvironment of the BBB endothelial cells and the special role the single amino acids 
play in the CNS. For example, a greater activity of system y+ on the endothelial abluminal 
membrane was observed and suggested to be due to the proximity to the astrocytic arginine 
stores [6]. Arginine is an essential amino acid and precursor of the vasodilator nitric oxide 
(NO) [6]. ASCT2 (Slc1a5) is known to be involved in stereoselective L-aspartate efflux 
across the abluminal membrane [146]. This is consistent with the function of the different 
isomers (see also section 3.5.2). The accumulation of L-aspartate would lead to excitatory 
neurotoxicity. Contrary, D-aspartate influences the secretion of hormones like testosterone, 
melatonin and oxytocin, and needs therefore to be stored [146]. 
The first described and best characterized amino acid transporter of the BBB, the sodium-
independent exchanger of the system-L family, LAT1 (Slc7a5), is composed of two subunits 
that are both required for functional cell-surface expression (see Table 3 and Table 4). The 
catalytic subunit of this heterodimeric transporter is LAT1, which was first cloned 1998 [147-
148]; the second subunit is a type-II glycoprotein called 4F2hc or CD98 (Slc3a2). The two 
subunits of the LAT1-4F2hc heterodimer are linked by a disulfide bridge and together 
mediate transport of LNAAs, T3, T4, and L-DOPA into growing cells and across secretory or 
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bidirectionally transporting endothelial / epithelial barriers [138]. Along with its role in amino 
acid transport, 4F2hc is also involved in cell survival, cell fusion, and integrin activation, and 
LAT1 contributes to neuronal cell proliferation [149]. In functional studies it was found that 
the affinity of BBB neutral amino acid transport is higher than in peripheral organs, also 
compared to plasma amino acid concentrations, leading to renaming it system L1 [86]. 
System L1 is localized to both the luminal and abluminal membrane of the BBB [3, 150], 
with equal expression but different activity [5]. The clearance by the luminal membrane is 
with 32 µl•min-1•mg-1 higher than the one by the abluminal membrane (14 µl•min-1•mg-1) [5]. 
Transport via LAT1-4F2hc is competitive (see section 3.5.4.3 and 3.6.1.1) and almost fully 
saturated at normal plasma LNAA concentrations. Therefore, the uptake of each LNAA into 
brain is dependent on its own plasma concentration but also on that of each of its competitors 
[113]. It also has been shown that entry into the brain of excluded amino acids can be 
increased by raising their concentration in the blood [101]. 4F2hc shows a broader expression 
pattern in brain than LAT1 since it is needed for the proper membrane insertion also of other 
SLC7 family members highly expressed in whole brain, e.g. y+LAT2 (Slc7a6) and xCT 
(Slc7a11) [151]. The localization of LAT1-4F2hc on both membranes and its role as tertiary 
active transporter (see section 3.6) puts it in a position to participate in transendothelial 
transport and in modulation of intracellular amino acid concentrations. This view was 
supported by our recent study comparing the mRNA expression of Lat1-4F2hc in the mouse 
BBB in vivo and in vitro [2]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Introduction.  55 
 
Table 4: Overview of amino acid transport systems.  
Transport system Transporter Transport mechanism 
A SNAT1 (Slc38a1); SNAT2 (Slc38a2); 
SNAT4 (Slc38a4) 
 
1 Na+ / AA (symport) 
ASC ASCT1 (Slc1a4); ASCT2 (Slc1a5) 
 
1 Na+ / AA (symport); AA (antiport) 
asc Asc1/4F2hc (Slc7a10/Slc3a2) 
 
AA (antiporter) 
B0 B0AT2 (Slc6a15); B0,+AT3/Coll 
(Slc6a18); B0AT1/Coll (Slc6a19) 
 
1 Na+ / AA (symport) 
B0,+ ATB0,+ (Slc6a14) 
 
2 Na+ / 1 Cl- / AA (symport) 
b0,+ b0,+AT/rBAT (Slc7a9/Slc3a1) 
 
AA (antiport) 
β GAT1 (Slc6a1); TAUT (Slc6a6); GAT3 
(Slc6a11); BGT1 (Slc6a12); GAT2 
(Slc6a13) 
 
2-3 Na+ / 1 Cl- / AA (symport) 
Gly GlyT2 (Slc6a5); GlyT1 (Slc6a9) 
 
2-3 Na+ / 1 Cl- / AA (symport) 
IMINO SIT1/Coll (Slc6a20) 
 
2 Na+ / 1 Cl- / AA (symport) 
L LAT1/4F2hc (Slc7a5/Slc3a2); 
LAT2/4F2hc (Slc7a8/Slc3a2);  
LAT3 (Slc43a1); LAT4 (Slc43a2) 
 
AA (antiport) 
 
AA (uniport) 
N SNAT3 (Slc38s3); SNAT5 (Slc38a5) 
 
1 Na+ / AA (symport) / 1 H+ (antiport) 
PAT PAT1 (Slc36a1); PAT2 (Slc36a2) 
 
1 H+ / AA (symport) 
T TAT1 (Slc16a10) 
 
AA (uniport) 
X-AG EAAT3 (Slc1a1); EAAT2 (Slc1a2); 
EAAT1 (Slc1a3); EAAT4 (Slc1a6); 
EAAT5 (Slc1a7) 
 
3 Na+ / 1 H+ / AA (symport) / 1 K+ (antiport) 
x-c xCT/4F2hc (Slc7a11/Slc3a2)  
AA (antiport) 
y+ CAT-1 (Slc7a1); CAT-2A/B (Slc7a2); 
CAT-3 (Slc7a3) 
 
AA (uniport) 
 
y+L y+LAT2/4F2hc (Slc7a6/Slc3a2); 
y+LAT1/4F2hc (Slc7a7/Slc3a2) 
 
1 Na+ / AA (symport); AA / AA+ (antiport) 
 
Overview of amino acid transport systems, corresponding proteins and genes (in brackets). Corresponding 
substrates are listed in Table 3. Accessory proteins are given where known: 4F2hc, rBAT, and Coll (Collectrin). 
Slc, solute carrier; AA, amino acid. Adapted from Bröer (2008) [130], Bröer (2002) [142], and Hyde et al. 
(2003) [126]. Systems used in Hawkins et al. (2006) [1] correspond, based on substrate profiles, most properly to 
system X-AG (“EAAT”), system N (“n”, but sodium-dependent), and system “Na+-LNAA” shows overlapping 
profiles with B0AT1 (system B0) and LAT2 (system L). 
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3.6.1.1 Short literature review on BBB amino acid transport. 
The following section includes a selective chronological review of the research progress 
concerning amino acid transport across the BBB. It has to be mentioned that the interpretation 
of the data given by the authors and reported here was limited by the absence of kinetic 
information of the involved transporters that were identified only very recently after their 
cloning during the last 20 years. In particular, many of the given interpretations do not 
account for the fact that LAT1-4F2hc (corresponding to system L1) functions as an obligatory 
exchanger (antiport) and not as a facilitated diffusion pathway (uniport). To underline this 
crucial interpretation problem, evident questionable interpretations are labeled in the 
following review (and in section 3.6.1.2) with a “(!)”. Nonetheless, the interpretations of the 
authors are given here without pointing each time to their limitations. 
 
In 1978 Betz and Goldstein demonstrated that αMeAIB‡ was not transported from blood to 
brain in vivo and concluded that system A transport does not exist at the BBB [3]. On the 
other hand, some system A substrates were found to be transported from brain to blood 
against a concentration gradient [3]. They finally concluded that system A transport occurs at 
the abluminal, but not on the luminal membrane [3]. They also already pointed out the impact 
of this polarity in actively regulating the composition of brain ISF against a concentration 
gradient [3]. Furthermore, they saw a link between the operation of abluminal sodium-
dependent transporters and the high mitochondrial density in BBB endothelial cells, and 
pointed out the difficulty to interpret in vivo data due to the presence of amino acid 
transporters in choroid plexus and brain cells [3]. 
 
Also James and Fischer (1981) [152] examined the transport of neutral amino acids at the 
BBB. They discussed the existence of exclusively system L at the luminal membrane. 
However, they also pointed out that transendothelial transport is the sum of influx and efflux 
and that it is not known if efflux is mediated via the same transport systems than influx, 
different from or supplementary to it. This lack of knowledge regarding efflux, together with 
the possible impact of metabolism and cooperation with astrocytes in transport processes led 
the authors to conclude that one can not judge the impact of transport in the regulation of 
brain neutral amino acid concentrations. 
It was previously proposed that transport of neutral amino acids into cells is mediated by 
systems L, A, ASC, and Gly. The participation of system ASC in blood to brain transport 
                                                 
‡ 2-(methylamino)isobutyric acid 
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could neither be confirmed nor disproven, whereas that of system Gly could be disproven. 
The properties of neutral amino acid transport into brain are consistent with the existence of 
an active L system and an absent or negligible A system. Influx of neutral amino acids 
showed substrate specificity, with most active uptake into brain for phenylalanine, leucine and 
tyrosine. In addition to saturable transport, a not characterized nonsaturable blood to brain 
transport of amino acids has been repeatedly demonstrated. 
The authors [152] also mentioned that BCAAs are metabolized to a higher extend than 
aromatic amino acids, and that the brain therefore must synthesize nonessential system-L 
substrates to guarantee equal exchange with essential amino acids. They suggested that 
system A on the abluminal membrane could act to concentrate nonessential amino acids such 
as alanine or glutamine, with a low affinity for system L, to high levels in the intraendothelial 
compartment, to then be exchanged with other neutral amino acids from blood. Glutamine 
would be a good candidate for exchange via system L due to its high CSF concentrations and 
since it could be shown that increased brain glutamine stimulates brain neutral amino acid 
uptake. They pointed out that an active uptake of amino acids on the abluminal side could also 
explain the low CSF / plasma ratios of most neutral amino acids. Another aspect the authors 
mentioned was competition for uptake among amino acids on the blood side. In this way the 
uptake of one neutral amino acid relative to that of another can be regulated. However, they 
point out that the factors regulating the uptake of all neutral amino acids, as a group, are not 
known. 
 
Cangiano et al. [153] showed two years later that in isolated brain microvessels an 
intracellular accumulation of glutamine via system A trans-stimulated the uptake of neutral 
amino acids via system L. Therefore the authors suggested cooperation between the two 
differentially localized transport systems to regulate the rate of neutral amino acid uptake into 
brain over the BBB. 
 
Five years later, Hargreaves and Pardridge (1988) [86] examined neutral amino acid 
transport at the human BBB, showing that phenylalanine is transported exclusively by system 
L, whereas leucine is transported equally by system L and ASC. They located system L 
activity to both the luminal and abluminal membrane, whereas system ASC seemed to be 
restricted to the abluminal membrane. They mentioned also an in vivo study in rats after 
which system ASC may also function at the luminal membrane. The affinity of human BBB 
neutral amino acid transport was shown to be very high, with an about 100-fold lower Km 
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value than in peripheral tissues. They also mention species differences, with 8-40-fold lower 
Km values in human BBB than in the rat BBB in vivo. In addition, the authors tested the 
inhibitory effect of other neutral amino acids on the transport of leucine into human brain 
capillaries and found inhibition by BCAAs and ArAAs, but none by glutamate, arginine or 
proline. Leucine, tyrosine, and tryptophan trans-stimulated phenylalanine transport, indicating 
transport via the same transport system. Contrary to previous studies, also glycine and alanine 
had an inhibitory effect on leucine transport. Therefore the authors suggested that more than 
one transport system for neutral amino acids exists. The transport of neutral amino acids into 
isolated human brain capillaries was found to be mediated, in most cases, by both a high 
affinity (up to 97% of amino acid transport) and a low affinity system. 
 
Four years later in a 1992 study Sánchez del Pino et al. [82] used membrane vesicles for the 
first time to investigate neutral amino acid transport at the BBB. They demonstrated the 
sodium- and proton-independence of L-phenylalanine transport and its almost complete 
inhibition by other LNAAs, BCH§, and D-phenylalanine. The authors mentioned a second, 
non-saturable, transport component that could be a low affinity, high capacity transport 
system, or a non-facilitated diffusion process. Furthermore, the authors pointed out the 
discrepancy between missing “obvious” morphological, but well established biochemical 
polarity of brain endothelial cells. For instance the abluminal, but not the luminal membrane, 
contains Na+/K+-ATPase activity, whereas γ-glutamyl transpeptidase and alkaline 
phosphatase are located luminal. The authors proposed that this enzymatic polarity also exists 
for transport of glucose and amino acids. In contrast to Hargreaves and Pardridge [86], 
Sánchez del Pino et al. debated the localization of system ASC. However, they agreed that 
there is no in vivo evidence for luminally expressed system A, and that sodium-dependent 
transport systems are restricted to the abluminal membrane. In addition Sánchez del Pino et 
al. pointed out that the methods on which the concept of system L localization on both BBB 
membranes rely on are relatively insensitive. 
 
In 1995 Sánchez del Pino et al. [79] characterized phenylalanine transport by the high affinity 
system L1 (Km = 10 ± 2 µM) using isolated luminal and abluminal BBB membranes. They 
described that both membranes contain the same sodium-independent transporter which is 
symmetrically distributed, and that system L1 has in both membranes the same substrate 
specificities. They found 65% of alanine uptake to be sensitive to MeAIB (system A), 24% to 
                                                 
§ BCH, 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid 
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BCH (system B0,+), and 11% of the uptake due to a non-saturable and sodium-independent 
mechanism. The remaining sodium-dependent alanine uptake was ascribed to system ASC. 
System A and B0,+ are both reported to be exclusively located at the abluminal membrane. 
Based on their experiments the authors [79] describe the transport polarity at the BBB such 
that sodium-dependent transport activities are enriched in the abluminal-rich membrane 
fraction, whereas the luminal-rich membrane fraction contains a greater extent of sodium-
independent transport activity. The observed sodium stimulated uptake by the luminal-rich 
membrane fractions was discussed to be completely due to abluminal vesicle contamination. 
They also mention system T, which they propose, if present, to be a minor transport 
component, and again pointed out the discrepancy regarding expression of system ASC at the 
BBB. 
 
In the same year, Sánchez del Pino et al. [154] examined the polarized expression of enzymes 
and transporters at the BBB to identify marker molecules. Isolated bovine brain endothelial 
cell membrane vesicles showed expression of γ-glutamyl transpeptidase restricted to the 
luminal and system A to the abluminal membrane. 5´-nucleotidase and alkaline phospatase 
were found to be symmetrically distributed on both membranes. Na+/K+-ATPase activity was 
mainly located to the abluminal membrane, but about 25% of the activity was found luminal, 
with a different ouabain sensitivity than the one expressed abluminal. Therefore the authors 
suggested that different Na+/K+-ATPase isoforms are expressed at the different membranes 
and that this distribution could favour a net blood to brain transport of sodium. 
 
Tamai et al. [155] examined transport of taurine at the BBB in vitro in bovine and in vivo in 
rats. Taurine was found to be taken up in a sodium-and chloride-dependent manner on both 
the luminal and abluminal membranes. The uptake of taurine, for which no metabolism in 
cells has been observed, was carrier mediated and transport was from blood to brain. 
Transport efficiency was similar on both membranes, but inhibition of taurine uptake by 
cysteine, methionine, and phenylalanine was found to be different. Furthermore, the luminal 
and abluminal transporter showed different substrate specificities, with glutamate stimulating 
taurine uptake at the luminal membrane, but inhibiting abluminal taurine uptake. 
 
Boado et al. 1999 [83] showed the selective expression of the system L1 transporter LAT1 at 
the BBB. LAT1 mRNA was not detected in rat liver, heart, lung, or kidney. In rat brain and 
rat C6 glioma cells LAT1 mRNA was present, but the level in isolated bovine brain 
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capillaries was 100-fold higher. Furthermore, LAT1 was found to be the most abundant 
transcript at the BBB, higher than 4F2hc, actin, or GLUT1. The level of 4F2hc mRNA in the 
BBB was <10% of than in either total brain or C6 glioma cells. The ratio of 4F2hc mRNA to 
LAT1 mRNA was shown to be <1 at the BBB. The authors suggest that this indicates that the 
availability of 4F2hc is rate limiting in the formation and membrane expression of LAT1-
4F2hc. They discussed the possibility that even if LAT1 mRNA is expressed at higher levels 
than GLUT1 mRNA, the reverse may be true on the protein level, since Vmax for D-glucose 
transport at the BBB is much higher than for LNAA transport. As another explanation they 
discussed the possibility that the LAT1 transcript has a high turnover rate. In addition, the 5`-
UTR and 3`-UTR of the BBB LAT1 transcript contain cis-regulatory sequences suggesting 
that LAT1 gene expression may be posttranscriptionally regulated. Further, bovine LAT1-
4F2hc injected into frog oocytes increased tryptophan transport 10-fold. This transport was 
characterized by a Km of 31.5 ± 5.5 µM, by sodium-independence and by transport inhibition 
by other LNAAs and BCH, but not by alanine, glutamate or arginine. They also suggested 
that LAT1 seems to be the major system L transporter at the BBB, since LAT2 represents a 
high-Km system and is not selective for LNAAs. The authors mention that this selective 
expression of LAT1, normally saturated by the plasma concentrations of LNAAs, is believed 
to be the reason why the brain is selectively sensitive to hyperaminoacidemias (see section 
3.5.5) but not to hypoaminoacidemias. 
 
In the same year, O'Kane et al. [156] described the expression of the sodium-dependent 
glutamate transporters EAAT1, EAAT2, and EAAT3 in bovine cerebral capillaries and 
showed that their protein expression is restricted to the abluminal membrane of BBB 
endothelial cells. By examining the three transporters as aggregate, voltage dependence, 
potassium dependence, an apparent Km of 14 µM (at -61 mV), a Vmax of 151 ± 20 pmol•mg-
1•min-1, and inhibition of glutamate transport by kainic acid (EAAT2) and cysteine (EAAT3) 
could be shown. The relative activity of the transporters was measured as 1:3:6 
(EAAT1:EAAT2:EAAT3). Furthermore, glutamate transport in the absence of sodium was 
50-70% reduced and intravesicular potassium increased uptake by 56.5%. The authors 
assumed that other glutamate transporters do not play a significant role, since the activity of 
EAAT1-3 accounted for all the transport activity measured by the method. 
 
A 2000 review by Smith [17] summarized the expression and localization of different amino 
acid transport systems as followed: system L (high affinity), system y+ (moderate affinity), 
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system T (high affinity), and system x- (high affinity), with systems L and y+ localized to 
both membranes. In contrast, systems A, B0,+, ASC, and X- were found to be primarily 
expressed at the abluminal membrane. Transport of β-alanine and taurine was shown to be 
mediated by system β. System N mediates glutamine uptake into brain and was found on 
either luminal or abluminal membrane by different studies. The author also pointed out that in 
1993 system y+ (CAT-1) was the first molecular characterization of a BBB amino acid 
transporter. 
 
Also in 2000, Matsuo et al. [150] showed for the first time immunohistochemical evidence for 
the assumption, based on functional data, that LAT1 and 4F2hc are symmetrically expressed 
on both membranes of the endothelial BBB. Both LAT1 and 4F2hc were found in a “double 
line appearance” surrounding endothelial cell nuclei. The authors proposed due to the co-
expression of the heterodimer LAT1-4F2hc, that LAT1 is functional in the plasma membrane. 
The authors also speculate that LAT1 function is highly regulated at the BBB, e.g. via protein 
kinase-dependent phosphorylation. They also mention that even if GLUT1, MCT1 and MDR1 
have been identified previously at the BBB, LAT1-4F2hc is the first amino acid transporter. 
They pointed out that the molecular identity of other proposed BBB amino acid transport 
systems, such as N, A, and y+, remained to be determined. 
 
A second study examining LAT1 CNS localization using immunohistochemistry was 
published in the same year by Kageyama et al. [149]. They found LAT1 expressed in 
microvessels in the brain parenchyma and in the ependymal cells, but neither in the choroid 
plexus nor in neuronal and glial cells in the cerebral cortex, caudate putamen, cerebellum and 
brain stem. LAT1 showed a high expression in the subfornical organ (see section 3.3), 
therefore the authors suggested that this organ may play a role in amino acid homeostasis by 
monitoring peripheral amino acid contents. It had been previously demonstrated that the 
uptake of neutral amino acids from the blood into the choroid plexus is mediated by system L, 
which stands in contrast to the present study. In contrast the authors found 4F2hc to be 
expressed and therefore they suggested that in the choroid plexus of mice other system L 
isoforms are expressed. They pointed out that LAT1 mRNA expression was generally found 
to be correlated with proliferating cells rather than differentiated cells of the same origin, and 
that there is the possibility that LAT1-4F2hc might regulate the migration of neuronal 
progenitor cells. 
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Takanaga et al. [157] showed for the first time brain to blood transport of glycine and L-
proline and the involvement of system A transport in this process. The primary system A 
transporter at the BBB, ATA2 (SNAT2; see section 3.6.1.3), was found to be upregulated by 
373% under hypertonic conditions. Therefore the authors suggested that ATA2 may play a 
role in maintaining cerebral osmotic pressure and in maintaining barrier properties of the BBB 
due to endothelial cell volume regulation. The system A specific substrate MeAIB was not 
found to be transported into the blood, in contrast to L-proline and glycine, suggesting that 
system A expression is restricted to the abluminal membrane and that there may be another 
transport system responsible for transport of the amino acids across the luminal membrane. 
 
In 2003 Tetsuka et al. [124] demonstrated ASCT2 expression at the abluminal membrane of 
BBB endothelial cells, with mRNA expression of ASCT2 being 6.67-fold greater than of 
ASCT1. They also showed for the first time that these transporters mediate stereoselective 
brain to blood transport of L-aspartate across the mouse BBB (see section 3.6.1), mainly via 
ASCT2 in a pH-dependent manner with low affinity. L-aspartate uptake was found to be both 
sodium-dependent and -independent, while D-aspartate uptake was mainly sodium-
independent. Sodium-independent L-aspartate uptake could be inhibited by L-glutamate 
(85.7%) and D-aspartate (41.5%), and could be increased by L-serine to 146%. ATB0+ mRNA 
expression was found to be absent in BBB cells, and therefore it was concluded that system 
B0,+ is not involved in L-aspartate uptake. The authors mentioned the discrepancy between 
transport affinity of BCH and L-leucine for system ASC and the lack of inhibition by these 
two substrates for sodium-dependent L-aspartate uptake. They also concluded that further 
studies are needed to identify efflux systems for L-aspartate on the luminal membrane, to 
identify the possible additional contribution of sodium-independent L-aspartate transport, and 
the contribution of other amino acid transporters. 
 
O'Kane et al. (2003) [4] used isolated cow brain microvascular abluminal-enriched membrane 
fractions to study sodium-dependent transport of LNAAs. The yet unknown transport system 
was characterized by voltage sensitivity, inhibition by BCH, high affinity for leucine (Km 21 ± 
7 µM) and inhibition by other neutral amino acids. The spectrum of inhibitors was similar to 
the ones of LAT1. The authors excluded a role of system ASC / B0 in the observed transport 
process since alanine transport could not be inhibited by phenylalanine, tryptophan or 
tyrosine. 
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They also described the results of previous studies showing sodium-dependent systems A, 
ASC, B0,+, N and EAAC are expressed at the abluminal membrane, and showing that blood to 
brain transport of essential neutral amino acids is greater than of nonessential amino acids. 
The observed sodium-dependent brain to blood transport of essential amino acids further 
highlights the complex mechanisms controlling brain amino acid concentrations. 
 
One year later, O´Kane et al. [5] functionally described the four known sodium-dependent 
systems present at the abluminal membrane of the BBB transporting neutral amino acids, 
namely system A, ASC, N, and Na+-LNAA. The different systems are described by 
overlapping substrate specificities, and system A was shown to be voltage dependent, in 
contrast to system ASC and N. System A and N transport only nonessential amino acids, 
whereas system ASC and Na+-LNAA transport in addition essential amino acids. The authors 
point out that the primary focus in the past has been on facilitative transport via system L1 
(!), expressed on both membranes, which is believed to guarantee transport of (essential) 
neutral amino acids from blood to brain. The presence of sodium-dependent transporters on 
the abluminal membrane is believed to enable maintaining neutral amino acid concentrations 
in the brain ISF at ~10% those of the plasma. This situation was also accounted for by the 
presence of active amino acid uptake by brain cells, and metabolism, once they entered brain 
ISF. Since arteriovenous differences could never be measured, the authors favoured the 
explanation that brain influx and efflux of neutral amino acids occurs at the same rate, due to 
sodium-dependent transporters being exclusively located to the abluminal membrane. They 
pointed out that nonessential neutral amino acids have not been found to be transported from 
blood to brain, but that there is possibly a transport of small nonessential amino acids by a yet 
unknown system. 
 
Two years later, in 2006, O´Kane et al. [6] found transport of cationic amino acids across the 
BBB to be exclusively mediated by system y+. The authors hypothesized this may be 
important to provide arginine for NO synthesis, a statement supported by the fact that all three 
NO synthases are present in BBB endothelial cells. System y+ was shown to be voltage 
dependent, with highest affinity for arginine, followed by lysine and ornithine. System B0,+, 
b0,+, and y+L were not found to be active at the BBB in the past. Therefore, cationic amino 
acid transport at the BBB is unique since it is mediated exclusively by facilitative transport. 
The authors suggested that the majority of lysine transport is via system y+, and they showed 
that it is about 40-times higher expressed in microvessels than in whole brain. Previously it 
3. Introduction.  64 
 
was proposed that system y+ exists on both membranes, but this was not measured directly. 
The authors found cationic amino acid transport activity predominantly abluminal, with some 
activity on the luminal membrane (about 4:1 for lysine transport).  
 
A 2006 review by Hawkins et al. [1] summarized the current knowledge about polarized 
expression of amino acid transporters at the BBB. The authors described facilitated amino 
acid transporters as being expressed at the luminal membrane, and as being saturable and 
stereoselective (system L1, y+, xG-, n). System L1 and y+ were both shown to be expressed in 
the luminal and abluminal membranes, but with different luminal:abluminal stoichiometry 
(L1 2:1; y+ predominantly abluminal). Systems xG- and n were described to be restricted to the 
luminal membrane. The transport of glutamine was found to be not completely inhibited by 
the system L1 inhibitor BCH, therefore it was proposed that glutamine transport occurs also 
via system n. System y+ has been characterized by a weak sodium-dependent interaction with 
neutral amino acids, and an about 10-fold greater affinity compared to system L1. 
Sodium-dependent transport systems (A, ASC, N, EAAT, Na+-LNAA) are described to be 
exclusively expressed at the abluminal membrane and to show a higher or at least similar 
transport capacity than the facilitative (!) transporters. Glutamine transport was found to be to 
80% mediated by system N, and to 20% by system A, the latter being the first system 
characterized. Sodium-dependent transport of LNAAs was first thought to be mediated by 
system B0,+; and EAAT1-3 have been shown to be together the most effective clearance 
system at low amino acid concentrations. 
 
In 2008 Czeredys et al. [158] examined the localization of ATB0,+, a sodium-chloride-
dependent transporter of both neutral and cationic amino acids. ATB0,+ was shown to be 
expressed in brain capillary endothelial cells with mostly luminal localization, a small fraction 
being also localized to the abluminal membrane. Experiments showed ATB0,+ can mediate 
transport of D-serine, contributes by more than 1/3 to leucine accumulation in endothelial 
cells, and, in contrast to LAT1, can be activated by an increase in plasma amino acid 
concentrations. The authors also reviewed the localization of ASCT2, ATA2, EAAC, LNAA, 
OCTN2 and noradrenaline transporter at the abluminal membrane. Taurine, creatine and 
serotonine transporters were previously described to be localized to both membranes, and 
GAT2/BGT1 to colocalize with P-gp on the luminal membrane. 
 
3. Introduction.  65 
 
Taken together, these studies represent a sum of important observations on transendothelial 
BBB amino acid transport. However, they also point to the lack of sufficient knowledge of the 
involved transporters, of their kinetics and their cooperation, which was the motivation for the 
present work. 
 
 
3.6.1.2 Asymmetrical distribution of sodium-dependent transporters at the BBB. 
The two membranes of the brain endothelial cells face chemically different compartments. 
The luminal membrane is in direct contact with the blood and its constituents, the abluminal 
membrane faces the brain ISF. The amino acid concentration in the ISF is considered to be 
about 10% those of plasma, with exception of glutamine, a condition necessary for brain 
function [1, 5, 7-8] (see section 3.5.4 and Figure 8). Due to this gradient over the endothelial 
cells, it has been proposed that the two membranes work in a complementary fashion [7], with 
facilitated diffusion processes primarily at the luminal membrane (!), allowing amino acids to 
enter and exit the endothelial cells along their concentration gradient [6-7]. The abluminal 
membrane of the BBB was shown to express mostly sodium-dependent transport systems [7], 
i.e. systems A, ASC, N, Na+-LNAA, and EAAT [6] (see also section 3.6.1.1). In addition, 
facilitative transport occurs at the abluminal membrane (!) [5]. One example for coordinated 
transport between the two membranes is system N transport of glutamine and system EAAT 
transport of glutamate, which is directed from the brain ISF into the endothelial cell [5]. The 
luminal facilitative carriers for both glutamate and glutamine can then transport them to the 
plasma [5]. The asymmetrical distribution of transporters allows brain-derived amino acids, as 
well as amino acids previously transported from blood to brain, to be actively and selectively 
transported from brain to blood against their concentration gradient [1, 5, 7-8]. It even has 
been suggested that secondary active transporters expressed at the abluminal membrane are 
responsible for the existing amino acid gradient between plasma and brain ISF [120]. The 
existence of a sodium-gradient flowing from the brain ISF into the endothelial cytoplasm, 
which is maintained by the (abluminal) Na+/K+-ATPase, is consistent with this proposed 
mechanism [1, 8]. Together with the fact that transport systems show overlapping substrate 
specificities, this organization can also restrict the availability of amino acids to the brain [8] 
and can guarantee the access to essential amino acids (via the facilitative systems (!)) [5]. 
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Figure 10: Proposed distribution of transporter and systems based on literature.  
 
  
Transporters at the BBB. a) Transporters mediating the blood-to-brain influx transport. c) Transporters 
mediating the brain-to-blood efflux transport. Source: Figure 2 a, c from Ohtsuki and Terasaki (2007) [159]. 
 
 
3.6.1.3 The SLC38 gene family. 
The SLC38 gene family is a family of sodium-coupled neutral amino acid transporters 
(SNATs) with system A and system N transport activities [106] (see Table 4). With the 
exception of SNAT4, glutamine is the favoured substrate throughout the family [106]. SLC38 
transporters play an important role in the glutamate/GABA-glutamine cycle in brain (see 
section 3.5.3.2 and Figure 7). 
System A subtypes SNAT1 (Slc38a1), SNAT2 (Slc38a2), and SNAT4 (Slc38a4), transport 
small, aliphatic amino acids (alanine, asparagine, cysteine, glutamine, glycine, methionine, 
and serine) and MeAIB** [106]. It has been suggested that SNAT2 is the responsible 
transporter for system A efflux transport at the BBB [146]. A unique characteristic of system 
A transport is that cytoplasmic amino acids can inhibit the uptake of extracellular amino acids 
via the transporter, a phenomenon called trans-inhibition [126]. Furthermore, most of SNAT1 
and SNAT2 proteins are localized to intracellular organelles including endosomes [106]. 
System A is also known to be regulated by osmolarity, amino acid availability and hormonal 
stimuli [142]. 
                                                 
** transport of MeAIB, 2-(methylamino)isobutyric acid, is a characteristic of system A transport 
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System N subtypes SNAT3 (Slc38a3) and SNAT5 (Slc38a5) transport small, zwitterionic 
amino acids with a narrower substrate profile than system A subtypes (glutamine, histidine, 
and asparagine) and with low affinity [106]. 
It is known that system A transporters can accumulate and maintain high intracellular 
concentrations of nonessential amino acids, like glutamine and alanine, which can then be 
used to accumulate essential amino acids via exchangers like ASCT2 [142], LAT1 and LAT2 
[138] (tertiary active amino acid uptake system) (see section 3.6). System A can accumulate 
substrates to a much higher degree than the electroneutral transport of system N is able to. 
“Thus, glutamine transport via system N is readily reversible, whereas system A transport 
reverses only when the membrane is depolarized or when the intracellular sodium 
concentration is elevated” [142]. The presence of system N in addition to system A is 
probably important for the decision if a cell releases glutamine or accumulates it [142]. In 
general, expression of system N seems to indicate a glutamine releasing site [142]. 
 
 
3.6.1.3.1 The system A transporter SNAT1. 
SNAT1 (Slc38a1; previously referred to as ATA1, GlnT, SA2, SAT1, or mouse NAT2), a 
sodium-dependent, pH-sensitive, neutral amino acid transporter of the system A subfamily. 
SNAT1 transports small aliphatic amino acids, preferentially alanine, asparagine, cysteine, 
glutamine, glycine, methionine, histidine, and serine, in an unidirectional, concentrative 
manner with 1:1 stoichiometry [106]. The primary effect of protons is to reduce the apparent 
affinity for sodium [106]. SNAT1 is predicted to have eleven transmembrane domains 
(TMD), with a large glycosylated loop between TMD V and VI, a short extracellular C-
terminus, and a cytoplasmic N-terminus [106]. SNAT1 is predominantly expressed in brain, 
spinal cord, retina, placenta, and heart, but also in lung, skeletal muscle, spleen and intestine 
[106]. It is expressed in central glutamatergic and GABAergic neurons, in dopaminergic 
neurons of the substantia nigra, cholinergic motoneurons, and in retinal ganglion cells, but not 
in astrocytes [106]. On the other hand, Melone et al. [160] found that >95% of SNAT1 
expressing cells are neurons, but that SNAT1 is also expressed in non-neuronal cells in 
leptomeninges, in luminal membranes of the ependyma [106], in the choroid plexus, and in 
astrocyte foot processes facing the abluminal membrane of the BBB. Functional studies by 
Sánchez del Pino et al. [79] demonstrated system A activity at the BBB. It was shown that 
system A activity is linked to the cell cycle and cell growth rate [106, 161], is inhibited by 
high concentrations of intracellular amino acids [161], and is up-regulated in mammalian cells 
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in response to amino acid deprivation [161]. SNAT1 may also play a role in driving 
metabolism and in providing the precursors for glutathione synthesis [106] (see Table 3). 
Recently we showed Snat1-mRNA to be expressed at very low levels in primary, non-
cultured mouse brain microvascular endothelial cells, and to be linked to intraendothelial 
metabolism and cell proliferation [2]. 
 
 
3.6.1.3.2 The system N transporter SNAT3. 
SNAT3 (Slc38a3; also referred to as SN1, NAT, or g17) is a system N, sodium-dependent 
cotransporter for small, zwitterionic amino acids like glutamine, asparagine, alanine, and 
histidine across membranes with 1:1 stoichiometry [106]. System N transport is proposed to 
be electroneutral, and not unidirectional [106]. 
SNAT3 transport is inhibited at low extracellular pH due to the proton-coupled 
countertransport, which may explain the reversibility of amino acid transport [106]. It is 
known that sodium binding to SNAT3 promotes amino acid uptake, a process which can be 
competitively inhibited by protons, and that proton binding promotes amino acid efflux [107]. 
At pH 6.0 SNAT3 releases glutamine, while at pH 8.0 glutamine is accumulated [142]. It was 
also shown that at high glutamine levels (~0.5 mM) SNAT3 mediates substrate uptake, while 
at low glutamine concentrations SNAT3 mediates efflux [107]. Therefore, SNAT3 can just 
generate a shallow amino acid concentration gradient between blood and brain, suggesting 
that glutamine uptake into cells is mainly mediated by system A transporters [107]. 
SNAT3 is reported to be expressed abundantly in liver, kidney, heart, skeletal muscle, and 
adipose tissue [106]. It was also shown that SNAT3 plays a role in hepatic ammonia 
detoxification and is involved in the renal response to acidosis [106]. In brain, SNAT3 is 
abundant in astrocytes, expressed in the choroid plexus and ependyma, but absent from 
neurons and oligodendrocytes. In the adult, SNAT3 was suggested not to be expressed in the 
vascular endothelium [162] (however, see section 5 for details). SNAT3 expression peaks at 
P14 with twice the adult level, showing also strong expression in the vascular endothelium, 
which disappears before P21 [163]. The peak in the expression of SNAT3 protein in the 
developing rat brain (twice the level seen in adult) coincides with increasing CNS levels of 
glutamate and GABA and a critical period in synaptogenesis [106]. Functional studies by Lee 
et al. [9] demonstrated system N activity at the BBB. Recently, Snat3-mRNA was shown to 
be expressed at very high levels in primary, non-cultured mouse brain microvascular 
endothelial cells, and to be linked to BBB transendothelial transport in vivo [2]. 
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Generation of Snat3 knock-out (-/-) animals was done by treating male C57BL/6J mice with 
the potent mutagen, N-ethyl-N-nitrosourea (ENU), resulting in offspring carrying a single 
nucleotide polymorphism. This mutation was a “C” to “T” mutation, known as “SLC38a3-
Q263X”, causing a premature stop codon deleting the second half of the protein [164]. Snat3-/- 
mice die within the first 3 weeks after birth [164]. They show growth retardation, display mild 
forms of ataxia with an uncoordinated gait, and neurological disturbances. After postnatal day 
15-18, knock-out mice weigh significantly less than their wildtype or heterozygote littermates, 
with a larger mean relative brain weight in knock-out animals. [164] (see also section 5) 
 
 
3.6.1.4 γ-Glutamyl cycle as possible link between luminal and abluminal transport. 
In general, transporters in the plasma membrane are in a position to monitor extra- as well as 
intracellular amino acid concentrations and to integrate and coordinate intracellular events 
[126]. 
Transporters expressed at the luminal respective abluminal membrane could integrate the 
signals from both compartments, plasma and brain ISF, to respond to environmental changes 
and to keep the gradient over the BBB. One possible link between transport processes located 
to the luminal and abluminal membrane is the γ-glutamyl cycle (see Figure 11). 
The activity of γ-glutamyl transpeptidase (GGT) is high in tissues that actively transport 
amino acids, such as the apical portion of the intestinal epithelium [8, 165]. In contrast, brain 
capillaries have a high GGT activity without being associated with active amino acid uptake 
from plasma [8]. Expression of GGT has been identified as indicator of the barrier phenotype 
in endothelial cells. Levels of GGT have been found to be decreased when endothelial cells 
are placed in culture, whereas treatment of endothelial cells with TGF-β increased GGT 
activity [166], indicating an expression correlating with differentiation [163]. 
The first reaction of the γ-glutamyl cycle (GGC) occurs extracellularly and is catalysed by 
GGT, an integral protein of the luminal membrane of brain endothelial cells [154, 167]. 
Subsequently, pyroglutamate (also known as oxoproline, the cyclized amide of glutamate) is 
produced intracellularly (see Figure 11) [8]. The GGC was proposed to be directly involved in 
amino acid transport, but this suggestion has been controversial (e.g., support [168], criticism 
[169]) [8, 165]. An alternative theory, proposed by Viña et al. [170-171] is that pyroglutamate 
acts indirectly by stimulating sodium-dependent amino acid transport and thereby the uptake 
of amino acids [7, 165]. The role of pyroglutamate as a regulator of sodium-dependent amino 
acid transport by the BBB was further supported by Lee et al. [8] who found that intracellular 
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pyroglutamate stimulates systems A and B0,+ at the abluminal membrane by 70 and 20%, 
respectively. Hawkins et al. [165] found that pyroglutamate stimulates sodium-dependent 
transport of glutamate by 46%, and that it inhibits facilitative glutamate uptake in luminal 
membranes. Furthermore, the effect of pyroglutamate was found to be specific and not limited 
to glutamate, it stimulates system A [8] and ASC [165], but not system N [165]. System N 
transports glutamine, the only amino acid in brain ISF that has a similar concentration to that 
of plasma. Thus, glutamine appears to be treated differently [165]. It has been suggested that 
the GGC and luminal GGT serve to monitor the availability of amino acids to the brain, being 
at least part of a short-term regulatory mechanism that influences the accessibility and content 
of brain amino acids [8, 165]. 
In conclusion, pyroglutamate was shown to stimulate the sodium-dependent removal of 
glutamate from the brain ISF while simultaneously decreasing its plasma uptake [165], 
leading to an increased glutamate clearing efficiency from the CNS when the availability is 
excessive [8, 165]. 
 
Figure 11: γ-Glutamyl cyle – a possible (intracellular) link between luminal and abluminal transport processes.  
  
Scheme of the influence of pyroglutamate on amino acid transport across the BBB. γ-Glutamyl amino acids are 
formed at the outer surface of luminal membranes by transfer of the γ-glutamyl moiety of glutathione to 
extracellular amino acids, a reaction catalysed by GGT. The γ-glutamyl amino acids that result enter the 
endothelial cells by a transport system that is not shared by free amino acids. Intracellularly, γ-glutamyl amino 
acids are substrates of γ-glutamyl cyclotransferase, which converts the γ-glutamyl amino acids into 
pyroglutamate and the corresponding free amino acids. The subsequent conversion of pyroglutamate to 
glutamate by oxoprolinase is the rate-limiting step of the GGC [172]. The sodium-dependent transport systems 
B0,+ [8], A [1, 8], ASC, Na+-LNAA, EAAT, and y+ [1], all located on the abluminal side, are activated by 
pyroglutamate, thereby reducing the net influx of amino acids to the brain [1]. N was the only system not 
stimulated [1]. The transport system L1 is distributed symmetrically between luminal and abluminal membrane 
and is not affected by pyroglutamate [1, 8]. Source: Figure 6 from Hawkins et al. (2006) [1]. 
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3.6.2 Gene and protein expression of BBB transporters - a short review. 
To keep brain homeostasis, the concentration of each amino acid has to be tightly regulated to 
vary within fixed limits [122]. Different biochemical agents, protein-protein interactions and 
signalling pathways are reported in the literature to regulate transporter expression, 
localization, and function at various levels in response to certain triggers, like substrate 
deprivation. 
The knowledge on protein expression and localization of SLC members (see  
Figure 12 for overview), as well as their regulation, is less pronounced. One recent proteomics 
study identified and quantified the protein expression of several transport proteins and found 
Glut1 to be highest expressed in mouse brain capillaries, followed by 4F2hc, Taut, Lat1, and 
Asct2 [173]. Most effort so far was made to unravel gene expression pattern specific for BBB, 
recently also in different physiological situations. The anatomical gene expression of SLC 
members in the adult mouse brain is mapped in the Allen Brain Atlas [174], but their 
expression and distribution in the different brain cell types is still largely unknown. Dahlin et 
al. [175] discovered 36 SLC genes specifically enriched at the BBB, with ~70% being 
nutrient transporters and ~22% being amino acid transporters (Slc1a2, Slc3a1, Slc6a6, 
Slc6a20, Slc7a5, Slc7a11, Slc38a3, Slc38a5). Also in other studies, the expression of SLC 
members has been investigated by different approaches, broadening the knowledge of the 
single players of the BBB transportome [2, 173, 176-179]. Furthermore, the results of Lyck et 
al. [2] imply specific roles of the single transporters in the differentiated BBB, e.g. for 
transendothelial amino acid transport in vivo (Slc1a1, Slc3a2, Slc6a6, Slc7a1, Slc7a5, 
Slc38a2, Slc38a3, Slc38a5), and for providing amino acids for endothelial-cell metabolism 
(Slc7a6, Slc7a11, Slc38a1, Slc43a1-3). 
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Figure 12: Localization data available for amino acid transporters at the brain vasculature.  
A) B) 
 
C) 
 
D) 
 
E) 
 
  
 
  
Studies to examine the localization of amino acid transporters at the BBB using immunohistochemistry are rare. 
A) Double line appearance of immunoreactivity for LAT1 (a) is indicated by arrows. (b) LAT1 (red) and nucleus 
(blue). Scale bar: 10 µm. Source: Figure 4 a, b from Matsuo et al. [150]; B) Double line appearance of 
immunoreactivity for 4F2hc (c) is indicated by arrows. (d) 4F2hc (red) and nucleus (blue). Scale bar: 10 µm. 
Source: Figure 4 c, d from Matsuo et al. [150]; C) SNAT2 (green) and GFAP (red) co-localize (yellow) in glia 
limitans (arrowheads) and in astrocytes (arrows) surrounding blood vessels (asterisks). Scale bar: 33 µm. Source: 
Figure 5 M from González-González et al. [180]; D) Immunohistochemical analysis of mASCT2 (green) in 
mouse brain. 3D-reconstructed image, nucleus in red. Scale bar: 10 µm; Source: Figure 6 e from Tetsuka et al. 
[124]; E) Immunostaining of GLUT1 (red) in the cerebral cortex of rat brain. Scale bar: 10 µm. Source: Figure 5 
e from Hori et al. [181]. 
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4. Original research article: Culture-induced changes in blood-
brain barrier transcriptome: implications for amino-acid 
transporters in vivo. 
 
 
This section contains an original research article that was accepted for publication in the 
Journal of Cerebral Blood Flow & Metabolism and published online on June 3rd 2009 [2]. 
 
My contribution to this paper concerns the data analysis of microarray experiments, qPCR 
analyses, and data presentation. 
The cells were isolated, cultured, and the RNA extracted by Dr. Ruth Lyck with whom first 
authorship is shared. 
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Supplemental Information. 
 
Read me – instructions for supplemental information viewing. 
Supplemental information with: 1) Materials and methods for supplemental Figure 1, 2) Titles 
and legends to supplemental figures, and 3) 3 tables (microarray, qPCR data) is provided in a 
word file in compatibility mode.  
Supplemental Figure 1) images showing purification quality, and Supplemental Figure 2) 
graph of microarray mean hybridization signals v.s. qPCR data are provided as JPEG files. 
 
Supplemental Information. 
Supplemental information (.doc) with: 1) Materials and methods for supplemental figure 1, 2) 
Titles and legends to supplemental figures, and 3) 3 tables (microarray, qPCR data). Two jpg 
files show: Supplemental Figure 1) images showing purification quality, and Supplemental 
Figure 2) graph of microarray mean hybridization signals v.s. qPCR data.  
 
 
Supplemental Materials and Methods. 
 
Immunofluorescent staining of PECAM-1 purified MBMECs. 
For immunofluorescent staining of PECAM-1 purified ppMBMECs, 30 L of washed cell 
suspensions were allowed to adhere for 20 min to poly-d-lysine coated glass slides (SIGMA, 
Buchs, Switzerland), before fixation in ice cold methanol followed by permeabilization for 15 
min in 0.1% TX-100 in blocking solution (10% normal goat serum (NGS), PBS). Primary 
rabbit anti-Claudin5 antibody (10 µg/ml final concentration in blocking solution) was applied 
for 30 min, RT (Invitrogen, Basel, Switzerland). After washing, slides were incubated for 30 
min, RT with Alexa Fluor 488 conjugated goat anti-rabbit IgG secondary antibody in 
blocking solution (Invitrogen, Basel, Switzerland). During the final wash, nuclei were 
counterstained with 1 µg/ml DAPI in PBS (SIGMA, Basel, Switzerland). Preparations were 
mounted in Mowiol (Calbiochem, VWR International, Dietikon, Switzerland) and imaged 
with either an inverted fluorescence microscope ((200x magnification; Axiovert 35, Carl 
Zeiss, Germany) or Z-sections captured (60 slices,  0.2 µm) by confocal microscopy (LSM 
510 Meta, Carl Zeiss, Germany). Confocal image processing was carried out using the 
IMARIS software (Bitplane, Zurich, Switzerland).  
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Titles and Legends to Supplemental Figures. 
 
Supplemental Figure 1: Characterization of purified endothelial cells from freshly 
isolated mouse brain microvessels. Representative 200X phase contrast image of endothelial 
cells is shown before (A) and after (B) anti-PECAM-1 magnetic bead sorting. In panel B the 
phase contrast image is overlaid with DAPI (blue) staining of nuclei. Beads can be seen as 
dark spheres. In panels C and D, DAPI (blue) staining is coupled with anti-Claudin5 (green) 
immunofluorescence of endothelial preparations following purification (ppMBMEC). Panel D 
shows a high magnification image of a single isolated microvessel. Scale bars are 50 m for 
B and C, and 8 m for panel D. 
 
Supplemental Figure 2: Correlation of gene expression as determined by microarray vs. 
by qPCR. For each gene tested by both qPCR and microarray, mean CT values (qPCR) were 
plotted against mean normalized hybridization signals (microarray) for each of the MBMEC 
samples: A) non-cultured (r2=0.863 for genes with microarray mean hybridization signal 
above cutoff), B) single-cultured (r2=0.674), C) co-cultured (r2=0.591), and D) cell-line 
(r2=0.676).  The vertical line indicates the microarray cutoff level. 
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Supplemental Table 1: Real-Time RT-PCR primers and probes.  
SYBR Green® primers and probes used for data shown in Table 1. 
Target mRNA  Accession number Sequence 
   
Hbb-β1 NM_008220 sense:  TGCATGTGGATCCTGAGAAC 
antisense: GTGAAATCCTTGCCCAGGT 
Pdgfrβ NM_008809 sense:  TGCAGAGACCTCAAAAGGTG 
antisense:  CCTGATCTTCCTCCCAGAAA 
Gfap NM_010277 sense:  ACAGACTTTCTCCAACCTCCAG 
antisense:  CCTTCTGACACGGATTTGGT 
Syp NM_009305 sense:  AACAACAAAGGGCCAATGAT 
antisense:  TAGCCACATGAAAGCGAACA 
Transthyretin (Ttr) NM_013697 sense:  CATGAATTCGCGGATGTG 
antisense:  GATGGTGTAGTGGCGATGG 
VE-Cadherin NM_009868 sense:  GTTCAAGTTTGCCCTGAAGAA 
antisense:  GTGATGTTGGCGGTGTTGT 
ribosomal protein S16
(Rps16) 
NM_013647 sense:  GATATTCGGGTCCGTGTGA 
antisense:  TTGAGATGGACTGTCGGATG 
 
 
 
TaqMan® primers and probes used for data shown in Figures 3 and 4, Table 3, Supplemental Table 3. 
Target (mRNA) Accession number Sequence  
 
Claudin5 NM_013805 sense:  GCTCAGAACAGACTACAGGCACTTT 
antisense:  GTGGCCAACTGCGCATAGA 
probe:  AACTTGACCGACCTTTT 
Zo1 NM_009386 sense:  ACGAGGCATCATCCCTAATAAGAA 
antisense:  ACCCGCTGTCTTTGGAAGTG 
probe:  AACAGTTAGCCAGTGTACAGTA 
Occludin NM_008756 sense:  TGACTATGCGGAAAGAGTTGACA 
antisense:  GGCACCAGAGGTGTTGACTTATAGA 
probe:  CAAAGTGAATGGCAAGCGATCATACCCA 
Pecam1 (CD31) NM_008816 
NM_001032378 
sense:  TCCCCGAAGCAGCACTCT 
antisense:  CCGCAATGAGCCCTTTCTT 
probe:  TCAGAGTCTTCCTTGCCCCA 
VE-Cadherin 
(CD144) 
NM_009868 sense:  AGCGCAGCATCGGGTACT 
antisense:  TCGGAAGAATTGGCCTCTGT 
probe:  CATCCGCAAGACCAGT 
Pdgfrβ NM_008809 sense:  CCAACGGCATGGACTTCTTAG 
antisense:  CCCTCGCAGATGAGCACATT 
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probe:  TAAGAACTGTGTTCACCGAGAC 
Hbb-β1 NM_008220 sense:  GACAAGCTGCATGTGGATCCT 
antisense:  CCCAGCACAATCACGATCATA 
probe:  AGAACTTCAGGCTCCTG 
Synaptophysin 
(Syp) 
NM_009305 sense:  GGGCCAATGATGGACTTCCT 
antisense:  GGATGAGCTAACTAGCCACATGAA 
probe:  CACAGCAGTGTTCGC 
Gfap NM_010277 sense:  CACAGCGGCCCTGAGAGA 
antisense:  GTCTGCAAACTTAGACCGATACCA 
probe:       ACTCAATACGAGGCAGTGGCCACCAGTAA 
Slc2a1 (Glut1) NM_011400 sense:  TCGTCGTTGGCATCCTTATTG 
antisense:  TGCATTGCCCATGATGGA 
probe:  CCAGGTGTTTGGCTTAG 
Abcb1a (Mdr1a) NM_011076 sense:  GCATTCTGGTATGGGACTTCCT 
antisense:  CCAATTAACACGGAAAAGAAGACA 
probe:  AATACTCTATTGGACAAGTGC 
Abcc1 (Mrp1) NM_008576 sense:  CAGTGGCATGCGCATCAA 
antisense:  TTTCTAGCTGCATTGGTGATCAA 
probe:  CTGTGGTGGGCGCTGTCTATCGTAAGGC 
Slc1a1 (Eaat3) NM_009199 sense:  TGTTGACTGGCTCCTGGACC 
antisense:  GCTCCAGCTCCTTCTTCGAGA 
probe:  ATGCGTTTGGGACGGGCATCG 
Slc1a2 (Eaat2) NM_001077514 sense:  TGCTCATCCTCCCTCTTATCATC 
antisense:  GGCCGCTGGCTTTAGCAT 
probe:  AGTTTAATCACAGGGTTGTC 
Slc1a3 (Eaat1) NM_148938 sense:  GAAGCCATCATGCGATTGGT 
antisense:  CCCTGCGATCAAGAAGAGGAT 
probe:  CGGTGATAATGTGGTATGC 
Slc1a6 (Eaat4) NM_009200 sense:  CCCCAGGCAGGACTGGTTA 
antisense:  TTGTACGAAGTCGGTCAAGGAA 
probe:  TGATTGTGCTCACATCCGTCGGC 
Slc3a2 (4F2hc) NM_008577 sense:  GTTTTTGAATGCCACTGGCA 
antisense:  AAAGTCTGCGAGGAGTCCTGC 
probe:  ATGGTGCAGCTGGAGTGTGTCGCA 
Slc6a6 (Taut) NM_009320 sense:  GCAACGTCTGGCGTTTCC 
antisense:  AGGCCGCTCCCAAACAG 
probe:  TGCGTTCCTCATACCGT 
Slc7a1 (Cat-1) NM_007513 sense:  TGAGAAGTCCCACGAGTCTTACAG 
antisense:  TTCCGGCGCAGCATCT 
probe:  ATTCGCTCAGCACAATG 
Slc7a3 (Cat-3) NM_007515 sense:  CACTGACCTCGTGGACCTCAT 
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antisense:  TCTTCAACACTCTTCATTTCCTGATC 
probe:  TTGCTCACTCCCTGGTGTCCATTTGTGT 
Slc7a5 (Lat1) NM_011404 sense:  GGAGGATGGAACTATCTGAATTTTG 
antisense:  GGTTGGTAGAGAGGGTAGTGAAATAGG 
probe:  CTACAGGAACCTGCCCCTGGCCA 
Slc7a6 (y+Lat2) NM_178798 sense:  TACATCCTGACCAACGTGGC 
antisense:  ATGCCGAATGTCTGGTCAGC 
probe:  TCCATAAGAGTGACGCTGTGCCTGTGA 
Slc7a11 (xCT) NM_011990 sense:  TGGAACTGCTCGTAATACGCC 
antisense:  GGTTCCAGGATGTAGCGTCC 
probe:  TGGAGCTACTGCTGTGATATCCCTGGCAT 
Slc16a2 (Xpct) NM_009197 sense:  GCCGCTGTTGCTTTCATTG 
antisense:  GCAGCGACAACCAAACAGAAT 
probe:  CTCCTTCACCAGCTCCCTAAGCCTGC 
Slc36a1 (Pat1) NM_153139 sense:  TCTGCTGTGTCTACTTCGTGTTTCT 
antisense:  GTTGGTGGTGGTCCCATTG 
probe:  AACTTTAAGCAGGTGATAGAG 
Slc38a1 (Snat1) NM_134086 sense:  CGCGTGCACACCAAAGTATG 
antisense:  AGATTGGCAGGACGGACG 
probe:  TACCAACCATCGCCTTCGCGTTTG 
Slc38a2 (Snat2) NM_175121 sense:  CCAATGAGATCCGTGCAAAA 
antisense:  TGGACCCAATCCAGCACAAT 
probe:     TCTGTGTTTTCTCCTGAGTGGCATAGTGGTG 
Slc38a3 (Snat3) NM_023805 sense:  CGAATCATGCCCACTGACAA 
antisense:  AACCGCAGCGAAACAAAGG 
probe:  AGCCTGCAAGATCCACCCCTAAAATCCT 
Slc38a5 (Snat5) NM_172479 sense:  CCCTCACTGTGCCTGTTGTG 
antisense:  CTTGCTTGGAAAGAGCAGCTG 
probe:  CCCTATCCGCCGAGCCCTCCA 
Slc43a1 (Lat3) NM_001081349 sense:  CCCTGAATGAGAATGCTTCCTT 
antisense:  ATGGCATTGGTGAGCTTTTGT 
probe:        AGCACCAAGTTCACTAGACCACGCTACCG 
Slc43a2 (Lat4) NM_173388 sense:  GCTGATTGCATATGGAGCAAGTAAC 
antisense:  CGAAGTGAACGTCATGCACAT 
probe:  CTCTCTGTGCTCATCTTTATCGCCTTGGC 
Slc43a3 (Eeg1) NM_021398 sense:  GCTACATCTTTGACCGCTTCAA 
antisense:  CGCAGGTGTAGAAAAATATGGCTAT 
probe:  ACTACTGTGGCCCGCC 
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Supplemental Table 2. Mean expression and fold changes of aTJ, bABC and cnon-AA transporter dSlc family genes in eMBMECs determined by 
microarray. 
Gene / alias Accs. no.  Non-cultured Single-cultured Co-cultured Cell-line 
  Mean expression (log2) aFC                 bME FC                ME FC               ME 
      
Tight junction protein genes 
Zo1 NM_009386 +++ n.s. +++ n.s. +++ n.s. +++ 
Zo2 NM_011597 +++ n.s.1 +++ n.s.1 +++ -3.09 ++ 
Occludin NM_008756 +++ n.s. +++ -2.50 +++ -61.54 + 
Claudin5 NM_013805 +++ n.s. +++ n.s. +++ n.s. +++ 
Claudin6 NM_018777 + n.s. + n.s.1 + -4.54 bc 
Claudin12 NM_022890 +++ n.s.1 +++ n.s. +++ n.s. +++ 
JamA NM_172647 +++ n.s +++ n.s. +++ -5.62 ++ 
JamB NM_023844 +++ -11.46 ++ -5.16 ++ -5.18 ++ 
JamC NM_023277 + n.s. + 2.10 + 6.67 ++ 
Esam NM_027102 +++ n.s. +++ n.s. +++ n.s. +++ 
ABC transporter genes 
Abca1 / ABC1 NM_013454 +++ n.s.1 +++ n.s.1 +++ -4.98 + 
Abca2 / ABC2 NM_007379 + n.s.1 + n.s. bc n.s.1 + 
Abca3 / ABC3 NM_001039581 ++ n.s.1 ++ n.s.1 ++ n.s.1 ++ 
Abca4 / ABC10 NM_007378 + 4.53 ++ 5.17 ++ n.s. + 
Abca5 / ABC13 NM_147219 ++ 2.18 ++ 2.02 ++ -18.47 bc 
Abca7 / ABC51 NM_013850 + n.s.1 + n.s.1 + n.s. + 
Abcb1a / Mdr1a; Pgp NM_011076 +++ -4.75 +++ -5.45 +++ -62.64 + 
Abcb1b / Mdr1b NM_011075 bc 12.13 ++ 12.91 ++ 4.59 + 
Abcb2 / TAP1 NM_013683 ++ n.s. + n.s. + n.s.1 + 
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Abcb3 / TAP2 NM_011530 ++ n.s. + n.s. ++ n.s. ++ 
Abcb6 NM_023732 ++ n.s. ++ n.s. ++ n.s.1 ++ 
Abcb8 NM_029020 + n.s.1 + n.s.1 + n.s. + 
Abcb10 / ABCB12 NM_019552 + n.s.1 + n.s.1 + n.s. + 
Abcc1 / Mrp1 NM_008576 + 5.92 +++ 6.11 +++ 3.70 ++ 
Abcc3 / Mrp3 NM_029600 bc 8.99 + 13.51 + 18.45 ++ 
Abcc4 / Mrp4 NM_001033336 +++ -2.03 +++ -2.13 +++ -6.24 ++ 
n.s. ++ n.s.1 + n.s. ++ Abcc5 / Mrp5 NM_176839 
NM_013790 
++ 
+ n.s.1 + n.s. + n.s. + 
Abcc6 / Mrp6 NM_018795 + -9.43 bc -11.03 bc -16.14 bc 
Abcc9 / Sur2 NM_001044720 + -6.72 bc n.s.1 + -2.27 bc 
Abcd1 / Ald NM_007435 ++ n.s. + n.s. + -2.04 + 
Abcd3 / Pmp68 NM_008991 +++ n.s.1 +++ n.s.1 +++ n.s.1 +++ 
Abcd4 / P69r NM_008992 ++ n.s. ++ n.s. ++ n.s.1 ++ 
Abce1 / Oabp NM_015751 ++ n.s. +++ n.s. +++ n.s. +++ 
Abcf1 / ABC50 NM_013854 ++ n.s. ++ n.s. ++ n.s.1 ++ 
Abcf2 / Drr3 NM_013853 ++ n.s.1 ++ n.s.1 ++ n.s. ++ 
Abcf3 / AI326318 NM_013852 ++ n.s.1 ++ n.s.1 ++ n.s.1 ++ 
Abcg1 / WHITE NM_009593 +++ n.s.1 ++ n.s. ++ n.s.1 +++ 
Abcg2 / ABCP NM_011920 +++ n.s. +++ -2.76 +++ n.s. +++ 
Abcg3 / ABCP2 NM_030239 + n.s.1 + n.s.1 + -11.19 bc 
Non-AA Slc transporters  
Facilitative GLUT transporter family 
Slc2a1 / Glut1 NM_011400 +++ n.s. +++ n.s. +++ -3.96 +++ 
Slc2a8 / Glut8 NM_019488 + n.s. + n.s. + n.s. + 
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Slc2a9 / Glut9 NM_001102414 ++ n.s.1 ++ n.s.1 ++ 5.78 +++ 
Slc2a10 / Glut10 NM_130451 + n.s. + n.s. + 2.11 + 
Slc2a12 / Glut12 NM_178934 + -2.40 bc -2.64 bc -2.63 bc 
Bicarbonate transporter family 
Slc4a2 / Ae2 NM_009207 ++ n.s.1 ++ n.s.1 ++ n.s. ++ 
Slc4a4 / Nbce1 NM_018760 bc n.s.1 + n.s.1 bc -2.48 bc 
Slc4a7 / Nbcn1 NM_001033270 + n.s. ++ n.s. ++ 2.36 ++ 
Sodium glucose cotransporter family 
Slc5a2 / Sglt2 NM_133254 ++ n.s.1 + n.s. + n.s. + 
Slc5a3 / Smit NM_017391 ++ 2.03 ++ n.s.1 ++ n.s.1 ++ 
Slc5a6 / Smvt NM_177870 ++ -8.30 + -9.61 + -13.19 bc 
Sodium- and chloride- dependent neurotransmitter transporter family 
Slc6a8 / Crtr NM_133987 ++ n.s. ++ n.s. ++ n.s. ++ 
Slc6a13 / Gat2 NM_144512 + n.s.1 ++ -2.11 ++ n.s.1 ++ 
Na+/H+ exchanger family 
Slc9a1 / Nhe1 NM_016981 ++ n.s. ++ n.s.1 ++ n.s. ++ 
Slc9a2 / Nhe2 NM_001033289 ++ -5.21 + -3.57 + -8.52 bc 
Slc9a5 / Nhe5 NM_001081332 + n.s.1 + n.s. + 2.50 + 
Slc9a6 / Nhe6 NM_172780 + n.s.1 + n.s.1 + n.s.1 + 
Slc9a8 / Nhe8 NM_1489291 + n.s.1 + n.s.1 + n.s. + 
Sodium bile salt cotransport family 
Slc10a1 / Ntcp NM_011387 + -3.59 bc -6.85 bc -4.88 bc 
Slc10a3 / P3 NM_145406 ++ n.s.1 ++ n.s.1 + n.s.1 ++ 
Proton coupled metal ion transporter family 
Slc11a1 / Nramp1 NM_013612 + 6.16 ++ 6.87 ++ -2.60 bc 
Slc11a2 / Dmt1 NM_008732 ++ n.s.1 ++ n.s. ++ n.s.1 ++ 
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Electroneutral cation-Cl cotransporter family 
Slc12a2 / Nkcc1 NM_009194 ++ 3.04 +++ 2.14 +++ n.s. +++ 
Slc12a4 / Kcc1 NM_009195 ++ n.s. ++ n.s. ++ n.s.1 ++ 
Slc12a6 / Kcc3 NM_133648 +++ n.s. +++ n.s. +++ n.s.1 +++ 
Slc12a7 / Kcc4 NM_011390 ++ 2.21 ++ n.s.1 ++ n.s.1 ++ 
Slc12a9 / Cip NM_031406 + n.s.1 + n.s. + n.s. ++ 
Proton oligopeptide cotransporter family 
Slc15a3 / Pht2 NM_023044 bc 2.28 + 3.37 + n.s. bc 
Slc15a4 / Pht1 NM_133895 ++ n.s.1 ++ n.s.1 ++ n.s. ++ 
Monocarboxylate transporter family 
Slc16a1 / Mct1 NM_009196 +++ -10.93 + -8.07 + -24.66 + 
Slc16a2 / Xpct NM_009197 +++ -6.08 ++ -6.11 ++ -114.77 bc 
Slc16a3 / Mct4 NM_0010386546 bc 4.93 + 18.02 ++ n.s. + 
Slc16a4 / Mct5 NM_146136 +++ -18.52 + -19.55 + -39.23 + 
Slc16a6 / Mct7 NM_001029842 
NM_134038 
++ 
++ 
n.s. 
n.s. 
++ 
++ 
3.53 
3.53 
++ 
++ 
n.s.1 
n.s.1 
++ 
++ 
Slc16a9 / Mct9 NM_025807 ++ n.s.1 ++ -2.02 ++ -11.33 + 
Slc16a11 / Mct11 NM_153081 ++ -2.69 + -3.55 + -3.35 + 
Slc16a12 / Mct12 NM_172838 + -2.61 bc n.s. + 14.46 +++ 
Slc16a13 / Mct13 NM_172371 +++ n.s. ++ n.s. ++ n.s. ++ 
Vesicular glutamate transporter family 
Slc17a5 / Sialin NM_172773 + n.s.1 + n.s. + 2.06 ++ 
Vesicular amine transporter family 
Slc18a2 / Vmat2 NM_172523 ++ n.s.1 ++ n.s.1 ++ 3.51 ++ 
Folate/thiamine transporter family 
Slc19a1 / Rft NM_031196 + n.s. + n.s.1 + n.s. + 
4. Original research article: Culture-induced changes in blood-brain barrier transcriptome: implications for amino-acid transporters in vivo.  95 
 
Slc19a2 / ThTr1 NM_054087 + n.s. + n.s. ++ n.s. + 
Slc19a3 / ThTr2 NM_030556 +++ -57.64 bc -56.76 bc -189.08 bc 
Type III Na+-phosphate cotransporter family 
Slc20a1 / PiT-1 NM_015747 ++ n.s. +++ 2.70 +++ 2.05 +++ 
Slc20a2 / PiT-2 NM_011394 + n.s. + n.s. + n.s. + 
Organic anion transporting family 
Slco1a4 / Oatp1a4 NM_030687 +++ -3.30 +++ -6.18 +++ -1327.17 bc 
Slco1a5 / Oatp1a5 NM_130861 + 2.09 ++ n.s.1 + -3.53 bc 
Slco1c1 / Oatp1c1 NM_021471 +++ -7.26 +++ -11.03 +++ -742.26 bc 
Slco2a1 / Oatp2a1 NM_033314 + n.s. + n.s. + 19.35 +++ 
Slco2b1 / Oatp2b1 NM_175316 +++ -2.14 +++ n.s. +++ -171.24 bc 
Slco3a1 / Oatp3a1 NM_023908 
NM_001038643 
bc 
+ 
26.24 
14.48 
+++ 
++ 
20.32 
11.70 
++ 
++ 
43.83 
25.79 
+++ 
+++ 
Slco4a1 / Oatp4a1 NM_148933 bc 5.48 + 14.54 ++ 6.61 ++ 
Organic cation/anion/zwitterion transporter family 
Slc22a4 / Octn1 NM_019687 bc 3.01 + 2.76 + n.s.1 bc 
Slc22a8 / Oat3 NM_031194 +++ -73.64 + -82.10 + -202.74 bc 
Slc22a12 / Urat1 NM_009203 + n.s.1 + n.s. + n.s. + 
Slc22a17 / Boit NM_021551 + n.s. bc n.s. bc n.s.1 + 
Na+-dependent ascorbic acid transporter family 
Slc23a1 / Svct1 NM_011397 + n.s. + n.s. + n.s.1 + 
Slc23a2 / Svct2 NM_018824 + n.s. ++ n.s. ++ n.s.1 + 
Na+/(Ca2+-K+) exchanger family 
Slc24a1 / Nckx1 NM_144813 bc n.s. bc 2.27 bc 17.61 + 
Slc24a3 / Nckx3 NM_053195 bc n.s.1 bc n.s.1 bc 20.67 ++ 
Slc24a6 / Nckx6 NM_133221 + n.s. + n.s.1 + 2.30 + 
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Mitochondrial carrier family 
Slc25a1 / Cic NM_153150 + n.s. + n.s. + n.s. + 
Slc25a3 / Pic NM_133668 +++ n.s. +++ n.s. +++ n.s. +++ 
Slc25a4 / Aac1 NM_007450 +++ n.s. +++ n.s. +++ n.s.1 +++ 
Slc25a5 / Aac2 NM_007451 +++ n.s.1 +++ n.s.1 +++ n.s. +++ 
Slc25a8 / Ucp2 NM_011671 +++ -4.84 ++ -5.12 ++ -4.38 ++ 
Slc25a10 / Dic NM_013770 + n.s. + n.s. + 2.61 + 
Slc25a11 / Ogc NM_024211 ++ n.s. ++ n.s. ++ n.s.1 ++ 
Slc25a14 / Ucp5 NM_011398 ++ n.s.1 ++ n.s. ++ n.s. ++ 
Slc25a16 / Gdc NM_175194 ++ n.s.1 ++ n.s. ++ n.s. ++ 
Slc25a17 / Anc1 NM_011399 ++ n.s.1 ++ n.s.1 ++ n.s.1 ++ 
Slc25a19 / Dnc NM_026071 + n.s.1 + n.s.1 + n.s.1 + 
Slc25a20 / Cac NM_020520 +++ n.s. +++ n.s. +++ n.s. +++ 
Slc25a23 / Apc2 NM_025877 ++ -2.67 + -3.37 + -13.20 bc 
Slc25a24 / Apc1 NM_172685 ++ -2.18 + n.s. ++ n.s. ++ 
Slc25a25 / Apc3 NM_146118 ++ -2.69 + -2.43 ++ -3.55 + 
Slc25a27 / Ucp4 NM_028711 + n.s.1 + n.s. + n.s.1 + 
Slc25a28 / Mrs3/4 NM_145156 ++ n.s. ++ n.s. ++ n.s. ++ 
Slc25a30 / Kmcp1 NM_026232 + n.s. + n.s. + n.s. + 
Slc25a32 / Mftc NM_172402 +++ n.s. ++ n.s. ++ n.s. ++ 
Slc25a33 NM_027460 ++ n.s. ++ n.s. ++ -6.81 + 
Slc25a35 / FLJ40217 NM_028048 + -2.77 bc -3.55 bc -3.10 bc 
Slc25a36 / FLJ10618 NM_138756 ++ n.s.1 ++ n.s. ++ n.s.1 ++ 
Slc25a37 / HT015 NM_026331 + n.s.1 + n.s. + 4.03 ++ 
Multifunctional anion exchanger family 
Slc26a2 / Dtdst NM_007885 + n.s. + n.s. + n.s.1 + 
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Slc26a6 / Pat-1 NM_134420 + n.s.1 + n.s. + n.s.1 + 
Slc26a11 NM_178743 + n.s.1 + n.s.1 + n.s.1 + 
Fatty acid transport protein family 
Slc27a1 / Fatp1 NM_011977 ++ n.s. + -2.47 + -2.51 + 
Slc27a3 /  Fatp3 NM_011988 + -2.06 bc -2.23 bc n.s.1 + 
Slc27a4 / Fatp4 NM_011989 + n.s. ++ n.s. ++ n.s.1 + 
Facilitative nucleoside transporter family 
Slc29a1 / Ent1 NM_022880 + n.s.1 + n.s.1 + 2.90 + 
Slc29a3 / Ent3 NM_023596 + n.s.1 + n.s. + n.s.1 + 
Slc29a4 / Ent4 NM_146257 + -3.97 bc -4.16 bc -6.31 bc 
Zinc efflux family 
Slc30a1 / Znt1 NM_009579 +++ -2.24 +++ -2.42 +++ -3.08 +++ 
Slc30a4 / Znt4 NM_011774 +++ n.s. +++ n.s. +++ n.s. +++ 
Slc30a5 / Znt5 NM_022885 +++ n.s.1 +++ n.s. +++ n.s.1 +++ 
Slc30a6 / Znt6 NM_144798 ++ n.s.1 +++ n.s.1 ++ n.s. +++ 
Slc30a7 / Znt7 NM_023214 ++ n.s. ++ n.s.1 ++ n.s.1 ++ 
Slc30a9 / Znt9 NM_178651 ++ n.s. +++ n.s. +++ n.s. +++ 
Cooper transporter family 
Slc31a1 / Ctr1 NM_175090 +++ n.s. +++ -2.22 +++ -3.29 ++ 
Slc31a2 / Ctr2 NM_025286 ++ n.s. ++ n.s.1 ++ n.s.1 ++ 
Acetyl-CoA transporter family 
Slc33a1 / Acatn NM_015728 + n.s. ++ n.s. ++ 2.19 ++ 
Nucleoside-sugar transporter family 
Slc35a1 / Cst NM_011895 ++ n.s.1 ++ n.s.1 ++ n.s.1 ++ 
Slc35a2 / Ugt NM_001083937 + n.s.1 + n.s.1 + n.s.1 + 
Slc35a3 / UGTrel2 NM_144902 +++ n.s.1 +++ n.s.1 ++ n.s.1 +++ 
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Slc35a4 / UGTrel3 NM_026404 ++ n.s.1 ++ n.s.1 ++ n.s.1 ++ 
Slc35a5 / UGTrel5 NM_028756 + n.s. bc n.s. + n.s.1 + 
Slc35b1 / UGTrel1 NM_016752 +++ n.s.1 +++ n.s.1 +++ n.s.1 +++ 
Slc35b2 / UGTrel4 NM_028662 + n.s. + n.s.1 + n.s. + 
Slc35b3 / UGTrel6 NM_134060 ++ 2.50 ++ 2.21 ++ n.s. ++ 
Slc35b4 / Yea4 NM_021435 + 2.30 ++ n.s. ++ n.s. ++ 
Slc35c1 / Fuct1 NM_211358 + n.s. + n.s.. + n.s. + 
Slc35c2 / Ovcov1 NM_144893 + n.s.1 ++ n.s.1 + n.s. ++ 
Slc35d2 / UGTrel8 NM_001001321 ++ -2.03 ++ n.s. ++ n.s. ++ 
Slc35e1 / FLJ14251 NM_177766 ++ n.s. ++ n.s. ++ n.s.1 ++ 
Slc35e4 NM_153142 + n.s.1 + n.s.1 + n.s.1 + 
Slc35f1 NM_178675 bc 13.14 ++ 9.10 ++ n.s.1 bc 
Slc35f2 NM_028060 +++ -10.32 ++ -10.27 ++ -58.16 + 
Slc35f5 NM_028787 ++ n.s.1 ++ n.s. ++ n.s.1 ++ 
Sugar-phosphate/phosphate exchanger family 
Slc37a2 / Spx2 NM_020258 bc 2.03 + n.s. + 2.77 + 
Slc37a3 / Spx3 NM_028123 ++ n.s.1 ++ n.s.1 ++ n.s.1 ++ 
Slc37a4 / Spx4 NM_008063 ++ n.s. + n.s. + n.s. + 
Metal ion transporter family 
Slc39a1 / Zip1 NM_013901 +++ n.s. +++ n.s. +++ n.s. +++ 
Slc39a3 / Zip3 NM_134135 ++ n.s. ++ n.s. ++ n.s. ++ 
Slc39a4 / Zip4 NM_028064 bc 9.13 ++ 6.35 + n.s.1 bc 
Slc39a6 / Liv-1 NM_139143 ++ 2.04 ++ 2.31 ++ n.s. ++ 
Slc39a7 / Ke4 NM_008202 
NM_001077709 
+++ 
+++ 
n.s. 
n.s. 
+++ 
+++ 
n.s. 
n.s. 
+++ 
+++ 
n.s.1 
n.s.1 
+++ 
+++ 
Slc39a8 / BIGM103 NM_026228 +++ -2.73 +++ -3.14 ++ -6.78 ++ 
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Slc39a10 NM_172653 +++ -6.16 +++ -7.02 ++ -5.51 +++ 
Slc39a11 NM_027216 + 2.21 + 2.10 + 2.47 ++ 
Slc39a13 NM_026721 + n.s.1 + n.s. + n.s.1 + 
Slc39a14 / Zip14 NM_144808 bc 2.19 + 2.50 + 2.36 + 
Basolateral iron transporter family   
Slc40a1 / Ireg1 NM_016917 +++ -2.35 +++ -5.50 +++ -2.75 +++ 
MgtE-like magnesium transporter family 
Slc41a1 NM_173865 + n.s. + n.s.1 + n.s.1 + 
Slc41a2 NM_177388 + 6.74 ++ 4.02 + 4.19 + 
Na+-independent, system L-like amino acid transporter family 
Slc43a3 / Eeg1 NM_021398 + 4.50 ++ 6.41 +++ 12.03 +++ 
Choline-like transporter family 
Slc44a1 / Ctl1 NM_133891 ++ 2.26 +++ n.s. ++ n.s. ++ 
Slc44a2 / Ctl2 NM_152808 +++ n.s. +++ n.s.1 +++ 2.35 +++ 
Putative sugar transporter family 
Slc45a4 / KIAA1126 NM_001033219 bc 4.66 + n.s. bc n.s.1 bc 
Heme tranporter family 
Slc46a3 / LOC283537 NM_027872 +++ n.s.1 +++ n.s. +++ -6.03 + 
 
aFC: Fold-change relative to non-cultured MBMECs. bME: Mean expression (log2).  
Probesets of genes either showing expression below cut-off (bc) in all conditions or showing expression bc and q > 5% and/or fold change < 2: 
Tight junction protein genes: ZO-3 (NM_013769); Claudin-1 (NM_016674); Claudin-2 (NM_016675); Claudin-3 (NM_009902); Claudin-4 
(NM_009903); Claudin-7 (NM_016887); Claudin-8 (NM_018778); Claudin-9 (NM_020293); Claudin-11 (NM_008770); Claudin-13 
(NM_020504); Claudin-14 (NM_019500); Claudin-15 (NM_021719); Claudin-16 (NM_053241); Claudin-18 (NM_019815); Claudin-19 
(NM_153105); Claudin-23 (NM_027998); ABC transporter genes: Abca6 (NM_147218); Abca8a (NM_153145); Abca8b (NM_013851); 
Abca13 (NM_178259); Abcb4 (NM_008830); Abcb9 (NM_019875); Abcb11 (NM_021022); Abcc2 (NM_013806); Abcc7 (NM_021050); 
Abcc8 (NM_011510); Abcc10 (NM_145140; NM_170680); Abcd2 (NM_011994); Abcg4 (NM_138955); Abcg5 (NM_031884); Abcg8 
(NM_026180); Non-AA Slc transporters: Slc2a2 (NM_031197); Slc2a3 (NM_011401); Slc2a4 (NM_009204); Slc2a5 (NM_019741); Slc2a6 
(NM_172659); Slc2a13 (NM_001033633); Slc4a1 (NM_011403); Slc4a3 (NM_009208); Slc4a8 (NM_021530); Slc4a9 (NM_172830); Slc4a10 
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(NM_033552); Slc4a11 (NM_001081162); Slc5a1 (NM_019810); Slc5a5 (NM_053248); Slc5a7 (NM_022025); Slc5a9 (NM_145551); Slc5a10 
(NM_001033227); Slc5a11 (NM_146198); Slc5a12 (NM_001003915); Slc6a1 (NM_178703); Slc6a2 (NM_009209); Slc6a3 (NM_010020); 
Slc6a4 (NM_010484); Slc6a5 (NM_148931); Slc6a11 (NM_172890); Slc6a12 (NM_133661); Slc6a18 (NM_001040692); Slc7a4 
(NM_144852); Slc7a14 (NM_172861); Slc8a1 (NM_011406); Slc8a2 (NM_148946); Slc8a3 (NM_080440); Slc9a9 (NM_177909); Slc10a2 
(NM_011388); Slc10a6 (NM_029415); Slc12a1 (NM_183354; NM_001079690); Slc12a3 (NM_019415); Slc12a5 (NM_020333); Slc12a8 
(NM_134251; NM_001083902); Slc13a1 (NM_019481); Slc13a2 (NM_022411); Slc13a3 (NM_054055); Slc13a4 (NM_172892); Slc13a5 
(NM_001004148); Slc14a1 (NM_028122); Slc14a2 (NM_207651; NM_030683); Slc15a1 (NM_053079); Slc15a2 (NM_021301); Slc16a5 
(NM_001080934); Slc16a7 (NM_011391); Slc16a8 (NM_020516); Slc16a14 (NM_027921); Slc17a1 (NM_009198); Slc17a2 (NM_144836); 
Slc17a3 (NM_134069); Slc18a1 (NM_153054); Slc18a3 (NM_021712); Slco1a6 (NM_023718); Slco1b2 (NM_020495); Slco1b2 
(NM_178235); Slco4c1 (NM_172658); Slco5a1 (NM_172841); Slco6b1 (NM_001039475); Slco6c1 (NM_028942); Slco6d1 (XM_129964; 
XM_910370); Slc22a1 (NM_009202); Slc22a2 (NM_013667); Slc22a3 (NM_011395); Slc22a5 (NM_011396); Slc22a6 (NM_008766); Slc22a7 
(NM_144856); Slc22a9 (NM_144785); Slc22a13 (NM_133980); Slc22a14 (NM_001037749); Slc22a16 (NM_027572); Slc22a18 (NM_008767; 
NM_001042760); Slc23a3 (NM_194333); Slc24a2 (NM_172426); Slc24a4 (NM_172152); Slc25a7(NM_009463); Slc25a9 (NM_009464); 
Slc25a29 (NM_181328); Slc25a31 (NM_178386); Slc25a34 (NM_001013780); Slc26a1 (NM_174870); Slc26a3 (NM_021353); Slc26a4 
(NM_011867); Slc26a5 (NM_030727); Slc26a7 (NM_145947); Slc26a8 (NM_146076); Slc27a2 (NM_011978); Slc27a5 (NM_009512); 
Slc28a3 (NM_022317); Slc29a2 (NM_007854); Slc30a8 (NM_172816); Slc30a10 (NM_001033286); Slc34a1 (NM_011392); Slc34a2 
(NM_011402); Slc34a3 (NM_080854); Slc35a2 (NM_078484); Slc35d3 (NM_029529); Slc35f3 (NM_175434); Slc35f4 (NM_029238); Slc36a3 
(NM_172258); Slc37a1 (NM_153062); Slc39a2 (NM_001039676); Slc39a5 (NM_028051; NM_028092); Slc39a12 (NM_001012305); Slc41a3 
(NM_027868; NM_001037493); Slc44a3 (NM_145394); Slc44a4 (NM_023557); Slc45a1 (NM_173774); Slc45a2 (NM_053077); Slc45a3 
(NM_145977); Slc46a1 (NM_026740); Slc46a2 (NM_021053) 
 
Key: 1q-value > 5%; not significant (n.s.); below cut-off (bc; probeset expression values ≤ 5.78); +probeset expression values > 5.78-8; 
++probeset expression values > 8-10; +++probeset expression values > 10; down-regulation (-). Abbreviations: aTJ, tight junction associated 
protein; bABC transporter, ATP binding cassette transporter; cnon-AA transporter, non-amino acid transporter; dSlc, solute carrier family; 
eMBMEC, mouse brain microvascular endothelial cells. 
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Supplemental Table 3. Delta CT values of selected cell marker, TJ, ABC and SLC transporter gene mRNA levels in samples assessed by qPCR. 
Part A: delta CT values (SYBR Green® qPCR,  relative to S16 ribosomal protein mRNA )for genes reported in Table 1. 
mRNA 
Cell specificity 
ppMBMEC 
Pecam1 purified 
Crude EC fraction 
Freshly isolated 
pMBMEC 
single-cultured 
Glial3 
3 week cultures 
VE-Cadherin 
Endothelium 
-1.14±0.05 -1.78±0.12 -1.91±0.06 4.07±0.10 
Hbb-β1 
Erythrocytes 
-1.18±0.14 -7.17±0.13 n.d. n.d. 
Gfap 
Astrocytes 
n.d. 5.87±0.77 10.0±0.58 -4.19±0.06 
Pdgfrβ 
Pericytes 
4.49±0.15 1.17±0.12 4.43±0.08 2.11±0.07 
Syp 
Neurons 
n.d. 5.38±0.28 n.d. 7.58±0.28 
Ttr 
Choriod plexus 
4.36±0.24 -1.73±0.15 6.20±0.11 n.d. 
 
Part B: delta CT values (Taqman® qPCR,  relative to 18S  rRNA) of 1MBMEC samples previously  tested by microarray. 
 Non-cultured Single-cultured Co-cultured Cell-line  2Brain 3Glial 
Gene (protein)  Cellular markers 
Pecam1 (CD31) 12.1±0.08 9.68±0.11 11.3±0.04 11.0±0.08 20.7±0.43 n.d. 
VE-Cadherin 13.4±0.33 10.7±0.11 12.3±0.04 12.6±0.08 22.1±0.40 18.8±0.23 
Glut1 (Slc2a1) 9.87±0.04 11.2±0.75 11.7±0.10 15.3±0.11 17.4±0.31 15.6±0.17 
Pdgfrβ 17.4±0.12 15.9±0.09 16.3±0.08 n.d. 19.5±0.02 15.6±0.04 
Gfap 21.2±0.33 20.5±0.45 21.7±1.12 19.7±0.05 15.1±0.07 8.35±0.04 
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Syp 21.6±0.24 24.5±0.86 n.d. n.d. 13.4±0.13 20.1±0.18 
  Tight junctions 
ZO-1 12.4±0.05 12.3±0.03 13.6±0.12 13.4±0.07 17.0±0.17 15.0±0.18 
Cldn5 12.9±0.17 14.8±0.30 15.7±0.43 13.4±0.13 22.0±0.84 n.d. 
Ocldn 13.7±0.09 14.0±0.11 15.5±0.10 19.5±0.88 21.2±0.35 23.3±1.04 
  ABC transporters 
Mdr1a 12.9±0.05 15.2±0.41 16.6±0.02 19.8±0.41 21.8±0.38 23.3±0.10 
Mrp1 18.3±0.13 14.0±0.22 15.1±0.09 15.5±0.11 18.5±0.46 14.9±0.10 
  Solute carrier Amino Acid transporters 
 Slc1 – The high affinity glutamate and neutral amino acid transporter family 
Slc1a1 (Eaat3) 12.7±0.02 12.2±0.02 13.3±0.02 n.d. 15.2±0.12 18.8±0.85 
Slc1a2 (Eaat2) 22.2±0.39 25.3±0.42 25.3±1.39 n.d. 13.9±0.30 15.8±0.07 
Slc1a3 (Eaat1) 20.9±0.05 21.2±0.39 22.5±0.27 n.d. 15.4±0.04 13.3±0.19 
Slc1a6 (Eaat4) n.d. 18.1±0.04 18.9±0.32 n.d. 19.8±0.18 18.7±0.72 
 Slc6 – The sodium- and chloride- dependent neurotransmitter transporter family 
Slc6a6 (Taut) 12.0±0.10 14.0±0.52 16.7±0.30 17.0±0.09 18.2±0.10 16.2±0.48 
 Slc3 & Slc7 – The cationic amino acid transporter / glycoprotein- associated family 
Slc3a2 (4F2hc) 9.53±0.03 10.6±0.06 12.1±0.03 11.6±0.12 13.6±0.02 10.4±0.04 
Slc7a1 (Cat-1) 13.6±0.16 17.0±0.50 17.6±0.27 18.2±0.41 20.2±0.27 19.9±0.18 
Slc7a3 (Cat-3) 18.1±0.26 21.8±0.69 22.2±0.16 20.4±0.88 19.3±0.06 23.3±1.34 
Slc7a5 (Lat1) 11.9±0.01 14.2±0.05 15.6±0.05 17.6±0.19 18.0±0.04 16.9±0.17 
Slc7a6 (y+Lat2) 17.2±0.32 14.4±0.06 15.3±0.07 16.8±0.29 17.0±0.07 16.2±0.03 
Slc7a11 (xCT) 21.3±0.56 16.7±0.04 19.7±0.37 19.6±0.48 17.7±0.08 15.8±0.09 
 Slc16 – The monocarboxylate transporter family 
Slc16a2 (Xpct) 13.4±0.06 14.9±0.04 16.7±0.06 n.d. 18.1±0.14 13.9±0.13 
 Slc36 – The proton- coupled amino acid transporter family 
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Slc36a1 (Pat1) 16.5±0.12 16.8±0.09 18.3±0.13 17.3±0.27 17.8±0.27 18.2±0.20 
 Slc38 – The system A & N, sodium- coupled neutral amino acid transporter family 
Slc38a1 (Snat1) 22.0±0.65 16.3±0.04 17.1±0.04 22.2±0.04 15.9±0.11 13.4±0.08 
Slc38a2 (Snat2) 12.3±0.05 11.2±0.01 12.9±0.06 13.0±0.09 15.4±0.10 12.5±0.06 
Slc38a3 (Snat3) 13.3±0.11 16.6±0.16 16.5±0.05 21.2±0.39 17.8±0.18 14.3±0.22 
Slc38a5 (Snat5) 12.3±0.09 15.5±0.12 17.4±0.29 n.d. 20.4±0.40 n.d. 
 Slc43 – The sodium- independent, system-L like amino acid transporter  family 
Slc43a1 (Lat3) 23.3±0.10 19.3±0.63 20.9±0.34 19.3±1.87 n.d. 19.8±0.46 
Slc43a2 (Lat4) 16.7±0.20 14.3±0.06 16.5±0.05 17.2±0.11 17.8±0.04 16.1±0.10 
Slc43a3 (Eeg1) 21.2±0.27 16.5±0.03 17.5±0.06 15.4±0.09 25.0±0.29 18.5±0.23 
For samples tested by SYBR Green® qPCR (Part A), values are the mean delta CT values +/- s.d. relative to the endogenous reference RNA s16 ribosomal protein mRNA for 
biological triplicates.  For samples tested by Taqman® qPCR (Part B), values are the mean delta CT +/- s.d. relative to 18S ribosomal rRNA of technical triplicates. Key: n.d. (not 
detected) indicates CT values below limit of detection. 1MBMECs (mouse brain microvascular endothelial cells) RNA prepared from non-cultured, single-cultured, co-cultured or 
cell-line samples as defined in the text; 2Brain to RNA prepared from total brain homogenates; and 3Glial to RNA from 3 week mouse brain glial cultures.  
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5. Manuscript: Differential axial localization of luminal sodium-
dependent glutamine transporters Snat1 and Snat3 along the 
brain vascular tree. 
 
 
This section contains the above mentioned manuscript that was submitted October 25th 2010. 
 
My contribution to the manuscript concerns the performance of immunohistochemical as well 
as in vivo biotinylation experiments, data analysis, and data presentation. 
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6. Discussion and Outlook. 
The results presented in this thesis demonstrate that 75% of all known SLC amino acid 
transporters are expressed by the mouse BBB in vivo, the majority of which were not 
described previously to be present. Furthermore, the 30 transporters expressed on mRNA 
level by the endothelial cells show differential regulation once dissociated from their in vivo 
microenvironment created by the neurovascular unit. From this differential regulation in vitro 
we hypothesize that transporters such as Lat1-4F2hc and Snat3 are highly expressed 
specifically in differentiated in vivo brain vascular endothelial cells and thus presumably 
mediate transendothelial transport at the BBB in vivo, and that Snat1 expression is linked to 
intraendothelial metabolism and cell proliferation [2], a function being restricted to larger 
vessels in vivo and microvascular endothelial cells cultured in vitro. In addition, our 
immunohistochemistry and in vivo biotinylation experiments show Snat3 being localized to 
both membranes, luminal and abluminal, indicating that sodium-dependent, secondary active, 
transport is not an exclusive feature of the abluminal membrane of brain microvascular 
endothelial cells as previously suggested. This agrees with the contradictory data to this 
hypothesis on ATB0,+ [158] and Taut [155] (see section 3.6.1.1). 
 
Our results show the need to re-examine the proposed mechanisms by which the BBB 
endothelial cells participate in establishing brain (amino acid) homeostasis, by combining 
functional data from the literature and current results obtained with the techniques and the 
knowledge of the postgenomic era. 
 
What and where is the BBB? Localization of the BBB as layer between blood and brain and 
its high surface area compared to that of the choroid plexus [52] puts the endothelium in 
position to be the major site for exchange. Also the high number of transporters found to be 
expressed in our study of BBB endothelial cells supports the importance of this structure. On 
the other hand, the potential role of the choroid plexus in brain (amino acid) homeostasis may 
be underestimated since more recent studies suggest that the actual surface area due to the 
presence of microvilli is greater than estimated, and that the choroid plexus plays an important 
role in uptake of nutrients [19]. Also, the role of the endothelium in keeping the amino acid 
levels in brain ISF low may be overestimated and the role of transporters expressed on glial 
and neuronal plasma membranes underestimated, since they exhibit a higher surface area [3, 
5]. 
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The BBB endothelium and the other members of the neurovascular unit [22] may not only 
contribute to barrier function via cell-cell communication but also via interconnection of their 
transportomes [23] and by acting as “second line of defence” if the endothelial barrier is 
dysfunctional [26]. As an example, Snat3 is also expressed in astrocyte endfeet, highlighting 
their possible involvement in endothelial abluminal membrane transport into or back out of 
the brain. Furthermore, one has to consider that the brain vasculature shows heterogeneous 
expression profiles along the vascular tree. This has been shown for P-gp [20] and, in this 
thesis, for Snat1 (see section 5). 
In conclusion, the role of the BBB endothelium in comparison to the other amino acid 
transporter expressing brain cells, and the role of the single segments of the vascular tree in 
keeping brain homeostasis, still needs further investigation. This is also true for the interplay 
of the neurovascular unit and the impact of the other brain barriers in this process. It seems 
clear that establishing the BBB properties is dependent on a complex interaction network of 
different cellular and acellular factors with many possible regulation points. 
 
What is the amino acid concentration in the different brain compartments? Keeping amino 
acid homeostasis actually means to maintain their level at about 10% those of plasma, with 
exception of glutamine [1]. These values are based on measurements of plasma and CSF 
samples, as representative fluids facing the two membranes of the brain microvascular 
endothelial cells. 
To equate CSF and brain ISF concentration is a simplification, based on the assumption that 
they are in equilibrium via diffusion [117] (see section 3.5.4 for details). This assumption on 
the other hand may underestimate local microenvironmental differences caused by local 
transport processes and metabolism of brain cells, characteristics of normal brain physiology. 
Even measuring plasma concentration represents a simplification, since the impact of plasma 
proteins and of blood flow in establishing a local environment near the luminal membrane 
may differ from that in the centre of the vasculature. Plasma levels of amino acids are also 
difficult to interpret since the plasma pool of free amino acids is very small compared with the 
intracellular pool of free amino acids, which is again small compared with the protein-bound 
amino acid pool, all three being in equilibrium [122]. Furthermore, the plasma concentration 
is also subject to high fluctuations, resulting in fluctuations of the gradient across the BBB. 
This implies that transport across the BBB may not exclusively be regulated via the gradient 
between blood and CSF. 
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In conclusion, the composition of the medium at both sides of the endothelial cell membranes 
is not accurately known [82]. The current assumption that BBB transport occurs according to 
the gradient between blood and CSF represents a simplification. It does not take into account 
existing differences between CSF and ISF, local differences in ISF concentrations, and the 
impact of intracellular amino acid concentration of endothelial and brain cells in regulating 
transcellular transport processes. Furthermore, the total cytoplasmic amino acid concentration 
may differ from that directly at the plasma membrane. This information is crucial for 
understanding the location and quantity of the gradient between blood and brain which drives 
the transport. It is also important to understand how transporters are localized in response to 
changes in the amino acid gradient, and how they are regulated to maintain this gradient.  
 
What role does the intraendothelial compartment play in transport processes? The 
intracellular amino acid concentration is assumed to be generally higher than in ISF and 
plasma, and transport of amino acids from brain ISF into endothelial cells is highly 
concentrative, also due to the very small cell volume [32]. Too high cytoplasmic 
concentrations would impede influx or cause efflux back into brain ISF [32]. The necessary 
tight regulation of cytoplasmic concentrations can be achieved by transport processes, 
metabolism [1, 182], compartmentation events like the glutamate-glutamine cycle [1] (details 
see section 3.5.3.1), and biochemical conversions. 
The glutamate-glutamine cycle is described between astrocytes and neurons, but has also been 
suggested to occur between astrocyte endfeet and brain endothelial cells [32] and even 
intraendothelial. In this scenario, glutamine would be taken up over the abluminal membrane, 
converted by the intraendothelial glutaminase to glutamate which than could diffuse into 
blood by a sodium-independent process. Such a mechanism could be involved in brain to 
blood transport of glutamate [32]. Glutaminase activity is regulated by end product inhibition, 
and increased levels of intracellular glutamate result in the accumulation of glutamine [32], 
the preferred substrate for tertiary active transport processes (see section 3.6 and 3.6.1.3). 
Another possible link coordinating transport processes at the luminal and abluminal 
membranes may be the γ-glutamyl cycle (details see section 3.6.1.4), the regulation of 
abluminal sodium-dependent transporters via intracellular synthesized pyroglutamate [8, 165]. 
Transporters are also suggested transceptors [183], integrating extracellular signals with 
intracellular events, possibly via intracellular amino acid sensors like ATF4 or a member of 
the TOR pathway. Also the intracellular abundance of amino acid metabolism products, such 
as ATP, may be involved in amino acid sensing [183].  
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The endothelial cells are highly metabolic active cells with a high number of mitochondria 
[52]. Therefore, the endothelial cytoplasm and processes affecting its content may play an 
important role in determining the gradient over the single membranes and over the whole cell, 
and in buffering changes in blood as well as brain ISF. 
Besides glutaminase, endothelial cells also contain the enzymes required for synthesis and 
metabolism of serotonin and for catabolism of norepinephrine and dopamine [184]. One 
example of the impact of these enzymes on BBB transendothelial transport is observed for 
treatment of patients with neurotransmitter precursors, e.g. L-DOPA used in Parkinson’s 
disease treatment. Large doses of L-DOPA are necessary to achieve a therapeutic effect since 
it is metabolized in endothelial cells before it reaches the brain parenchyma, the place of 
action [184].  
In conclusion, the role of the intraendothelial compartment in regulating transport processes 
across the BBB may be underestimated so far. Anatomically it represents the junction 
between the two endothelial membranes and is therefore in a position to integrate, coordinate 
and regulate transport processes across the whole endothelial cell. The amino acid transport 
across the BBB may therefore be divided, in a blood to cytoplasm and a cytoplasm to ISF 
transport. This would imply that the gradient driving amino acid transport in the first instance, 
transport across the luminal membrane, would be different from the blood to brain ISF 
gradient, and that transport over the abluminal membrane would not directly be affected by 
the plasma amino acid concentrations. This view is supported by findings that the Na+/K+-
ATPase may be localized on both endothelial membranes [185] and that the sodium gradient 
(extracellular higher intracellular [1]) driving secondary active transport exists over the 
abluminal as well as over the luminal membrane. In conclusion, regulation of transport 
mechanisms over the BBB may have to be re-thought under consideration of these aspects. 
 
What are the different possibilities for polarization of transport? Transport polarity is 
probably a key feature of BBB function [79], since asymmetrical distribution allows vectorial 
transport which can create and sustain ionic and metabolite gradients, as seen for amino acids. 
In this context, asymmetrical expression of Glut1, Snat3 and Cd71 at the two membranes of 
the BBB endothelium has been shown in this thesis (see section 5). However, heterogeneity in 
expression and localization of transporters can happen on several levels, between different 
cell types, between the same cell type according to the environmental input, and in different 
developmental stages. One example for this is Snat3, which was previously reported to be 
only transiently expressed in the vascular endothelium during formation of the BBB [163], a 
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fact disproven in this thesis. Snat1 was found to be expressed at higher levels in the bigger 
vessels compared to brain capillaries. This highlights that expression heterogeneity seems to 
be a common feature of many transporters, since also for P-gp, an ABC transporter expressed 
on the luminal membrane [186], an segmental difference in expression along the brain 
vascular tree has been shown, with highest expression in capillaries [20]. Furthermore, 
differences between different vascular segments within the same organ may even be small 
compared to differences between neighbouring cells. Also within the same endothelial cells, 
expression and regulation of transporters on the two different membranes may vary since they 
face different cellular and mechanical environments. There is the possibility of polarized 
expression on either the luminal or abluminal membrane, and if expressed on both membranes 
there is the possibility of unequal expression levels, activities, affinities or regulation 
processes. 
Transport processes at the BBB can also be influenced by changing the substrate 
concentration in one of the compartments involved. It has been shown for example that a 
reduction of glutamate levels in blood increases the glutamate efflux from endothelial cells 
into blood and from brain ISF to blood [32]. An increased glutamate efflux is expected to also 
influence the transport of glutamine from brain ISF into endothelial cells [32]. This is of 
interest since glutamine can be used to accumulate essential amino acids (details see section 
3.5.3.1) and seems to be a possible link between driving and regulating transport processes. 
Amino acid gradients over the two membranes may also be influenced by biochemical 
conversions in the cytoplasm such as transamination, oxidation, hydroxylation, etc [94]. In 
this way the gradient over the membrane for the original amino acid can be sustained, and its 
transport further facilitated. Another possibility to influence transport processes are different 
posttranslational modifications of transporters inserted in the two distinct membranes, as 
indicated for Snat3 by the in vivo biotinylation experiments presented in this thesis (see 
section 5). 
System L1 transport is determined by the plasma concentration and the affinity constants, 
different for the different neutral amino acids which compete with each other for transport by 
L1 [5]. Since system L has a reported high exchanging activity, it has been considered certain 
LNAAs may be effluxed back out of the brain faster than brain cells take them up [184]. An 
important point that has not been considered adequately yet is the fact that the main neutral 
essential amino acid transporter expressed in both membranes of BBB endothelial cells, Lat1-
4F2hc, does not mediate net amino acid transport (uniport) but mainly amino acid exchange 
6. Discussion and Outlook.  134 
 
(see section 3.6.1.1). Thus influx of essential amino acids is always coupled to an equimolar 
efflux of amino acids that may be nonessential. 
The complexity of the system is pointed out by the fact that amino acid transport follows not 
only concentration gradients, also need, nutritional status, plasma and ISF concentrations of 
single amino acids and of a group of amino acids transported by the same transporter have to 
be considered, as well as regional differences [94]. The environmental impact on expression 
profiles could be shown, e.g. xCT (Slc7a11) and 4F2hc (Slc3a2) expression was found to be 
upregulated under influence of laminar flow [187]. On the abluminal membrane it has been 
suggested that gene expression within the neurovascular unit is highly interdependent [23] 
and that non-endothelial metabolism and transport processes regulating brain ISF 
concentration may have impact on transport across the abluminal endothelial membrane and 
therefore participate in the transport from blood to brain via the endothelial cytoplasm [184] 
(see section 3.6.1). 
In conclusion, there are numerous possibilities to coordinate amino acid transport across the 
BBB. Differences may exist between different organs, within the same organ in different parts 
of the vascular tree, between neighbouring endothelial cells and within the same endothelial 
cell. The transportomes of the two membranes may differ, and even if they don’t differ on the 
expression level they may do so by regulation of their function. Polarization may be achieved 
by substrate conversion, by transport of co-transported substrates, and by asymmetrical 
distribution of the single transporters. Membrane expression of the transporters may also be 
influenced by trafficking and protein-protein interactions. Furthermore, transporters often 
show overlapping properties [122], may depend on amino acid gradients established by other 
transporters, and some, like SNAT3, can operate in reverse (see section 3.6.1.3.2). In general, 
uniport mechanisms (facilitated diffusion) seem not to play a major role in establishing brain 
homeostasis since for instance Tat1, Lat3, and Lat4 expression was found to be very low in 
vivo in this thesis [2]. 
Interpretation of in vivo data is difficult since reports about transporter localization in the 
literature are often contrary or difficult to interpret (see section 3.6.1.1) and the complexity of 
the system is far from being understood. 
 
Does sodium-dependent amino acid transport just make sense on the abluminal membrane? 
Considering the participation of many amino acids in neurotransmission, together with 
functional data, and taking into account the existing amino acid gradient from blood to brain, 
it has been generally postulated that sodium-dependent amino acid transport is a feature of the 
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abluminal membrane of the BBB, which is absent from the luminal membrane where 
exclusively facilitative diffusion processes take place (which is of course not true in view of 
the obligatory exchange mode of Lat1 for instance) [3-6]. The finding of Snat3 presence on 
the luminal membrane of the BBB challenges this hypothesis and highlights the so far 
underestimated contribution of this membrane in actively regulating brain amino acid 
homeostasis.  
The hypothesis is based on results obtained from functional studies, like transendothelial 
transport across the BBB in vivo, and transport studies using isolated luminal and abluminal 
plasma membrane vesicles, a method developed by Betz et al. [43]. But, by performing in 
vivo studies, one cannot distinguish between different functions of the luminal and abluminal 
membrane in the transendothelial transport process [1], and vesicle studies have the 
disadvantage of working with unpure fractions that are distinguished based on nonspecific 
marker proteins [87]. In addition, sodium-dependent transport activities observed in luminal 
membrane-rich fractions was completely accounted for by abluminal vesicle contamination 
[79] and therefore not investigated further. And, since many amino acid transporters have 
only recently been cloned, previous functional studies were only able to define transport 
systems, based on substrate specificity, specific transport inhibiting compounds, and ion 
dependencies. However, amino acid transporters show overlapping substrate specificities, and 
the contribution of high-affinity systems with low transport capacities might have remained 
undetected. 
System L, even if not directly coupled to the sodium gradient, is dependent on the amino acid 
gradient generated by sodium-dependent, secondary active transporters of the System N and 
System A families [138]. Therefore, Lat1-4F2hc can also be seen as tertiary active 
transporter, allowing net cellular accumulation or depletion of specific System L substrates 
like leucine, without any change in the total amino acid concentration on either side of the cell 
membrane. Glutamine is the best candidate for hetero-exchange via system L, since glutamine 
is the only amino acid with similar concentrations in plasma and brain, and since it can be 
accumulated intracellularly by system N and A members. In this way essential amino acids 
can also be accumulated by Lat1-4F2hc. 
The localization of Snat3 on the luminal membrane may indicate a functionally association of 
Lat1-4F2hc with this secondary active transporter to enhance availability of essential amino 
acids to brain. Snat3 is not the first secondary-active transporter found to be localized at the 
luminal membrane, also ATB0,+ (Slc6a14) and the serotonin transporter SERT (Slc6a4) have 
been detected in this membrane (see section 3.6.1.1). The luminal expression was justified by 
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the fact that serotonin acts as vasoconstrictor and that its clearance from blood is important to 
maintain cerebral blood flow [188]. Amino acids like aspartate, glutamate, and glycine may 
exhibit the same function [189] and would offer one explanation for potential luminal 
localization of EAATs (see addendum) found in this thesis. Another explanation would be 
that the transported substrate exerts a function in interorgan communication. The need to 
actively regulate the amino acid clearance from the endothelial cytoplasm may be also one 
explanation of secondary-active transporters being localized to the luminal membrane like 
seen in this thesis (see section 5). 
Furthermore, amino acid transporters may be involved in other mechanisms than pure 
transport, opening the possibilities for further regulatory mechanisms affecting localization 
and function. Amino acid transporters at the plasma membrane represent the first contact 
between cell and environment, sensing both extracellular and intracellular amino acid 
concentrations, and are therefore in a position to play a role in nutrient sensing and signalling.  
Amino acid transporters have also been shown to change between localization at the plasma 
membrane and intracellular storage places. Depending on environmental stimuli, like 
starvation, trafficking from these subcellular localizations to the plasma membrane to 
guarantee nutrition has been shown. 
In conclusion, the gradient driving active transport may be over both membranes and the role 
of the intraendothelial compartment in transport processes may be underestimated. Therefore 
the current hypothesis, that sodium-dependent transport is exclusively expressed abluminally, 
may represent a simplification and needs further investigation. Also the view of blood to brain 
transport serving nutritional needs and brain to blood transport preventing neurotoxic amino 
acid levels in the brain ISF may be too simple, highlighting the need to measure brain to 
blood transport in vivo which is less studied. Further, the exact role of facilitated diffusion on 
the abluminal membrane is not well studied. One has also to consider that efflux, influx and 
metabolism occur simultaneously and that one can not see the processes separated from each 
other. Even if no differences can be measured it does not mean that there is no flux existing, it 
just tells that the sum of all events equals up. 
 
Is it important to study amino acid transport across the BBB? To understand the functional 
organisation of the BBB and the role of the BBB transportome in physiological and 
(neuro)pathophysiological states, many of them characterized by impaired brain amino acid 
concentrations, it is necessary to not only determine which transporters are expressed at the 
BBB, but also whether these transporters are expressed at the luminal or abluminal 
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membrane, and how they are regulated. Sodium-dependent transporters expressed on the 
luminal membrane of vascular endothelial cells may play an important role in situations 
characterized by limited amino acid supply, like during stroke. Furthermore, luminal 
expressed amino acid transporters potentially could represent an interesting route for 
pharmacological interventions due to their easy accessibility. Novel therapeutic approaches, 
based on the findings how the neurovascular unit communicates to establish the BBB 
phenotype, may be obtained for improved drug delivery across the BBB [23]. 
There is a research gap regarding nutrient transporters at the BBB, also since the effort 
nowadays lies on research of ABC transporters due to their importance for the pharmaceutical 
industry.  
 
What comes next? Future investigations should aim at determining the molecular nature, 
subcellular expression, and activity of other, still not characterized, SLC members at the BBB 
and other brain barriers. Since the basis of normal brain function is not sufficiently 
understood, the basis of abnormal function is also poorly understood [123]. The BBB 
transportome, the players presented in this thesis, at least on mRNA level, should be studied 
by combining expression with functional analysis to give the single players a name and face. 
In vivo studies are necessary to avoid culture induced artefacts [2, 150], also if one keeps in 
mind that many if not most features of the BBB phenotype can be subject to modulation [14].  
One interesting family to examine is system X-AG (see Table 4). In neurons they have been 
found to be subject to intracellular trafficking and highly regulated expression. But also the 
brain vasculature is rich in EAATs, suggesting a role in brain ISF glutamate homeostasis [32]. 
Preliminary results (see addendum in this thesis and mRNA results in Lyck et al. [2]) suggest 
that the EAATs may play a major role in BBB physiology.  
The possibility of differences in regulatory mechanisms on the luminal compared to the 
abluminal membrane has to be considered and examined, since the two membranes face 
different biochemical and physical environments. Also, the role of the BBB transportome and 
single transporters within, in adaptation to regional differences in brain ISF composition, and 
their developmental and physiological modulations needs further observations. The question 
of polarity should also be viewed under the light of regulated expression and activity. 
Localization and activity of a transporter, as well as total expression and functional activity, 
can be different, highlighting the importance to find a way to characterize brain to blood 
transport in vivo. In general, the methods to examine transport processes should be optimized 
to be able to measure transendothelial transport of also small hydrophilic solutes like amino 
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acids. It is difficult to distinguish between unidirectional flux and uptake, since membrane 
transport processes are very rapid and equilibrium is reached within 1-5 s for glucose or 
amino acids, and therefore intracellular metabolism may dominate the uptake process [119]. 
In the past, an inability to measure transendothelial transport of a substance was interpreted in 
a way that there is no movement of this substance occurring (see section 3.6.1.1). One has 
also to consider that transport happens not only according to a substrate gradient, also to need, 
relevance (essential vs. non-), energy-dependency, to plasma and brain ISF concentrations of 
single amino acids and of a group of amino acids transported by the same transporter. One 
future focus should also be to identify how amino acids are retained by the brain once they 
have entered [1]. 
Furthermore, a functional in vitro system would be one of the greatest achievements in BBB 
research of the last years (see section 3.4.2). With an in-vivo like in vitro model a high-
throughput system would exist allowing to screen for the impact of intraendothelial 
metabolism on various aspects of barrier physiology. By performing co-culture experiments 
the interaction of several transporters expressed in the various cells of the neurovascular unit 
and the impact of compartmentalization events could be studied. Also the measurements of 
transport processes in vivo, e.g. with positron emission tomography (PET), together with the 
determination of cellular and brain ISF amino acid concentrations over time, would further 
allow to better understand the gradients driving BBB transport.  
In general, the inconsistent use of methodical approaches and transporter nomenclature in the 
past (see section 3.6.1.1) resulted in difficulties to compare the published data and see them in 
context to each other. One issue is that characterization of transport systems was mainly 
performed in the pregenomic era, using bovine and pig material, and that this data was not 
aligned to the identified and characterized single transporters. One example to mention is the 
described system Na+-LNAA, a system not known outside the BBB literature and not 
described elsewhere. Thus effort should be done to combine the data on expression of single 
transporters at the BBB with the ones obtained by functional studies describing mainly 
transport systems. 
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10. Addendum. 
 
1. Introduction. 
 
EAAT3 (SLC1A1), also known as EAAC1, is a member of the SLC1 family of high-affinity 
glutamate and neutral amino acid transporters. It has been classified as a system X-AG 
transporter (see Table 4 in section3.5.4), co-transporting one molecule L-glutamate or D/L-
aspartate with three sodium and one proton ions, in exchange for one potassium ion [I]. Due 
to this stoichiometry it has been calculated that EAAT3 is able to accumulate glutamate 
5x106-fold inside cells [I], helping to keep the glutamate concentration in brain ISF low (see 
section 3.5.3.1 and 3.5.4). Besides substrate uptake, EAAT3 has been shown to also mediate 
facilitative substrate exchange, with uptake being the predominant transport mechanism [I]. 
EAAT3 is reported to be highly expressed in brain neurons, in the intestine, kidney, liver and 
heart [II]. In brain, EAAT3 is predominantly expressed in neurons of hippocampus, cerebral 
cortex, olfactory bulb, striatum, superior colliculus and thalamus [I]. More precise, in 
glutamatergic and GABAergic neurons, in cholinergic and aminergic neurons [III], but also in 
a few astrocytic processes in both gray and white matter and in glial cells other than 
astrocytes [IV], as well as in ependymal cells and in epithelial cells of the choroid plexus of 
the four ventricles [V]. EAAT3 is reported to be concentrated in the neuronal cell bodies 
(somata) and dendrites, avoiding the nerve terminals [VI]. Exceptions are presynaptic 
GABAergic terminals, where EAAT3 uptake of glutamate contributes to re-synthesis of 
GABA [VII]. In the kidney, EAAT3 is expressed in the apical membrane of the proximal 
tubules [I], and the concentration of EAAT3 in the kidneys is reported to be higher than in the 
hippocampus [V]. EAAT3 shows a developmental expression profile with early expression 
but rather low expression level in the adult [III]. In addition, EAAT3 is present mainly in the 
intracellular compartment and only for about 20% at the plasma membrane [III]. 
It is suggested that the primary physiological function of EAAT3 is to regulate the excitability 
of postsynaptic neurons [IV] and to protect neurons from excitotoxicity by maintaining the 
extracellular glutamate concentration low [I] (see Table 2). One condition where glutamate 
excitotoxicity can be observed is during ischemia, where the insufficient energy supply leads 
to reversal of the electrochemical gradients and therefore to glutamate release due to reversal 
of the transport [I]. The detection of EAAT3 protein in all parts of the neurons suggests a 
function other than solely the uptake of synaptically released glutamate [III]. The role of 
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EAAT3 in clearing glutamate from the extracellular space is thought to be quantitatively 
minor compared to the role glial glutamate transporters (EAAT1/SLC1A3, EAAT2/SLC1A2) 
are playing [VII]. Another suggested function of EAAT3 is the protection of neurons against 
oxidative stress [III]. This is based on the finding that neuronal cysteine uptake occurs mainly 
via EAAT3, and that dysfunction leads to impaired glutathione homeostasis and 
neurodegeneration [VII].  
Slc1a1-/- mice develop dicarboxylic aminoaciduria, but no neurodegeneration in a period of 
over one year [VIII]. However, they have reduced neuronal glutathione levels and, with aging, 
develop brain atrophy and behavioural changes [VII]. 
Recently, expression of Eaat3 mRNA in cultured and non-cultured primary MBMECs was 
examined by us and shown to be lower than the expression of 4F2hc (Slc3a2; see section 
3.6.1), Lat1 (Slc7a5; see section 3.6.1), Snat2 (Slc38a2), and Snat5 (Slc38a5), but to be higher 
than the one of Snat3 (Slc38a3; see section 3.6.1.3.2) and Snat1 (Slc38a1; see section 
3.6.1.3.1) [IX]. Surprisingly, the “neuronal” transporter Eaat3 turned out to be the most 
prominent expressed Slc1 member. Furthermore, Eaat3 expression in cultured and non-
cultured primary MBMECs was found to be higher than in whole brain, suggesting an 
accumulation of Eaat3 in endothelial cells of the brain vasculature. This stands in contrast to 
the view that Eaat3 is mainly expressed in neurons, shown to be involved in the glutamate-
glutamine cycle (see section 3.5.3.1). On the other hand, functional data using isolated bovine 
brain endothelial membrane vesicles supported the view of Eaat3 being expressed at the BBB, 
with restricted localization to the abluminal membrane and suggested based on inhibitor 
studies a relative activity of 1:3:6 for EAAT1:EAAT2:EAAT3, respectively [X]. 
In the following section an overview on data generated during this PhD thesis is presented, 
supporting the view that Eaat3 is an important player in the BBB endothelial cell 
transportome and that it may be expressed on both membranes, luminal and abluminal. 
 
 
2. Material and Methods. 
 
Animals. Female C57BL/6JOlaHsd mice were purchased from Harlan Laboratories B.V. 
(Venray, Netherlands). The mice were housed in standard conditions and fed a standard diet. 
All animal procedures were according to the Swiss Animal Welfare laws and approved by the 
Kantonales Veterinäramt Zurich (permission number 119/2008). 
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Primary cortical neurons. Primary cortical neurons isolated from embryonic rat brains were a 
kind gift of Thomas Grampp and Corinne Sidler, Institute of Pharmacology and Toxicology, 
University of Zurich. 
 
Antibodies. The following commercial available primary antibodies were used: mouse-anti-
glucose transporter 1 (Glut1) monoclonal ab40084 (dilution 1:200; Abcam, Cambridge, MA, 
USA); chicken-anti-laminin polyclonal ab14055 (1:200; Abcam); rabbit-anti-EAAC1 
polyclonal cat#EAAC11-A (1:200; Alpha Diagnostic, San Antonio, TX, USA); mouse-anti-
microtubule associated protein-2 (MAP2) monoclonal MAB3418 (Millipore); mouse-anti-P-
glycoprotein, mAB (C219) monoclonal ALX-801-002-C100 (1:100; Alexis Biochemicals, 
San Diego, CA, USA); guinea-pig-anti-Mrp1 polyclonal (1:3,000; kind gift of Jean-Marc 
Fritschy, Institute of Pharmacology and Toxicology, University of Zurich [XI]); mouse-anti-
β-actin monoclonal A5316 (Sigma-Aldrich, Steinheim, Germany). The following secondary 
antibodies were used as indicated: Alexa Fluor® 488 goat anti-rabbit IgG (1:400/500; 
Invitrogen, Eugene, OR, USA); Alexa Fluor® 568 goat anti-guinea pig IgG (1:500; 
Invitrogen); DyLightTM 549 goat anti-chicken IgY (1:400; Jackson ImmunoResearch, Suffolk, 
UK); Cy5 goat anti-mouse IgG (1:400/500; Jackson ImmunoResearch); Texas Red®-X 
phalloidin T7471 (1:500; Invitrogen); PO-PROTM-1 iodide (1:400; Invitrogen); ECLTM anti-
mouse IgG, HRP linked whole antibody (1:10,000; GE Healthcare, Little Chalfont 
Buckinghamshire, UK); anti-rabbit IgG (Fc) AP conjugate (1:5,000; Promega, Madison, WI, 
USA); Streptavidin-HRP conjugate (1:20,000; GE Healthcare). 
 
Immunohistochemistry. The cellular localization of EAAT3 was assessed by quadruple 
immunofluorescence staining with antibodies against specific markers, raised in different 
species (specifications and dilutions described under “antibodies”). Five-week-old female 
mice were anesthetized and perfused through the left cardiac ventricle with PBS, pH 7.4, 
followed by 2% paraformaldehyde (PFA), 0.2% glutaraldehyde in PBS. The brains were 
harvested and postfixed by immersion in fixative for 2 h at 4 °C. After an overnight washing 
step in PBS at 4 °C, they were stored in 0.02% PFA at 4 °C. For staining, 20-µm thick tissue 
sections were prepared using a vibrating microtome (Leica VT 1000S; Leica, Heerbrugg, 
Switzerland). Fluorescence triple immunolabeling was carried out on free-floating sections at 
RT. The sections were immersed and gently agitated in 0.5% Triton X (TX)-100 in PBS for 
30 min, followed by 10 min blocking (Protein Block Serum-Free; Dako, Carpinteria, CA, 
USA), and incubation with the primary antibodies overnight at 4 °C. Sections were then 
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incubated for 45 min with the appropriate secondary antibodies, followed by 10 min in 4% 
PFA. Between each step, sections were washed three times 5 min in PBS. Nuclear 
counterstaining was performed by incubation in PO-PROTM-1 iodide (Invitrogen). The 
sections were transferred onto PolysineTM slides (Kindler, Freiburg, Germany), drained, and 
mounted in Vectashield mounting medium (Vector Laboratories) for imaging. 
Alternatively, unperfused brains were rapidly excised and frozen with powdered dry ice. 
Sections were cut at 14 µm with a cryostat (Leica CM 1850, Leica Microsystems, Nussloch, 
Germany), mounted onto PolysineTM slides, fixed in ice-cold methanol for 10 min at -20 °C 
and rinsed with PBS. Sections were then immersed in 0.1% SDS for 5 min, rinsed in PBS and 
blocked in blocking solution (PBS containing 2% BSA, 0.02% TX-100) for 15 min at RT. 
After, sections were incubated overnight at 4 °C with a mixture of primary antibodies raised 
in different species and diluted in blocking solution. They were then rinsed with PBS and 
incubated with the corresponding fluorophore-conjugated secondary antibodies diluted in 
blocking solution for 1 h at RT. Sections were washed three times for 10 min with PBS and 
coverslipped in Dako® fluorescent mounting medium (Dako Corporation, Carpinteria, CA, 
USA). 
Control experiments were always performed by omitting the primary antibodies. The 
secondary antibodies alone did not produce any significant staining in all tissues tested (data 
not shown). 
 
Immunocytochemistry. Cultures of rat primary neuronal cells were washed with PBS, fixed 
with PFA (3%) in PBS containing 0.2% TX-100 for 15 min at RT. The cells were rinsed in 
PBS and further processed as described under “immunohistochemistry on methanol-fixed 
mouse brain tissue sections”. 
Control experiments were performed by omitting the primary antibodies. The secondary 
antibodies alone did not produce any significant staining in all tissues tested (data not shown). 
 
Data analysis. The sections were viewed with a Leica TCS SP2 confocal laser scanning 
microscope (Leica) using a 63x objective lens (numerical aperture of 1.4, pinhole set to 1.0 
airy unit) with different zoom factors (5-8). A sequential scan procedure was applied during 
image acquisition of the fluorophores and acquisition parameters were adjusted to use the full 
dynamic range of the photomultipliers. Typically, stacks of four to eight images (512 x 512 
pixels) were taken and analysed at 122-nm intervals through the z-axis of the section. 
Representative images from the examined samples were chosen for figure editing. Digital 
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images were processed using the software Imaris® (Imarisx64 7.1.1, Bitplane, Zurich, 
Switzerland) and Huygens (CMLE algorithm; SVI, The Netherlands). 
 
Surface biotinylation of rat primary neurons. Experiments were performed as described 
elsewhere [XII], with minor modifications. Shortly, neurons have been isolated and plated in 
12-well plates. After eleven days, cells were placed on ice at 4 °C, washed in HBSS (14025-
050; Invitrogen / Gibco, Paisley, UK), and incubated in HBSS containing 1 mg/mL EZ-Link® 
sulfo-NHS-LC-biotin (Thermo Scientific, Rockford, IL, USA) or, as control, in HBSS 
without biotin, for 30 min. After a washing step in TBS (20 mM Tris pH 7.4, 150 mM NaCl) 
containing 5 mg/mL glycine, cells were extracted by adding 100 µL TE (5 mM Tris pH 8, 5 
mM EDTA) containing 1% NP40 and 1x PIC and placed for 30 min on a shaker. Cells were 
scraped, the wells washed with 100 µL TE, and the extracts of two wells pooled. After storing 
the samples at -80 °C, the extract has been drawn several times through a 23-gauge needle, 
followed by heating at 70 °C for 5 min, and drawing several times through a 27g-needle. The 
resulting extract has been centrifuged (13,000xg, 10 min, RT), and the supernatant (= T) 
separated from the pellet. The next steps included to add IP (100 mM NaCl, 20 mM sodium 
borate, 15 mM EDTA, pH 8.5) containing 1.2% TX-100 and 1x PIC) (300 uL) to the 
supernatant, to wash the Neutravidin-agarose twice in IP containing 0.17% SDS, 0.85% TX-
100, to add the diluted extract to the washed agarose resin (Thermo Scientific, 60 µl / 
sample), and to incubate with mixing overnight at 4 °C. After centrifugation (1,000xg, 2 min, 
4 °C), the supernatant containing non-biotinylated proteins was collected (= U) and the 
Neutravidin-agarose resin washed four times with chilled IP containing 0.1% SDS, 0.5% TX-
100, and once with chilled PBS. The biotinylated proteins were released by adding 60 µL 4x 
Laemmli buffer / DTT to the Neutravidin-agarose, then incubated with mixing 2 h at 4 °C, 
followed by 5 min at 90 °C, and the supernatant (= B) collected by centrifugation (1,000xg, 2 
min, RT). 
 
Total membrane protein and whole cell lysate preparation. Whole nonperfused mouse brains 
and kidneys were snap frozen in N2(l), sonicated with 200 µL RB (200 mM mannitol, 80 mM 
HEPES, 41 mM KOH, pH 7.5, along with 1x Complete EDTA-free proteinase inhibitor 
cocktail (Roche Diagnostics, Mannheim, Germany)) on ice, and subsequently centrifuged for 
20 min at 2,000 rpm at 4 °C. The supernatant was aspirated (= whole cell lysate), centrifuged 
(41,000 rpm, 1 h, 4 °C), the resulting supernatant containing cytosolic proteins was removed, 
whereas the pellet (= total membrane proteins) was resuspended in RB and sonicated briefly 
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to evenly distribute proteins. Protein concentration was measured using the BioRad DC protein 
assay (Bio-Rad Laboratories, Hercules, CA, USA). Samples were mixed with Laemmli 
sample buffer, and further processed as described under “Gel electrophoresis and Western 
blot analysis”. 
 
In vivo biotinylation. In vivo biotinylation experiments were performed as described 
elsewhere [XII, XIII], with minor modifications, using perfusion conditions to maintain the 
integrity of the BBB. Shortly, five-week-old female mice were anesthetized, the abdominal 
aorta clamped, and the brain perfused through the left cardiac ventricle with PBS (Invitrogen, 
Paisley, UK) containing 10% (wt/vol) dextran 40 (Sigma-Aldrich). Drainage was from the 
right atrium. Perfusion of the prewarmed solutions (38 °C) was performed applying a pressure 
of 100 mm Hg. Immediately afterwards, the mice were perfused with 5 ml of freshly prepared 
biotinylation solution, containing 3 mg/ml EZ-Link® sulfo-NHS-LC-biotin (Thermo 
Scientific) in PBS and 10% (wt/vol) dextran 40. The biotinylation solution was incubated for 
5 min at RT, before non-reacted biotin was quenched by perfusion with 50 mM Tris in PBS, 
10% (wt/vol) dextran 40. As non-exogenously biotinylated negative control, mice were 
perfused as above with PBS and 10% (wt/vol) dextran 40, but without added biotin. 
Immediately after perfusion, the brain was excised, the cerebellum removed, and the brain 
snap-frozen in liquid nitrogen. 
 
Protein extraction and purification of biotinylated proteins. Experiments were performed as 
described elsewhere [XII, XIII], with minor modifications. Shortly, perfused brains were 
resuspended in lysis buffer (2% SDS, 50 mM Tris, 10 mM EDTA, Complete EDTA-free 
proteinase inhibitor cocktail (Roche Diagnostics) in PBS; pH 6.8; 25 mg brain per ml of lysis 
buffer) and homogenised using an disperser (Polytron PT 2100, Kinematica AG, Littau, 
Switzerland). Homogenates were sonicated (Labsonic 1510, B. Braun, Bender + Hobun, 
Zurich, Switzerland), incubated at 95 °C for 20 min and centrifuged at 17,000g for 20 min at 
25 °C. Total protein concentration was determined using the BCATM protein assay (Thermo 
Scientific). Neutravidin-agarose resin (Thermo Scientific, 500 µl / sample) was washed three 
times in buffer A (1% Nonidet P-40 and 0.1% SDS in PBS) and once in lysis buffer. 15 mg of 
total protein extract (total protein lysate) were added to the washed resin, and incubated with 
mixing for 2 h at RT. The supernatant containing non-biotinylated proteins was collected 
(unbound protein fraction) and the Neutravidin-agarose resin washed four times with buffer A 
and two times with buffer B (0.1% Nonidet P-40 and 1 M NaCl in PBS). The biotinylated 
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proteins were released by resuspending the Neutravidin-agarose in solution C (2% SDS, 30 
mM biotin (Sigma-Aldrich), 50 mM phosphate, 100 mM NaCl, 6 M urea, 2 M thiourea; pH 
~12) [XIV], incubated 15 min at RT, followed by 15 min at 96 °C, and the supernatant 
collected. The supernatant containing biotinylated proteins was concentrated with 
trichloroacetic acid (final concentration 10%) overnight at 4 °C, the precipitated proteins 
washed four times with ice-cold ethanol, lyophilized, and resuspended in Laemmli buffer 
(Neutravidin-agarose-bound protein fraction). 
 
Gel electrophoresis and Western blot analysis. For SDS polyacrylamide gel electrophoresis 
(SDS-PAGE) fractionation, 25% of the total Neutravidin-agarose-bound protein fraction from 
mouse brains with and without in vivo biotinylation vs. 20 µg of the corresponding unbound 
protein fraction and total protein lysate, were analysed by Western blotting. Samples from 
independently perfused and processed mouse brains were isolated and analysed in at least 
triplicate. Samples were reduced by heating at 95 °C for 5 min in Laemmli buffer and 
fractionated on a 7.5 or 8.5% SDS-PAGE. For immunoblotting, proteins were transferred 
electrophoretically from unstained gels to PVDF membranes (Immobilon-P; Millipore, 
Bedford, MA, USA). After being blocked with Tris-buffered saline supplemented with 2% 
TopblockTM powder (VWR, Dietikon, Switzerland) and 0.1% TX-100 for 2 h at RT, the blots 
were incubated with the primary antibodies overnight at 4 °C. All primary antibodies were 
used at a 1:500 dilution, except β-actin (1:5,000). After being washed, blots were incubated 
with the corresponding secondary antibody for 1 h at RT. Antibody binding was detected with 
ImmobilonTM Western Chemiluminescent HRP or AP Substrate (Millipore, Billerica, MA, 
USA). Chemiluminescence was detected with a Fuji LAS-4000 camera (Bucher Biotec, 
Basel, Switzerland). The same membrane first used to detect Eaat3 was stripped, blocked, and 
re-probed with Streptavidin-HRP and β-actin.  
Whole cell and total membrane preparations from mouse kidney and brain have been diluted 
in Laemmli buffer (25-100 µg protein) and further processed as described. 
Surface biotinylated neuronal membrane proteins (total fraction obtained), as well as the 
corresponding non-biotinylated and total protein lysates (20 µg each), were analysed by 
Western blot as described. 
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3. Results. 
 
3.1 Characterization of the antibody against Eaat3 (Eaac1; Slc1a1) used. 
The antibody directed against a C-terminal antigen of EAAT3 was previously successfully 
used in several publications (see manufacturer’s data sheet). Also the experiences in the 
laboratory of C.A. Wagner, Institute of Physiology, University of Zurich, have been positive 
(personal communication). Therefore we have chosen to use this antibody to test the 
expression and localization of Eaat3 in the mouse endothelial cells comprising the BBB. 
First, by performing Western blot analysis using total kidney and brain lysates and kidney 
membrane preparation, we could detect one band of the expected size in all samples tested 
(~69 kDa, according to the manufacturer) (see Figure I). Furthermore, the signal was 
dependent on the amount of protein loaded and of the antibody dilution used. The signal 
intensity in the kidney membrane preparation was higher than in the kidney total lysate, and 
in both cases higher than in the total brain protein lysate. 
 
Figure I: Expression of Eaat3 in mouse kidney and brain samples. 
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Western blot analysis of total protein and membrane fractions of mouse kidney and brain. Different protein 
concentrations (25/50/75/100 µg) have been loaded on a gel, SDS-PAGE performed, transferred to a PVDF 
membrane, and subsequently stained for Eaat3 using different antibody concentrations (1:500/1,000). A band of 
expected size (~69 kDa) could be detected in all cases. Eaat3 expression in brain is low, lower than in kidney. M, 
total membrane preparation; T, whole cell preparation. Picture can be found under 160208_SNAT1_EAAT3_010. 
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In brain, Eaat3 has been described to be mainly expressed in neurons, in all their parts of the 
neurons. Therefore, immunocytochemistry on primary cortical neurons has been performed 
(see Figure II). The signal of Eaat3 showed the expected cellular distribution excluding the 
nuclear region, and a colocalization with the neuronal marker Map2. The Eaat3 staining 
pattern shown is consistent with more than one neuronal cell stained (see also nuclear 
staining, Figure II) and with the cells being grown in different planes. 
 
Figure II: Localization of Eaat3 in cortical neurons. 
 
A)  B)  C)  
D)  E)  
 
 
Immunocytochemistry on PFA fixed rat cortical neurons. A) Staining for Eaat3 (green), nucleus (white), Map2 
(blue), and phalloidin (red). Map2 (microtubule associated protein) is an established neuronal marker, phalloidin 
binds to F-actin; B) Colocalization of Map2 (blue) with Eaat3 (green); C) Staining for Eaat3 (green) and 
phalloidin (red); D) Staining for Eaat3 (green) and nucleus (white); E) Eaat3 (green) staining alone, showing the 
reported broad distribution of Eaat3 in the whole neuronal body and possibly intracellular storage vesicles. Scale 
bar = 5 µm. Pictures can be found under neurons_151009_Eaat3_series011. 
 
The specificity of the antibody was further tested by surface biotinylation of primary cultures 
of cortical neurons. After subsequent purification of the exogenously labeled proteins, 
Western blot analysis of the different fractions obtained during the purification procedure has 
been performed (total protein lysate, biotinylated proteins captured by Neutravidin and 
proteins of the total lysate not binding to Neutravidin) (see Figure III). The staining for Eaat3 
showed a band of the expected size (see Figure I) in all fractions, with low expression in the 
Neutravidin-bound fraction of exogenously biotinylated samples. In the control without 
exogenously biotinylation, the Eaat3 signal was below the detection limit in the Neutravidin-
bound protein fraction, like expected. 
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Figure III: Expression of Eaat3 on the membrane of surface biotinylated cortical neurons. 
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Western blot analysis of surface biotinylated rat cortical neurons. Fractions in different stages of purification 
show expression of Eaat3 (~69 kDa), with highest expression in the exogenously biotinylated protein fractions. 
Control experiments without added biotin show a less strong signal. The results suggest a detectable amount of 
Eaat3 being expressed at the membrane of cortical neurons. T, total protein (non- and biotinylated proteins); U, 
Neutravidin-unbound, non-biotinylated proteins; B, Neutravidin-bound, biotinylated proteins. Pictures can be 
found under WB from 211009_221009_gel 3_Eaat3_30 sec; WB from 211009_221009_gel 3_biotin_30 sec. 
 
 
3.2 Expression of Eaat3 on both membranes of mouse brain vascular endothelial cells. 
The high expression of Eaat3 mRNA in MBMECs [IX] suggested an important role of this 
transporter on the protein level. Therefore, two independent approaches have been chosen to 
examine the expression and localization of Eaat3 in the mouse brain in vivo. 
First, immunohistochemistry on fresh frozen, methanol fixed, tissue and tissue fixed by 
perfusion with a PFA/glutaraldehyde mixture has been performed. By using the former 
method, the signal for Eaat3 was shown to colocalize with that of the ABC-transporter Mdr1, 
a known marker of the luminal membrane of the BBB (see Figure IVC). On the abluminal 
membrane the signal for Eaat3 was shown to colocalize with the one of the abluminal 
expressed ABC-transporter Mrp1 (see Figure IVD). To improve the tissue quality, perfusion 
and fixation of the mouse brain with PFA/glutaraldehyde was chosen. By staining of in this 
way processed tissue sections the expected localization of the sodium-dependent transporter 
Eaat3 on the abluminal membrane of brain vascular endothelial cells could be shown by 
colocalizing the signal with the one of Glut1 (see Figure VC/G/K). The endothelial cell 
specific staining was further shown by localizing it luminally relative to the signal of the 
extracellular matrix marker laminin (see Figure VD/K). Also the luminal localization of Eaat3 
could again be shown by colocalizing it with the luminal signal of Glut1 staining (see Figure 
VC/G). The obtained staining pattern highlights the possibility of Eaat3 being localized in 
intracellular storages like shown in neurons. 
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Figure IV: Localization of Eaat3 on the luminal and abluminal membrane of BBB endothelial cells. 
 
A)  B)  C)  
D)  E)  
 
 
Immunohistochemistry on methanol fixed mouse brain tissue sections. A) Colocalization of Mdr1 (blue) with 
Mrp1 (red). Like previously shown [XI], the ABC transporter Mdr1 can be used as marker for the luminal 
membrane of BBB endothelial cells, Mrp1 as marker for the abluminal membrane; B) Colocalization of Eaat3 
(green) with Mdr1 (blue) and Mrp1 (red); C) Colocalization of Eaat3 (green) with Mdr1 (blue) on the luminal 
membrane of BBB endothelial cells; D) The luminal signal of Eaat3 (green) does not colocalize with the 
abluminal signal of Mrp1 (red); E) Eaat3 (green) staining alone. Scale bar = 5 µm. Pictures can be found under 
slide31_63x_Series014. 
 
Figure V: Localization of Eaat3 on the luminal and abluminal membrane of BBB endothelial cells. 
 
A)  B)  C)  
D)  E)  
 
 
Figure legend see next page. 
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Figure V: Localization of Eaat3 on the luminal and abluminal membrane of BBB endothelial cells. 
 
F)  G)  H)  
I)   K)  L)  
 
Immunohistochemistry on PFA/glutaraldehyde fixed mouse brain tissue sections. A), F) and I) Colocalization of 
Glut1 (blue) and nucleus (white), showing that Glut1 can be used as marker for the luminal and abluminal 
membrane of BBB endothelial cells; B) Staining for Glut1 (blue) and laminin (red), showing that Glut1 staining 
is specific for BBB endothelial cells and does not stain brain parenchymal cells; C) and G) Colocalization of 
Eaat3 (green) and Glut1 (blue) on the luminal and abluminal membrane of BBB endothelial cells; D) and K) 
Eaat3 (green), Glut1 (blue), and laminin (red) staining, showing Eaat3 being localized to vascular endothelial 
cells, as well as to brain parenchymal cells; E), H) and L) Eaat3 (green) staining alone, highlighting the 
possibility of Eaat3 being localized in intracellular storages like shown in neurons. A)-E) small cortical vessel 
with one nucleus; F)-H) small cortical vessel with two nuclei; I)-L) bigger cortical vessel. Scale bar = 5 µm. 
Pictures can be found under 270110_Snat1 etc_Eaat3_series 068; 270110_Snat1 etc_Eaat3_series 044; 
EAAT3_050110_slide2_series031. 
 
Second, to probe for proteins expressed at the luminal surface of the vasculature, the brains of 
anesthesized mice were perfused with the membrane-impermeable biotinylation reagent sulfo-
NHS-LC-biotin. The total protein lysate (input) out of one mouse brain, containing both 
labeled luminal proteins and non-in vivo biotinylated proteins (unbound protein fraction), was 
purified using Neutravidin-coated agarose. As expected, by Western blot analysis a strong 
biotin signal of multiple diffuse bands was detected in the Neutravidin-agarose-bound protein 
fractions, absent or only weakly found in the total protein lysates and unbound protein 
fractions (see Figure VI). Further, consistent with a lack of intracellular protein labeling, β-
actin was almost not detected in the Neutravidin-agarose-bound protein fractions, but was 
present in all other fractions (see Figure VI). Taken together, the data is consistent with the 
preservation of the BBB integrity during the in vivo biotinylation procedure and the restriction 
of the labeling by in vivo biotinylation to proteins expressed on the luminal cell surface of the 
vasculature. To probe for possible luminal localization of Eaat3, Western blot analysis of the 
different fractions obtained after in vivo biotinylation of the brain vascular lumen was 
performed. A weak band corresponding to the expected molecular weight of Eaat3 (~69 kDa) 
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was found in the Neutravidin-agarose-bound protein fraction from in vivo biotinylated mice 
and to a lesser extent in the corresponding fraction from the non-exogenously biotinylated 
negative control brains (see Figure VI). 
 
Taken together, Eaat3 shows endothelial expression, that is suggested to be also on the 
luminal membrane of brain vascular endothelial cells comprising the BBB. 
 
Figure VI: Possible expression of Eaat3 in the lumen of mouse brain vascular endothelial cells. 
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Western blot analysis of in vivo biotinylated mouse brain vascular endothelial cells. Different fractions obtained 
after exogenously biotinylating proteins expressed on the luminal membrane of brain vascular endothelial cells 
were loaded on a SDS-PAGE gel, transferred to a PVDF membrane and subsequently stained for Eaat3, biotin, 
and β-actin. In all fractions a signal for Eaat3 at the expected size could be detected. The signal in the 
exogenously biotinylated protein fraction was stronger than the one in the control without added biotin in the 
perfusion solution. The controls showing effective exogenously biotinylation (biotin) of the luminal membrane 
(β-actin) show the expected pattern. T, total protein (non- and biotinylated proteins; 20 µg loaded); U, 
Neutravidin-unbound, non-biotinylated proteins (20 µg); B, Neutravidin-bound, biotinylated proteins (25% of 
total fraction). Pictures can be found under WB from 200110_210110_Eaat3_gel 3_30 sec; WB from 
200110_220110_biotin_gel 3_30 sec; WB from 200110_220110_actin_gel 3_30 sec. 
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4. Discussion. 
 
The results on Eaat3 expression and localization presented in this thesis show the potential 
significance of this high-affinity glutamate transporter in the endothelial cells of the BBB. 
Eaat3 was shown to be highly expressed on mRNA level in MBMECs and not to be subject to 
culture-induced changes [IX]. The observed stable and high expression in non-cultured and 
primary cultured MBMECs and the expression below detection limit in the endothelial cell-
line b.End5 points up the possibility that Eaat3 may play an important role in cell nutrition as 
well as in transendothelial transport in vivo. 
Due to the proposed importance of Eaat3 in BBB endothelial cells, its expression and 
localization on the protein level was further studied. By using different methods, it appeared 
that Eaat3 localizes to both luminal and abluminal membranes of brain vascular endothelial 
cells along the vascular tree. This is analogous to the results presented in this thesis 
concerning the localization of Snat3, another sodium-dependent amino acid transporter 
unexpectedly found also at the luminal endothelial membrane (see section 5). These results 
are not compatible with the current hypothesis that sodium-dependent transporters are 
exclusively localized to the abluminal membrane, a hypothesis that is based on physiological 
considerations regarding the existing amino acid gradient between plasma and ISF / CSF (see 
section 3.5.4) and on functional in vivo and in vitro data (see sections 3.6.1.1/2 and literature 
cited therein).  
One possible pitfall in studying the expression and localization of Eaat3 might be the 
specificity of antibodies used [VI]. The antibody used in the present study was raised against 
a C-terminal, cytoplasmic 14 amino acid long peptide, that is 100% identical in mouse, rat, 
rabbit, and human. Previously, it has been reported that only by using EAAT3 antibodies to 
C-terminal peptides strong and specific signals can be obtained [VI]. Its specificity can be 
assumed, also based on the expected labeling pattern obtained in different tissues and cell 
types (see Figure I and II), and under use of different methododical approaches (see Figure I 
and III). However, the proposed luminal localization of Eaat3 has nonetheless to be validated 
by a different, non-antibody based, method like for instance the analysis of the Neutravidin-
captured surface protein fractions using mass spectrometry. 
In the BBB endothelial cells, Eaat3 may play a role in the suggested intraendothelial 
glutamate-glutamine cycle (see section 3.5.3.1 and 6), and may be involved in clearing brain 
ISF and therefore in preventing glutamate excitotoxicity. In this context it is important to 
mention that, contrary to the rather low expression of EAAT3 in the brain (see Figure I), the 
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expression in brain vascular endothelial cells was shown to be the highest of all Slc1 members 
[IX], and that the relative activity of EAAT3 in bovine cerebral capillaries was reported to be 
higher than that of EAAT1/2 [X]. Therefore one can hypothesize that Eaat3 expressed at the 
abluminal membrane of brain vascular endothelial cells may play an important role in keeping 
the brain ISF glutamate concentration low. Furthermore, since BBB endothelial cells do 
express all system X-AG members together, and also system A and N members at high levels 
[IX], the requirements for an intraendothelial glutamate-glutamine cycle are given. 
One should also consider the potential of Eaat3 as important site of regulation. Eaat3 in 
neurons has been shown to be expressed mainly intracellularly, similar to our observation in 
endothelial cells of the BBB (see Figure V), and to be rapidly trafficked to the membrane on 
demand. Another important role of Eaat3 is the transport of cysteine that may influence the 
endothelial glutathione homeostasis and suggests an important role of the BBB in the 
oxidative stress response protecting the brain from effects of low oxygen, radicals, and low 
energy. Especially luminal expressed Eaat3 may be important in this context if one considers 
that the vasculature represents a first barrier between circulation and brain parenchyma. 
Therefore, especially the luminal membrane may act as buffer, as metabolic and oxidative 
security system. The presence of Eaat3 at the luminal membrane may also suggest a 
participation of this transporter in brain nutrition and vascular reaction to brain events. 
Possibly, luminal expressed Eaat3 may be important to clear blood from the vasoconstrictors 
glutamate and aspartate to maintain cerebral blood flow (see section 6). 
Further studies should include functional analysis of Eaat3 at the BBB and verify the 
proposed importance of this “neuronal” transporter at the BBB. 
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